<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Memantine for dementia - McShane, R - 2019 | Cochrane Library</title> <meta content="Memantine for dementia - McShane, R - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Memantine for dementia - McShane, R - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003154.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Memantine for dementia" name="citation_title"/> <meta content="Rupert McShane&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="rupert.mcshane@oxfordhealth.nhs.uk" name="citation_author_email"/> <meta content="Maggie J Westby&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Manchester, Manchester Academic Health Science Centre" name="citation_author_institution"/> <meta content="Emmert Roberts" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Neda Minakaran" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Lon Schneider" name="citation_author"/> <meta content="Keck School of Medicine of the University of Southern California" name="citation_author_institution"/> <meta content="Lucy E Farrimond" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Nicola Maayan" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Jennifer Ware" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Jean Debarros" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD003154.pub6" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/03/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Activities of Daily Living; Akathisia, Drug‐Induced [etiology]; Alzheimer Disease [drug therapy]; Cognition Disorders [drug therapy]; Dementia [*drug therapy]; Dementia, Vascular [drug therapy]; Excitatory Amino Acid Antagonists [adverse effects, *therapeutic use]; Memantine [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Withholding Treatment" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003154.pub6&amp;doi=10.1002/14651858.CD003154.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003154\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003154\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ms","ja","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003154.pub6",title:"Memantine for dementia",firstPublishedDate:"Mar 20, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003154.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003154.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003154.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003154.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003154.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003154.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003154.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003154.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003154.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003154.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>30855 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003154.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-sec-0129"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-sec-0118"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/appendices#CD003154-sec-0134"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/table_n/CD003154StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/table_n/CD003154StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Memantine for dementia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="This author contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rupert McShane</a><sup>a</sup></li> <li class="author custom-tooltip" title="This author contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0003">Maggie J Westby</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0004">Emmert Roberts</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0005">Neda Minakaran</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0006">Lon Schneider</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0007">Lucy E Farrimond</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0008">Nicola Maayan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0009">Jennifer Ware</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information#CD003154-cr-0010">Jean Debarros</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information/en#CD003154-sec-0158">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 March 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003154.pub6">https://doi.org/10.1002/14651858.CD003154.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003154-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003154-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003154-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003154-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003154-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003154-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003154-abs-0001" lang="en"> <section id="CD003154-sec-0001"> <h3 class="title" id="CD003154-sec-0001">Background</h3> <p>Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is also widely used off‐label for mild AD. </p> </section> <section id="CD003154-sec-0002"> <h3 class="title" id="CD003154-sec-0002">Objectives</h3> <p>To determine efficacy and safety of memantine for people with dementia. To assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs). </p> </section> <section id="CD003154-sec-0003"> <h3 class="title" id="CD003154-sec-0003">Search methods</h3> <p>We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's register of trials (http://www.medicine.ox.ac.uk/alois/) up to 25 March 2018. We examined clinical trials registries, press releases and posters of memantine manufacturers; and the web sites of the FDA, EMEA and NICE. We contacted authors and companies for missing information. </p> </section> <section id="CD003154-sec-0004"> <h3 class="title" id="CD003154-sec-0004">Selection criteria</h3> <p>Double‐blind, parallel group, placebo‐controlled, randomised trials of memantine in people with dementia. </p> </section> <section id="CD003154-sec-0005"> <h3 class="title" id="CD003154-sec-0005">Data collection and analysis</h3> <p>We pooled and analysed data from four clinical domains across different aetiologies and severities of dementia and for AD with agitation. We assessed the impact of study duration, severity and concomitant use of ChEIs. Consequently, we restricted analyses to the licensed dose (20 mg/day or 28 mg extended release) and data at six to seven months duration of follow‐up, and analysed separately results for mild and moderate‐to‐severe AD. </p> <p>We transformed results for efficacy outcomes into the difference in points on particular outcome scales. </p> </section> <section id="CD003154-sec-0006"> <h3 class="title" id="CD003154-sec-0006">Main results</h3> <p>Across all types of dementia, data were available from almost 10,000 participants in 44 included trials, most of which were at low or unclear risk of bias. For nearly half the studies, relevant data were obtained from unpublished sources. The majority of trials (29 in 7885 participants) were conducted in people with AD. </p> <p>1. Moderate‐to‐severe AD (with or without concomitant ChEIs). High‐certainty evidence from up to 14 studies in around 3700 participants consistently shows a small clinical benefit for memantine versus placebo: clinical global rating (CGR): 0.21 CIBIC+ points (95% confidence interval (CI) 0.14 to 0.30); cognitive function (CF): 3.11 Severe Impairment Battery (SIB) points (95% CI 2.42 to 3.92); performance on activities of daily living (ADL): 1.09 ADL19 points (95% CI 0.62 to 1.64); and behaviour and mood (BM): 1.84 Neuropsychiatric Inventory (NPI) points (95% CI 1.05 to 2.76). There may be no difference in the number of people discontinuing memantine compared to placebo: risk ratio (RR) 0.93 (95% CI 0.83 to 1.04) corresponding to 13 fewer people per 1000 (95% CI 31 fewer to 7 more). Although there is moderate‐certainty evidence that fewer people taking memantine experience agitation as an adverse event: RR 0.81 (95% CI 0.66 to 0.99) (25 fewer people per 1000, 95% CI 1 to 44 fewer), there is also moderate‐certainty evidence, from three additional studies, suggesting that memantine is not beneficial as a <i>treatment</i> for agitation (e.g. Cohen Mansfield Agitation Inventory: clinical benefit of 0.50 CMAI points, 95% CI ‐3.71 to 4.71) . </p> <p>The presence of concomitant ChEI does not impact on the difference between memantine and placebo, with the possible exceptions of the BM outcome (larger effect in people taking ChEIs) and the CF outcome (smaller effect). </p> <p>2. Mild AD (Mini Mental State Examination (MMSE) 20 to 23): mainly moderate‐certainty evidence based on post‐hoc subgroups from up to four studies in around 600 participants suggests there is probably no difference between memantine and placebo for CF: 0.21 ADAS‐Cog points (95% CI ‐0.95 to 1.38); performance on ADL: ‐0.07 ADL 23 points (95% CI ‐1.80 to 1.66); and BM: ‐0.29 NPI points (95% CI ‐2.16 to 1.58). There is less certainty in the CGR evidence, which also suggests there may be no difference: 0.09 CIBIC+ points (95% CI ‐0.12 to 0.30). Memantine (compared with placebo) may increase the numbers of people discontinuing treatment because of adverse events (RR 2.12, 95% CI 1.03 to 4.39). </p> <p>3. Mild‐to‐moderate vascular dementia. Moderate‐ and low‐certainty evidence from two studies in around 750 participants indicates there is probably a small clinical benefit for CF: 2.15 ADAS‐Cog points (95% CI 1.05 to 3.25); there may be a small clinical benefit for BM: 0.47 NOSGER disturbing behaviour points (95% CI 0.07 to 0.87); there is probably no difference in CGR: 0.03 CIBIC+ points (95% CI ‐0.28 to 0.34); and there may be no difference in ADL: 0.11 NOSGER II self‐care subscale points (95% CI ‐0.35 to 0.54) or in the numbers of people discontinuing treatment: RR 1.05 (95% CI 0.83 to 1.34). </p> <p>There is limited, mainly low‐ or very low‐certainty efficacy evidence for other types of dementia (Parkinson's disease and dementia Lewy bodies (for which CGR may show a small clinical benefit; four studies in 319 people); frontotemporal dementia (two studies in 133 people); and AIDS‐related Dementia Complex (one study in 140 people)). </p> <p>There is high‐certainty evidence showing no difference between memantine and placebo in the proportion experiencing at least one adverse event: RR 1.03 (95% CI 1.00 to 1.06); the RR does not differ between aetiologies or severities of dementia. Combining available data from all trials, there is moderate‐certainty evidence that memantine is 1.6 times more likely than placebo to result in dizziness (6.1% versus 3.9%), low‐certainty evidence of a 1.3‐fold increased risk of headache (5.5% versus 4.3%), but high‐certainty evidence of no difference in falls. </p> </section> <section id="CD003154-sec-0007"> <h3 class="title" id="CD003154-sec-0007">Authors' conclusions</h3> <p>We found important differences in the efficacy of memantine in mild AD compared to that in moderate‐to‐severe AD. There is a small clinical benefit of memantine in people with moderate‐to‐severe AD, which occurs irrespective of whether they are also taking a ChEI, but no benefit in people with mild AD. </p> <p>Clinical heterogeneity in AD makes it unlikely that any single drug will have a large effect size, and means that the optimal drug treatment may involve multiple drugs, each having an effect size that may be less than the minimum clinically important difference. </p> <p>A definitive long‐duration trial in mild AD is needed to establish whether starting memantine earlier would be beneficial over the long term and safe: at present the evidence is against this, despite it being common practice. A long‐duration trial in moderate‐to‐severe AD is needed to establish whether the benefit persists beyond six months. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003154-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003154-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003154-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003154-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003154-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003154-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003154-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003154-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003154-abs-0009">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003154-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003154-abs-0008">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003154-abs-0005" lang="en"> <h3>Memantine as a treatment for dementia</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence on memantine, which is one of the main drugs for treating people with dementia. We wanted to find out if memantine can slow down the course of dementia and if it is harmful in any way. We also wanted to know if adding memantine to other dementia drugs gives an extra effect. </p> <p><b>Background</b> </p> <p>The commonest type of dementia is Alzheimer's disease (AD), followed by vascular dementia. About one or two people in 100 have AD at age 65, and this rate doubles every five years. Dementia involves loss of memory, difficulty thinking and often changes in mood and behaviour. </p> <p>There are two main types of treatment: acetyl cholinesterase inhibitor (ChEI) drugs and memantine. These drugs work differently and we wanted to find out whether giving the two drug types together would work better than the ChEI drugs on their own. </p> <p><b>Study characteristics</b> </p> <p>We searched for as many relevant studies as we could find that had a reliable design (randomised controlled trials) and had compared memantine with placebo for each type of dementia. We found 44 studies involving about 10,000 people. Most studies (29 in 7885 people) were in people with AD. Most studies were well conducted, but some were not well reported and we got extra information from the drug companies. We analysed the results separately for people with mild dementia and those with moderate‐to‐severe dementia. </p> <p><b>Key results</b> </p> <p>Memantine has a small beneficial effect in people with moderate‐to‐severe AD. This benefit affects thinking, the ability to carry on normal daily activities, and the severity of behaviour and mood problems. Overall, it is well tolerated in those with moderate‐‐to‐severe AD, but it may cause dizziness in a few of the people taking it. </p> <p>An important result is that adding memantine to established ChEI treatment also results in less deterioration than placebo. </p> <p>However, in people with mild AD, memantine is probably no better than placebo. This is mainly moderate‐quality evidence. </p> <p>In vascular dementia, two studies in about 750 people indicated there is probably a small benefit for thinking difficulties, behaviour and mood, and there may be less agitation for memantine compared with placebo. This is moderate‐ or low‐quality evidence. </p> <p><b>Quality of the evidence</b><br/> Overall, the evidence on memantine for AD is high quality, and comes from many trials in thousands of people. We can be confident in the findings for AD, but less so in people with other types of dementia. </p> <p>This plain language summary is up to date as of March 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003154-sec-0129" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003154-sec-0129">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003154-sec-0205">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003154-sec-0129"></div> <h3 class="title" id="CD003154-sec-0130">Implications for practice</h3> <section id="CD003154-sec-0130"> <p>A substantial volume of high‐certainty evidence shows that memantine has a small, beneficial, clinically detectable effect in people with moderate‐to‐severe Alzheimer's disease (AD) at six months. The additional benefit is also apparent in those taking cholinesterase inhibitors (ChEIs). </p> <p>Clinical heterogeneity in AD means that optimal drug treatment may involve multiple drugs, each having an effect size that may be less than the minimum clinically important difference. </p> <p>There is moderate‐certainty evidence that memantine is of no benefit in mild AD over six months and that there is a possibility of increased discontinuation due to adverse events. There is no clinical trial evidence to support the suggestion that memantine reduces disease progression any more than placebo. Current practice should more closely reflect this evidence. </p> <p>The timely release of data remains problematic. Meta‐analyses that attempt to avoid bias by restricting included studies to published data, or which over‐rate the risk of bias due to last observation carried forward (LOCF) or observed case (OC) methods of analysis, incur a risk of bias due to selective publication. </p> </section> <h3 class="title" id="CD003154-sec-0131">Implications for research</h3> <section id="CD003154-sec-0131"> <p>A large trial of at least two to three years duration in mild AD is needed to definitively rule out benefit of long duration treatment in earlier dementia. Similarly, a three‐year study in moderate‐to‐severe AD would establish whether there are any continuing effects beyond six months. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003154-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003154-sec-0029"></div> <div class="table" id="CD003154-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Moderate‐to‐severe AD, six to seven months</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg or equivalent compared to placebo for moderate‐to‐severe Alzheimer's disease (AD) 24‐ to 30‐week data. OC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: Alzheimer's disease (AD), moderate‐to‐severe</b> <br/> <b>Intervention</b> : memantine 20 mg or equivalent<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CIBIC+)<br/> 7‐point Likert scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Median CIBIC+ score was 4.60 <sup>3</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 0.21 (0.14 to 0.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.28 to ‐0.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2797<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0010" title="">Analysis 1.1</a>) </p> <p>Converted to CIBIC+ scale; median SD(pooled) = 1.06.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function (SIB)<br/> 100‐point scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Median SIB score at baseline: 75.2.</p> <p>Median change from baseline (positive scale): ‐2.4 <sup>4</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 3.11 (2.42 to 3.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.27 (‐0.34 to ‐0.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3337<br/> (13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0011" title="">Analysis 1.2</a>). </p> <p>Converted to SIB scale (and scale direction inverted); median SD (pooled) = 11.53.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functional performance on activities of daily living: ADCS‐ADL19<br/> 54‐point scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Median ADCS‐ADL19 score at baseline: 33.2</p> <p>Median change from baseline (positive scale): ‐2.8 <sup>5</sup> (i.e. deterioration with time) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 1.09 (0.62 to 1.64)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.16 (‐0.24 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2687<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD for decline in ADL (a negative outcome)</p> <p>(<a href="./references#CD003154-fig-0012" title="">Analysis 1.3</a>). </p> <p>Converted to ADCS‐ADL19 scale (and scale direction inverted); median SD(pooled) = 6.84. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood (NPI)</p> <p>144‐point scale</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median baseline NPI score was 17.0.</p> <p>Median change from baseline (negative scale): 2.80 <sup>6</sup> (i.e. deterioration with time) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 1.84 (1.05 to 2.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.14 (‐0.21 to ‐0.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3674<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0013" title="">Analysis 1.4</a>) </p> <p>Converted to NPI scale; median SD(pooled) = 13.15.</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000<br/> (151 to 189) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.83 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5087<br/> (17 RCTs) </p> <p>924 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control group risk in people with moderate‐to‐severe AD without agitation (<a href="./references#CD003154-fig-0142" title="">Analysis 16.5</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Difference: 13 fewer people per 1000 discontinued treatment for any cause (95% CI 31 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>716 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>737 per 1000<br/> (716 to 759) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>). </p> <p>Median control group risk for moderate‐to‐severe AD studies (<a href="./references#CD003154-fig-0016" title="">Analysis 1.7</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Difference: 21 more people per 1000 suffered adverse events<br/> (95% CI 0 to 43 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(93 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6482</p> <p>(19 RCTs)</p> <p>918 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control risk from all AD studies (except those with agitation) (from <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 10 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 21 fewer to 2 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/> (85 to 128) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.66 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4395<br/> (12 RCTs) </p> <p>321 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all AD studies (apart from those in people with agitation) (<a href="./references#CD003154-fig-0083" title="">Analysis 8.11</a>). </p> <p>Median control group risk for moderate‐to‐severe AD studies (<a href="./references#CD003154-fig-0018" title="">Analysis 1.9</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Difference: 25 fewer people per 1000 suffered agitation as an adverse event<br/> (95% CI 44 to 1 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Some inconsistency in point estimates, but not enough to downgrade </p> <p><sup>2</sup> Some inconsistency in point estimates (downgrade once) </p> <p><sup>3</sup> Median control group values for 8 studies reporting CIBIC+ (<a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>) </p> <p><sup>4</sup> Median control group baseline scores and median control group change from baseline for 5 studies reporting SIB (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>) </p> <p><sup>5</sup> Median control group baseline scores and median control group change from baseline for the 4 studies reporting ADCS‐ADL19 (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>;<a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>) </p> <p><sup>6</sup> Median control group baseline scores and median control group change from baseline for the 10 studies reporting NPI (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003154-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vascular dementia ‐ mild‐to‐moderate severity. six months</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg compared to placebo for mild‐to‐moderate vascular dementia. six‐month studies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: vascular dementia, mild‐to‐moderate severity</b> <br/> <b>Intervention</b> : memantine 20 mg<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (mean)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global: (CIBIC+)<br/> 7‐point Likert scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CIBIC+ score<br/> (<a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>)<br/> was 4.19 </p> <p>(i.e. no change with time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 0.03 (‐0,28 to 0.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.02 (‐0.23 to 0.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome;</p> <p>random effects (<a href="./references#CD003154-fig-0049" title="">Analysis 5.1</a>). </p> <p>Converted to CIBIC+ scale; SD(pooled) = 1.46.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function: ADAS‐Cog<br/> 70‐point scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ADAS‐Cog score at baseline was 23.6.</p> <p>Mean change from<br/> baseline (negative scale) was 1.68 </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 2.15 (1.05 to 3.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.32 (‐0.48 to ‐0.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>569<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0050" title="">Analysis 5.2</a>) </p> <p>[SMD as a negative outcome <a href="./references#CD003154-fig-0074" title="">Analysis 8.2</a>] </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL</p> <p>(NOSGER self care subscale)</p> <p>Subscale 5 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline scores not reported.</p> <p>Change from baseline<br/> for the NOSGER II<br/> self care subscale<br/> (negative scale) was<br/> 0.40 (one study) </p> <p>i.e. deterioration with time</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 0.11 (‐0.35 to 0.54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.04 (‐0.20 to 0.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD for decline in ADL (a negative outcome)</p> <p>(<a href="./references#CD003154-fig-0051" title="">Analysis 5.3</a>). </p> <p>Converted to NOSGER II self‐care subscale (<a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>) SD(pooled) = 2.69. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour: NOSGER disturbing behaviour subscale</p> <p>Subscale 5 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline scores not reported.</p> <p>Change from baseline</p> <p>for the NOSGER<br/> disturbing behaviour subscale (negative scale) was 0.57 (one study) </p> <p>i.e. deterioration with time</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 0.47 (0.07 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.37 to ‐0.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0052" title="">Analysis 5.4</a>). </p> <p>Converted to NOSGER II disturbing behaviour subscale (<a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>) SD(pooled) = 2.34. </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>229 per 1000<br/> (181 to 292) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.83 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>900<br/> (2 RCTs) </p> <p>678 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk for studies in people with vascular dementia (<a href="./references#CD003154-fig-0054" title="">Analysis 5.6</a>.) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 11 more people per 1000 discontinued treatment for any cause (95% CI 37 fewer to 74 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>742 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>764 per 1000<br/> (742 to 787) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>). Control group risk taken from studies in vascular dementia (<a href="./references#CD003154-fig-0056" title="">Analysis 5.8</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 22 more people per 1000 suffered adverse events<br/> (95% CI 0 to 45 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000</p> <p>(95% CI 131 to 230)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82</p> <p>(0.62 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>900</p> <p>(2 RCTs)</p> <p>162 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from vascular dementia studies (<a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 38 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 80 fewer to 19 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>44 per 1000<br/> (26 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/> (0.33 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>900<br/> (2 RCTs) </p> <p>54 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from vascular dementia studies (<a href="./references#CD003154-fig-0057" title="">Analysis 5.9</a>); random effects </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 33 fewer people per 1000 suffered agitation as an adverse event<br/> (95% CI 52 to 2 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Inconsistency in point estimates (and I² = 48%); some imprecision (95% CI crossed null and was consistent with benefit and no difference) but may be consequence of inconsistency (downgraded once overall) </p> <p><sup>2</sup> Majority of the information at high risk of bias (downgrade once). Some inconsistency (but insufficient to downgrade) </p> <p><sup>3</sup> Majority of the information at high risk of bias for 2 domains (downgrade twice) </p> <p><sup>4</sup> Majority of the information at high risk of bias (downgrade once); some inconsistency and some imprecision (crossed null and 1.25) (downgrade once) </p> <p><sup>5</sup> Majority of the information at high risk of bias (downgrade once); imprecision (162 events and crossed both 0.75 and null)) (downgrade once) </p> <p><sup>6</sup> Majority of the information at high risk of bias (downgrade once); imprecision (only 54 events) (downgrade once) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003154-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003154-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003154-sec-0167">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD003154-sec-0030"></div> <section id="CD003154-sec-0031"> <h3 class="title" id="CD003154-sec-0031">Description of the condition</h3> <p>This review covers the effect of memantine in dementia of all aetiologies.</p> <p>Alzheimer's disease (AD) is the commonest cause of dementia, and is found in approximately 70% of autopsies of people with dementia. The prevalence of the disease is approximately 1% to 2% at the age of 65, but doubles every five years to at least the age of 90 (<a href="./references#CD003154-bbs2-0223" title="QiuC , KivipeltoM , vonStraussE . Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues in Clinical Neuroscience2009;11(2):111‐28. ">Qiu 2009</a>). The disease is progressive. For the purposes of drug trials, people with AD who have a score on the brief mini mental state examination (MMSE) of more than 20 have come to be labelled as having 'mild' AD. However, the combination of loss of memory, disorientation and frequent loss of insight which accompanies this stage means that the impact on caregivers is often very far from 'mild'. It is not uncommon for patients to need admission to care homes in this stage. 'Moderate' AD has come to be defined as those with an MMSE score of 20 to 10. In this range, patients decline more rapidly. The impairment in patients' ability to manage everyday tasks becomes marked and is obvious during even brief conversation. By the time patients have progressed to an MMSE score of 10 or less ('severe' dementia), the deficits are profound and 24‐hour supervision is required. Approximately 70% of people with AD require admission to care homes. </p> <p>Aside from age, the biggest risk factor for developing AD is possession of the ApoE4 gene, which is present in 17% to 30% of the population. Other risk factors include all vascular risks (diabetes, hypertension, high cholesterol, lack of exercise), any cerebral injury (trauma or stroke), and being female (<a href="./references#CD003154-bbs2-0219" title="PattersonC , FeightnerJ , GarciaA , MacKnightC . General risk factors for dementia: a systematic evidence review. Alzheimer’s &amp; Dementia2007;3:341‐7. ">Patterson 2007</a>; <a href="./references#CD003154-bbs2-0235" title="SibbettRA , RussTC , DearyIJ , StarrJM . Risk factors for dementia in the ninth decade of life and beyond: a study of the Lothian birth cohort 1921. BMC Psychiatry2017;17:205 DOI 10.1186/s12888‐017‐1366‐3. ">Sibbett 2017</a>). </p> <p>Cellular and animal models, genetic, neuroimaging, clinical and postmortem brain studies have all been important in advancing understanding of the many changes which occur in the brains of people with AD. Nerve cell loss and disruption of neurotransmitter systems becomes widespread throughout many brain areas, particularly the hippocampus and cerebral cortex. Aggregation of peptide fragments of the amyloid precursor protein, which probably holds nerve cells close enough together for signals to be transmitted between them, causes malfunction of processes within cells. Large deposits of these fragments, amyloid plaques, develop outside neurones and are associated with a mild inflammatory response. However, removal of existing plaques does not appear to result in improvement in symptoms so it is unclear to what extent the amyloid plaques are a cause of AD or a consequence of some other, more fundamental, disturbance. Within the neurons, the transport of cellular components becomes disrupted because tau, which helps to keep the microtubule scaffolding together, becomes hyperphosphorylated and itself forms into paired helical filament 'tangles'. No drugs affecting this process have been proven to benefit symptoms. Cholinergic function, which mediates attention, tends to be impaired in people with AD. This can be partially corrected by cholinesterase inhibitors (ChEIs) which reduce the breakdown of acetylcholine. </p> <p>Vascular dementia, in which cognitive decline is attributed to some form of vascular injury, typically ischaemic, is the second most common cause of dementia in Western societies. Developing a valid definition, distinct from AD, has been problematic. It is a heterogeneous condition and clinical manifestations differ depending on the size and location of the cerebrovascular lesions. In autopsy studies, 'mixed' AD and vascular dementia has been reported as accounting for between 0% and 55% of cases of dementia. In addition to co‐occurrence due simply to chance, AD and vascular dementia may have aetiological or pathogenetic factors in common (<a href="./references#CD003154-bbs2-0203" title="KalariaRN , BallardC . Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Disease and Associated Disorders1999;13(suppl 3):S115‐23. ">Kalaria 1999</a>). In comparison with sufferers from AD, people with mixed dementia show higher frequencies of depressed mood, focal motor or sensory findings and gait disturbances, but the neuropsychological pattern is not distinctive. Using criteria which demand imaging evidence of discrete vascular lesions and a clinical event associated with cognitive decline, or evidence of marked small vessel disease, vascular dementia affects 1% to 20% of people aged 65 years or older. </p> <p>Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) are closely related. The main clinical distinction is one of definition: those with PDD have had parkinsonism a year or more before developing dementia, whereas in DLB the onsets of dementia and any parkinsonism are closer in time. Some people with DLB show no signs of parkinsonism. Both groups are more likely to experience visual hallucinations, marked fluctuations in functional ability, and REM (rapid eye movement) sleep behaviour disorder. </p> </section> <section id="CD003154-sec-0032"> <h3 class="title" id="CD003154-sec-0032">Description of the intervention</h3> <p>Memantine was first synthesised at Eli Lilly as an agent to lower elevated blood sugar levels, but was ineffective. It has since been tested in over 100 randomised controlled trials in a wide variety of neurological and psychiatric conditions, including dementia of different sorts, depression, neuropathic pain, Parkinson's disease and autism. </p> <p>In 1972, Merz applied for a German patent for memantine as a potential treatment for a wide range of cerebrovascular conditions, citing evidence of reduced degeneration and nerve cell loss following experimentally induced ischaemia in animal models. In 1975 and 1978, patents were granted in Germany and the USA, respectively (<a href="./references#CD003154-bbs2-0218" title="ParsonsCG , DanyszW , QuackG . Memantine is a clinically well tolerated N‐methhyl‐D‐aspartate (NMDA) receptor antagonist‐ a review of preclinical data. Neuropharmacology1999;38:735‐67. ">Parsons 1999</a>). This basis for the original patent for memantine (<a href="./references#CD003154-bbs2-0169" title="BormannJ , GoldMR , SchattonW , inventors . Adamantane derivatives in the prevention and treatment of cerebral ischemia. United States Patent 5061703 1991 Oct 29. ">Bormann 1991</a>), which was due to expire in April 2010, was contested by manufacturers of generics (<a href="./references#CD003154-bbs2-0185" title="ForestLaboratories . Forest Laboratories receives notification of ANDA filings for generic equivalents of Namenda(R). http://www.frx.com/news/PressRelease.aspx?ID=1087334 13‐12‐2007. ">Forest 2007</a>). Forest and Merz settled an agreement to provide licenses to each of Amneal, Cobalt, Dr. Reddy’s, Lupin, Orchid, Sun, Teva, Upsher−Smith, and Wockhardt that permitted these companies to launch their generic versions of 'Namenda' within three months prior to the expiration of the original patent (<a href="./references#CD003154-bbs2-0186" title="Annual report pursuant to section 13 and 15(d). http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐sec&amp;control_symbol= Vol. 26 May 2010. ">Forest 2010a</a>). However, in March 2009, the U.S. Patent and Trademark Office issued a Notice of Final Determination that, after review of the regulatory timeline for approval, Namenda was entitled to a patent term extension until April 2015 and the patent finally expired in October 2015. Generic memantine is now available, but in 2010 the US Food and Drug Administration (FDA) awarded a license for an extended release, once daily preparation Namenda XR 28 mg (<a href="./references#CD003154-bbs2-0187" title="ForestLaboratories . Forest and Merz announce FDA approval of NAMENDA XR for the treatment of moderate to severe dementia of the Alzheimer's type. http://www.frx.com/news/PressRelease.aspx?ID=1440385 21 June 2010. ">Forest 2010b</a>). The patent for this expires in September 2029. </p> <p>Memantine was approved in February 2002 by the European Agency for the Evaluation of Medical Products (EMEA) for the treatment of "moderately severe to severe Alzheimer's disease" (<a href="./references#CD003154-bbs2-0178" title="European Medicines Agency. Ebixa. European Public Assessment Report. www.emea.eu.int/humandocs/Humans/EPAR/ebixa/ebixa.htm2004. ">EMEA 2004</a>) and in 2003 by the FDA for the treatment of moderate‐to‐severe AD (MMSE up to 14) (<a href="./references#CD003154-bbs2-0167" title="Anonymous . FDA approves memantine drug for treating AD. American Journal of Alzheimer's Disease and other Dementias2003;18(6):329‐30. ">Anonymous 2003</a>; <a href="./references#CD003154-bbs2-0183" title="FDA approves Namenda(TM)(Memantine HCl) for the treatment of moderate to severe Alzheimer's disease. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=459801&amp;highlight=.. ">Forest 2003</a>). In 2006, the EMEA expanded its indication to 'moderate‐to‐severe AD' (MMSE up to 19) (<a href="./references#CD003154-bbs2-0179" title="EMEA Committee for Medicinal products for Human Use. Plenary meeting monthly report.  17‐11‐2005. October 2005 Vol. http://www.emea.europa.eu/pdfs/human/press/pr/36234805en.pdf. ">EMEA 2006</a>). In June 2008, the EMEA granted a license for a once daily 20 mg dosing schedule (<a href="./references#CD003154-bbs2-0180" title="European Commission. Memantine receives European‐wide approval for once‐daily dosing. http://www.alzheimer‐europe.org/?content=shnw&amp;shnwid=5976E167EBBA. ">EMEA 2008</a>). Applications to the FDA and EMEA for licenses for the treatment of mild‐to‐moderate AD have been unsuccessful (<a href="./references#CD003154-bbs2-0184" title="Forest Laboratories announces FDA decision on supplemental new drug application for Namenda. http://www.frx.com/news/PressRelease.aspx?ID=734345. ">Forest 2005b</a>; <a href="./references#CD003154-bbs2-0208" title="Ebixa extended approval for the treatment of moderate Alzheimer's disease. http://www.lunbeck.com/investor/releases/ReleaseDetails/Release_173_EN.asp. ">Lundbeck 2005</a>). </p> <p>Memantine has not been approved for vascular dementia or earlier stages of AD in any jurisdiction. </p> <p>Memantine is marketed as Axura by Merz, as Ebixa by Lundbeck in Europe, as Namenda by Forest in North America and as Mamary by Daiichi Asubio in Japan. In 2010, memantine had 34.8% share of the US market for drugs for AD (<a href="./references#CD003154-bbs2-0186" title="Annual report pursuant to section 13 and 15(d). http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐sec&amp;control_symbol= Vol. 26 May 2010. ">Forest 2010a</a>). Annual global sales exceed 1 billion USD. In 2015, the UK price of memantine to the NHS decreased by 94%. Prescribing rates in England increased from approximately 100,000 items dispensed in 2011 to 784,000 (at a cost of £5.4m) in 2015 (<a href="./references#CD003154-bbs2-0221" title="Prescribing and Medicines Team, Health and Social Care Information Centre. Prescriptions dispensed in the community: England 2005‐2015. http://content.digital.nhs.uk/catalogue/PUB20664/pres‐disp‐com‐eng‐2005‐15‐rep.pdf accessed 10 May 2017. ">Prescriptions England 2016</a>). </p> <p>In May 2015, Actavis launched Namzaric (a fixed‐dose combination of 28 mg extended‐release memantine and the ChEI, donepezil 10 mg) for people with moderate‐to‐severe AD, following FDA approval in December 2014. </p> </section> <section id="CD003154-sec-0033"> <h3 class="title" id="CD003154-sec-0033">How the intervention might work</h3> <p>Memantine is a low affinity antagonist of the N‐methyl‐D‐aspartate (NMDA) glutamate receptor. L‐glutamate is the main excitatory neurotransmitter in the central nervous system and is implicated in neural transmission, learning, memory processes and neuronal plasticity (<a href="./references#CD003154-bbs2-0239" title="SucherNJ , AwobuluyiM , ChoiYB , LiptonSA . NMDA receptors: from genes to channels. Trends in Pharmacological Science1996;17:348‐55. ">Sucher 1996</a>). Physiological glutamate activity is required for normal brain activity and so cannot be abolished completely (<a href="./references#CD003154-bbs2-0206" title="KornhuberJ , WellerM . Psychotogenicity and N‐methyl‐D‐aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biological Psychiatry1997;41:135‐44. ">Kornhuber 1997</a>). The hippocampus and other brain regions which are affected in AD, are rich in glutamate receptors of the NMDA class. Consolidation of new memories is also mediated through these receptors. </p> <p>Excessive glutamate‐induced excitation, which results in excessive flow of calcium into neurons through NMDA receptors, plays a role in the pathogenesis of AD and in the damage due to an ischaemic stroke (<a href="./references#CD003154-bbs2-0170" title="CacabelosR , TakedaM , WinbladB . The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease. International Journal of Geriatric Psychiatry1999;14:3‐47. ">Cacabelos 1999</a>). The clinical actions of memantine may be mediated by preventing this excitotoxicity. </p> <p>NMDA receptor‐induced responses may depend on the receptor location. Stimulation of synaptic NMDA receptors, acting primarily through nuclear Ca(2+) signalling, leads to the build‐up of a neuroprotective 'shield', whereas stimulation of extrasynaptic NMDA receptors promotes cell death (<a href="./references#CD003154-bbs2-0195" title="HardinghamGE , BadingH . Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nature reviews. Neuroscience2010; Vol. 11, issue 10:682‐96. ">Hardingham 2010</a>) and increases amyloid production (<a href="./references#CD003154-bbs2-0168" title="BordjiK , Becerril‐OrtegaJ , NicoleO , BuissonA . Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid‐ss production. Journal of Neuroscience2010; Vol. 30, issue 47:15927‐42. ">Bordji 2010</a>). The differing pharmacodynamics of memantine at synaptic and extrasynaptic NMDA receptors may mean that there is a 'therapeutic window' for memantine at doses where inhibition of extrasynaptic receptors is greater than for synaptic receptors (<a href="./references#CD003154-bbs2-0195" title="HardinghamGE , BadingH . Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nature reviews. Neuroscience2010; Vol. 11, issue 10:682‐96. ">Hardingham 2010</a>). Inhibition of both subtypes occurs at higher doses. </p> <p>It is possible that the effect of memantine is related to reduction of tau phosphorylation (<a href="./references#CD003154-bbs2-0173" title="Degerman GunnarssonM , KilanderL , BasunH , LannfeltL . Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;24:247‐52. ">Degerman Gunnarsson 2007</a>) or of amyloid toxicity (<a href="./references#CD003154-bbs2-0236" title="SongMS , RauwG , BakerGB , KarS . Memantine protects rat cortical cultured neurons against beta‐amyloid‐induced toxicity by attenuating tau phosphorylation. European Journal of Neuroscience2008;28:1989‐2002. ">Song 2008</a>). </p> <p>Memantine also preserves cerebral energy status during experimentally induced hypoglycaemia in healthy people (<a href="./references#CD003154-bbs2-0243" title="WillenborgB , SchmollerA , CasparyJ , MelchertUH , Scholand‐EnglerHG , Jauch‐CharaK , et al. Memantine prevents hypoglycemia‐induced decrements of the cerebral energy status in healthy subjects. Journal of Clinical and Endocrinology Metabolism2011; Vol. 96, issue 2:E384‐8. ">Willenborg 2011</a>). Although this effect could be related to its actions in dementia, this has yet to be established. </p> </section> <section id="CD003154-sec-0034"> <h3 class="title" id="CD003154-sec-0034">Why it is important to do this review</h3> <p>First, since the last update of our review in 2006, the UK National Institute for Health and Care Excellence (NICE) has, on the basis of its 2011 appraisal (TA 217) revised an earlier recommendation that memantine was insufficiently cost‐effective to warrant prescription on the UK's National Health Service (NHS), and produced new recommendations outlining its use (<a href="./references#CD003154-bbs2-0215" title="National Institute for Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. Technology appraisal guidance 217 (Review of NICE technology appraisal guidance 111). http://guidance.nice.org.uk/TA217/Guidance/pdf/English2011. ">NICE 2011</a>). In a further update in 2015, NICE stated that they "identified nothing new that affects recommendations 1.1, 1.2" (those concerning memantine). Concurrent with the update of our Cochrane Review, NICE's clinical guideline on dementia (CG 42) has been partially updated, to review further the effect of two topics relevant to this memantine review: concurrent treatment with memantine and cholinesterase inhibitors (ChEIs), and memantine for non‐AD dementias. The guideline has not updated recommendations 1.1 and 1.2 (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>). The Cochrane Dementia and Cognitive Improvement review group is a stakeholder for this guideline and the authors of this review have shared data and evidence synthesis with NICE. </p> <p>The UK recommendations regarding memantine monotherapy (TA 217 recommendations 1.1 and 1.2) therefore remain unchanged: that is, that memantine should be available at public expense for people who either (a) have moderate AD and are intolerant of, or have a contraindication to ChEIs or (b) have severe AD. The Appraisal Committee also concluded that "if cognitive scales are not appropriate for assessing the need for treatment, or whether to continue treatment, then clinicians should use another appropriate method of assessment". </p> <p>NICE's 2011 updated decision was based on consideration of data from four studies, with emphasis on statistical significance. Their analysis showed a significant benefit on cognitive function assessed by the Severe Impairment Battery (SIB) at three months, but not at six months. Two studies provided data for assessment of activities of daily living (ADL) using the Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living (ADCS‐ADL)19 scale, showing marginal significance at six months. No statistically significant effect was seen on behaviour. NICE's model suggested that memantine delayed time to institutional care by 0.8 months. Thus, NICE's 2015 decision to transfer recommendations 1.1 and 1.2 to their 'static list of technology appraisals' was taken on the basis of relatively few studies for clinical effectiveness. Memantine is now off‐patent so cost‐effectiveness will be affected. </p> <p>NICE's original 2011 guidance also concluded that there was a "lack of evidence of additional clinical efficacy (of concurrent therapy with ChEIs) compared with memantine monotherapy" (<a href="./references#CD003154-bbs2-0215" title="National Institute for Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. Technology appraisal guidance 217 (Review of NICE technology appraisal guidance 111). http://guidance.nice.org.uk/TA217/Guidance/pdf/English2011. ">NICE 2011</a>). However, this aspect of the TA has now been updated in the newly published 2018 guideline (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>), which recommends that for people with an established diagnosis of AD who are already taking a ChEI, memantine should be additionally considered in moderate disease and additionally offered in severe disease (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>). A lack of clarity still remains because of the decision not to update the monotherapy recommendations, and there is potential confusion arising from conflating the old and new recommendations. The British Association for Psychopharmacology guideline suggests that there is "type I evidence [ie based on meta‐analysis of RCTs] for adding memantine to a cholinesterase inhibitor" (<a href="./references#CD003154-bbs2-0217" title="O'BrienJT , HolmesC , JonesM , JonesR , LivingstonG , McKeithI , et al. Clinical practice with anti‐dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology2017;31(2):1‐22. ">O'Brien 2017</a>). </p> <p>Second, the German Institute for Quality and Efficiency in Healthcare (IQWIG) has revised its conclusions on memantine. In 2009, they concluded that "there is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine". Their last search of registries for studies was in January 2009. Data from nine studies of 16 to 28 weeks duration were eventually included. IQWIG pointed to a lack of 'reliable responder analysis', which prevents an understanding of whether 'more patients in the memantine group notice a perceptible improvement in their symptoms than in the placebo group' and argued that it was "not possible to deduce a proof of a relevant effect" on clinical global because, although showing a significant benefit (standardised mean difference (SMD) 0.18, 95% confidence interval (CI) 0.05 to 0.3), the lower confidence limit fell below a threshold of 0.2. The majority of included studies collected data on the amount of care required ('resource utilisation') but this was not made available. However, in response, in 2011 Merz submitted post‐hoc findings on responder analyses which led to changes to IQWIG's conclusions (<a href="./references#CD003154-bbs2-0202" title="Institute for Quality and Efficiency in Health Care. Responder analyses on memantine in Alzheimer’s disease. https://www.iqwig.de/download/A10‐06_Executive‐summary_Responder_analyses_on_memantine_in_Alzheimers_disease.pdf (accessed 6 January 2018). ">IQWIG 2011</a>), "The data provide proof of a benefit of memantine in patients with Alzheimer’s disease with regard to the prevention of a relevant deterioration in cognitive function. For activities of daily living, taking into account the uncertain response criteria, as well as the concurrent minor size of the effect, the data provide an indication of a benefit of memantine." </p> <p>Third, France's Minister for Health de‐listed all drugs routinely used for AD from August 2018 (memantine and the ChEIs, donepezil, galantamine and rivastigmine), stating, "The drugs available in early 2018 for Alzheimer's disease have only minimal and transient efficacy. They are also difficult to use because of their disproportionate adverse effects and many interactions with other drugs. None of the available drugs has been shown to slow down progression toward dependence, yet all carry a risk of life‐threatening adverse effects and severe drug interactions". De‐listing means the drugs are no longer reimbursed by the national health insurance system (<a href="./references#CD003154-bbs2-0222" title="Drugs for Alzheimer's disease: finally delisted in France. http://english.prescrire.org/en/81/168/55126/0/NewsDetails.aspx (accessed 28 October 2018). ">Prescrire 2018</a>). The French dementia guideline was updated at the same time and indicated that the 'medical service' was insufficient to justify national support, although noting the marketing authorisation and stating that drugs can be prescribed in line with their summary of product characteristics (<a href="./references#CD003154-bbs2-0197" title="Haute Autorité deSanté . Care Pathway Guide for Patients with Neurocognitive Disorders Associated with Alzheimer's Disease or Related Disease [Guide parcours de soins des patients présentant un trouble neurocognitif associé à la maladie d’Alzheimer ou à une maladie apparentée]. https://www.has‐sante.fr/portail/upload/docs/application/pdf/2018‐05/parcours_de_soins_alzheimer.pdf (accessed 28 October 2018). ">HAS 2018</a>). </p> <p>Fourth, many patients in North America are taking memantine outside the terms of its license, perhaps in the belief that 'if it works for moderate AD it must work in mild AD'. In 2006, it was prescribed to 19% of people with mild AD, despite the fact that, in 2005 the FDA did not approve a supplemental new drug application (sNDA) by Forest Labs which sought specific marketing approval for a mild AD indication (<a href="./references#CD003154-bbs2-0212" title="McManusT . Stakeholder Insight: Alzheimer's Disease ‐ prescribing trends indicate that neurologists are not adhering to guidelines. DatamonitorDecember 2006. ">McManus 2006</a>). In the mainly academic centres that comprise the Alzheimer Disease Neuroimaging Initiative (ADNI) 45.7% of people with mild AD were receiving memantine (<a href="./references#CD003154-bbs2-0230" title="SchneiderLS , InselP , WeinerMW , Alzheimer's Disease Neuroimaging Initiative. Treatment with Cholinesterase inhibitors and memantine of patients in the Alzheimer Disease Neuroimaging Initiative. Archives of Neurology2011;68(1):58‐66. ">Schneider 2011a</a>). Nearly 40% of US neurologists report prescribing memantine at least sometimes to people with mild cognitive impairment (<a href="./references#CD003154-bbs2-0225" title="RobertsJS , KarlawishJH , UhlmannWR , PetersenRC , GreenRC . Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology2010;75(5):425‐31. ">Roberts 2010</a>). </p> <p>Fifth, the regulations governing publication of trial results have changed since the last update of this review in 2006. Trials conducted by US sponsors now have to be reported on clinical registries within a year of the last data being collected from the last participant in the trial. This greater transparency has led to data becoming available which is not subject to peer review, and to the possibility of identifying data which was collected but remains unavailable ('known unknowns'). The inclusion of non peer‐reviewed registry data in meta‐analysis reduces the risk of bias due to selective publication. It also helps to restore the breach of ethical contract with trial participants and their families which occurs when data remain unpublished: they usually agree to participate in the belief that the experience will contribute to publicly available knowledge. </p> <p>Sixth, pharmacological strategies for managing some of the behavioural changes associated with dementia are of low benefit, often have side effects, and are overused. Considerable marketing activity, especially in the 2000s, asserted that memantine might be an alternative. </p> <p>Seventh, there may be a therapeutic window for memantine that impacts on the timing of when memantine is prescribed. Trials in cognitive impairment in multiple sclerosis have consistently found a dose‐related worsening of neurological and psychiatric symptoms (<a href="./references#CD003154-bbs2-0120" title="LoveraJF , FrohmanE , BrownT . Randomized double‐blind placebo‐controlled trial of memantine 10mg twice a day for three months as a treatment for cognitive impairment in multiple sclerosis. Neurology2009; Vol. 72, issue 11 Suppl 3:A112. LoveraJF , FrohmanE , BrownTR , BandariD , NguyenL , YadavV , et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo‐controlled trial. Multiple Sclerosis2010; Vol. 16, issue 6:715‐23. NCT00300716 . Trial of memantine for cognitive impairment in multiple sclerosis [Double blind placebo controlled pilot trial of memantine for cognitive impairment in multiple sclerosis]. https://clinicaltrials.gov/ct2/show/NCT003007162004. ">Lovera 2010</a>; <a href="./references#CD003154-bbs2-0134" title="PeyroSP , CreveuilC , HeinzlefO , DeSezeJ , VermerschP , CastelnovoG , et al. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo‐controlled study. Journal of the Neurological Sciences2016;363:69‐76. ">Peyro‐Saint‐Paul 2016</a>; <a href="./references#CD003154-bbs2-0153" title="VillosladaP , ArrondoG , SepulcreJ , AlegreM , ArtiedaJ . Memantine induces reversible neurologic impairment in patients with MS. Neurology2009;72(19):1630‐3. ">Villoslada 2009</a>), consistent with preclinical work suggesting the possibility of a therapeutic window (<a href="./references#CD003154-bbs2-0195" title="HardinghamGE , BadingH . Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nature reviews. Neuroscience2010; Vol. 11, issue 10:682‐96. ">Hardingham 2010</a>). In the ADNI, <a href="./references#CD003154-bbs2-0230" title="SchneiderLS , InselP , WeinerMW , Alzheimer's Disease Neuroimaging Initiative. Treatment with Cholinesterase inhibitors and memantine of patients in the Alzheimer Disease Neuroimaging Initiative. Archives of Neurology2011;68(1):58‐66. ">Schneider 2011a</a> and colleagues found that people taking memantine and ChEIs declined faster on the MMSE and Clinical Dementia Rating (CDR) scales (but not Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) or a functional questionnaire) than those taking ChEIs alone. Whilst this was probably because memantine was started early by clinicians faced with patients who were declining more rapidly, and the results of the two cognitive scales are not wholly consistent, the result is also consistent with an adverse effect of memantine in early AD. </p> <p>It is therefore important to conduct this review to investigate these unanswered questions and inconsistencies, in order to give clear information. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003154-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003154-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003154-sec-0172">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003154-sec-0035"></div> <p>The primary aim of the review is to assess the efficacy and safety of memantine for the treatment of dementia, as revealed in clinical trials involving people with Alzheimer's, vascular, mixed or other forms of dementia. Additionally, the review aims to assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003154-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003154-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003154-sec-0173">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003154-sec-0036"></div> <section id="CD003154-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003154-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included studies for analysis in this review if they fulfilled the following criteria.</p> <p> <ol id="CD003154-list-0001"> <li> <p>Double‐blind, parallel‐group, placebo‐controlled, with randomised and unconfounded treatment assignment to memantine or placebo </p> </li> <li> <p>Sample selection criteria were specified and diagnosis used established criteria (e.g. Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) criteria) </p> </li> <li> <p>Outcome instruments were specified</p> </li> <li> <p>Duration was specified</p> </li> </ol> </p> <p>We also included studies for which data were known to exist but were not available in published reports, in order that the potential impact of publication bias could be assessed. </p> <p>Double‐blind randomised trials of memantine for cognitive impairment which did not meet the inclusion criteria (e.g. in participants with mild cognitive impairment, or head‐to‐head studies) are briefly discussed in 'Excluded studies'. </p> </section> <section id="CD003154-sec-0039"> <h4 class="title">Types of participants</h4> <p>People with Alzheimer's, vascular, mixed or other types dementia of all degrees of severity, treated as in‐ or out‐patients. </p> </section> <section id="CD003154-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Memantine at any dose and by any route of administration. Although there is evidence that 20 mg once daily is as well tolerated as 10 mg twice daily, an extended release formulation is now also available at an 'equivalent' dose (28 mg). Given this equivalence, and that it has a licence, it was included in analyses of the licensed dose and indication. </p> </section> <section id="CD003154-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>The primary outcomes of interest included the following.</p> <p> <ol id="CD003154-list-0002"> <li> <p>Clinical global rating</p> </li> <li> <p>Cognitive function</p> </li> <li> <p>Functional performance in activities of daily living (ADL)</p> </li> <li> <p>Behavioural disturbance</p> </li> <li> <p>Incidence of dropout and adverse events</p> </li> </ol> </p> <p>We also sought data on the following pragmatic outcomes.</p> <p> <ol id="CD003154-list-0003"> <li> <p>Effect on carer burden</p> </li> <li> <p>Quality of Life</p> </li> <li> <p>Institutionalisation</p> </li> <li> <p>Costs</p> </li> </ol> </p> </section> </section> <section id="CD003154-sec-0042"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003154-sec-0043"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>) ‐ the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register on 25 March 2018. We used the Advanced search, with the following search terms: memantine, D‐145, DMAA, DRG‐0267, ebixa, abixa, axura, akatinol, memox and namenda. </p> <p>ALOIS is maintained by the Information Specialists of the Cochrane Dementia Group and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy people. The studies are identified from:   </p> <p> <ol id="CD003154-list-0004"> <li> <p>monthly searches of a number of major healthcare databases: MEDLINE, Embase, CINAHL, PsycINFO and LILACS; </p> </li> <li> <p>monthly searches of a number of national and international trial registers: ISRCTN; UMIN (Japan's Trial Registry); ICTRP / WHO portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others); </p> </li> <li> <p>quarterly search of the Cochrane Library’s Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>six‐monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses. </p> </li> </ol> </p> <p>To view a list of all sources searched for ALOIS see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS web site. </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, from Cochrane CENTRAL and from conference proceedings can be viewed in the ‘methods used in reviews’ section within the editorial information section of the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <p>We carried out additional searches in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up‐to‐date as possible. The search strategies used can be seen in <a href="./appendices#CD003154-sec-0135">Appendix 1</a>. </p> <p>We searched press releases from Merz, Lundbeck and Forest Laboratories (April 2017) and examined all releases pertaining to memantine. </p> <p>The Forest, Lundbeck and JAPIC clinical trials registry and ClinicalTrials.gov were re‐examined for the final time in April 2017. </p> </section> <section id="CD003154-sec-0044"> <h4 class="title">Searching other resources</h4> <p>All conference posters sponsored by Forest Laboratories, Merz or Lundbeck presented before end 2009 were provided through the medical information department of Merz.. </p> <p>We wrote to authors, Lundbeck, Forest, Merz and Daiichi Asubio for details about various studies as detailed in <a href="./references#CD003154-sec-0164" title="">Characteristics of included studies</a>. </p> <p>Additionally, we were aware of conference posters reporting data from the <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a> study. Review author RMcS had access to additional data from the <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a> study ‐ therefore we also included this information. </p> </section> </section> <section id="CD003154-sec-0045"> <h3 class="title" id="CD003154-sec-0045">Data collection and analysis</h3> <section id="CD003154-sec-0046"> <h4 class="title">Selection of studies</h4> <p>For this update, the abstracts of references newly retrieved by the search since the search conducted for the previously published version of this review were read by review authors MW, ER, JD or LF and checked by RMcS. Any disparity in the final lists was resolved by discussion in order to arrive at the final list of included studies. </p> </section> <section id="CD003154-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For all studies conducted since the introduction of ICH‐GCP (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ‐ Good Clinical Practice), we assumed that sequence generation, allocation concealment and blinding were all adequate and carried a low risk of bias. This was informed by prior findings, which were confirmed in the current review, of a low incidence of side‐effects which could potentially unmask allocation. </p> <p>Incomplete outcome data due to participant dropout is a very common problem in dementia trials. We recorded the number of participants in each arm who did not have outcome data at the measurement point, alongside the reasons for 'missingness', and we calculated for each arm the proportion missing of those randomised. We used this approach to missing data, regardless of the method of analysis (see <a href="#CD003154-sec-0049">Dealing with missing data</a>). In assessing risk of attrition bias for the continuous efficacy outcomes, we considered the following factors: the level of missing data, the difference between groups and the reasons for missingness. We also took into account whether the approach to missing data (e.g. observed case (OC) or last observation carried forward (LOCF)) gave different effect estimates. For the adverse events dichotomous outcome, we compared the proportions missing in each group with each other and with the adverse event risk. If there were substantial differential missing data or the missing data proportion was comparable with the adverse events risk, we rated the risk of attrition bias as high. </p> <p>A further common problem is reporting bias, in which positive trials, or positive results within trials, are preferentially reported. We used funnel plots to assess whether results reported solely in trial registries were more likely to be positive than those published in peer review literature, or whether there were likely to be 'unknown unknowns': trials whose existence was not apparent despite the systematic searching. We noted in the 'Risk of bias' tables when outcomes had not been reported at all, but did not assign high risk of outcome reporting bias. Instead, we presented the results in forest plots for those studies that were known to exist, but for which no data were available. This approach did not alter estimates of effect size but was designed to show the extent of the ‘known unknowns’. In the absence of definitive information, we assumed that the numbers in the placebo and drug arms were the same. Then, for GRADE assessment, we considered downgrading on risk of bias if the potential contribution from missing studies could affect the summary statistics for studies with available data for that outcome. </p> </section> <section id="CD003154-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>As described in <a href="#CD003154-sec-0041">Types of outcome measures</a>, the analysis is focused on the five domains of clinical global, cognitive function, performance on activities of daily living (ADL) function, behaviour and adverse events. The measures used are described in more detail in <a href="./appendices#CD003154-sec-0136">Appendix 2</a>. <a href="#CD003154-tbl-0003">Table 1</a> details which measures were used in the AD and vascular dementia studies. For data on adverse events, we sought the numbers in each treatment group and the numbers experiencing the outcome of interest. </p> <div class="table" id="CD003154-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Efficacy outcome measures in Alzheimer's disease (AD) and vascular dementia trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Clinical Global</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cognitive function</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Decline in ADL</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Behaviour and mood</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIBIC‐Plus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CGIC/<br/> CGI‐I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CDR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADAS‐<br/> Cog</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SIB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADCS‐<br/> ADL23</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADL‐19</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BADLS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BGP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DAD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NPI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BEHAVE<br/> ‐AD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alzheimers' disease studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese versions.</p> <p>DAD, Caregiver‐rated Crichton Scale, MMSE, CDR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese versions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE, Caregiver activity survey</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI nursing home version; CMAI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI, NPI‐Agitation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI, MMSE, QOL‐AD, incidence of agitation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FLCI, ASHA FACS (caregiver assessment)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DriveABLE On‐Road Test, MMSE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese versions.MMSE, FAST, BEHAVE‐AD. ADL scale not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EQ‐5D, GHQ‐12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Final values only, no change scores</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese versions; Crichton scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDR sum of boxes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FAST; ADL modified for severe dementia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE; ADL scale not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FAST</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE, ADAS‐Cog</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in total brain volume, Agitation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="15" rowspan="1" valign=""> <p><b>Vascular Dementia or dementia syndrome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (PGI scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician's Global Impression, Syndrom Kurztest, SCAG; ADL scale not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GBS, Tapping test, Trace test, SCAG; modified ADL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (NOSGER)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (NOSGER)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGIC, GBS, MMSE, NOSGER subscales for self‐care ADL and disturbing behaviour</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment of clinical efficacy, NOSIE‐Index, SCAG</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (NOSGER)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (NOSGER)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOSGER subscales for self‐care ADL and disturbing behaviour</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (BGP<br/> cognitive subscale) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D‐scale, AD subgroup also reported</p> </td> </tr> </tbody> </table> </div> <p>For analysis, we transformed the data so that all outcomes were treated as negative (i.e. a higher score indicating a worse result), as is usual in the dementia field. We transformed data for individual scales for some outcomes, but for the outcome, functional performance on ADL ‐ a positive outcome ‐ we converted the positive emphasis into a negative one, analysing the outcome as a 'lack of functional performance on ADL' and reversing the sign of the change scores. For the purposes of analysis, we have described the outcome as a 'decline in ADL'. </p> <p>For interpretation of this outcome, however, we discuss the clinical effect in terms of the functionality itself, reporting the performance on ADL (so, a mean difference of 1.07 points between memantine and placebo is a clinical <i>benefit</i>). </p> </section> <section id="CD003154-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>People with dementia often drop out from studies. The treatment of such missing data is controversial. The options include: (1) ignore participants who drop out and present data only on those who complete the trial and the final assessment ('completers' ‐ closely related to 'observed case' (people who had an observation at the end point) and 'per protocol' analyses); (2) impute a value of 'no change from baseline' for those who were randomised but dropped out; (3) carry forward the last value obtained from whatever time point, as if it were the value for the final time point (last observation carried forward (LOCF)); (4) include people who have dropped out of the trial but have been encouraged to return for scheduled assessments ('retrieved dropouts'); or (5) use mixed methods to take into account the data at several time points. </p> <p>In dementia, which is characterised by progressive decline, the final (latest) scores for participants who drop out early will, on average, be closer to the baseline values (i.e.less severe) than for those who do not. The use of LOCF in ChEI trials has been criticised because the higher dropout rates on drug meant that it inflated estimates of the drug effect. However, when dropout rates are lower in those taking the active drug than amongst those taking placebo, the LOCF technique yields a more conservative estimate of the size of the effect of the drug than analysis of 'observed cases'. Given that a lower dropout rate on drug probably reflects a beneficial effect of the drug, this is illogical and suggests that preference for the LOCF strategy in such cases reflects either misunderstanding or mere conservatism. The 'retrieved dropout' approach may reflect better the effectiveness of the drug, but large amounts of missing data, especially differential missing data, can still lead to more conservative results. Imputation of 'no change from baseline' is the most conservative analytical strategy. The high rates of dropout in dementia trials due to factors such as caregiver and patient physical ill health mean that the use of any of these strategies reduces the power of studies to show any effect, even if real. If these results are applied in cost‐effectiveness modelling, the benefit of a drug will be underestimated because of underestimated efficacy, and also because the costs incurred by those who do not continue the drug or placebo will be less. </p> <p>Because of this controversy, peer reviewed publications typically present both OC and LOCF analyses. This is not the case with summary results presented in trial registries, and in the memantine trials, registries usually, but not invariably, present OC data. </p> <p>In this review, we planned to use OC analyses wherever possible, but in some analyses, we had to pool trials reporting OC and LOCF data. This is made explicit in the footnotes of the relevant forest plots. We assessed the impact of this OC approach in a sensitivity analysis, which compared the results of analyses based on the two main approaches (OC and LOCF). The sensitivity analysis supported our strategy of using OC analyses in the rest of the review. We reported explicitly the degree of missing data in the <a href="./references#CD003154-sec-0164" title="">Characteristics of included studies</a>. Where mixed methods or area‐under‐the curve methods were reported by study authors, we extracted results from these analyses only if OC results were unavailable. For the <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a> study, a per protocol analysis was conducted (this excluded participants who received less than 70% of their treatment) and we used this analysis in preference to retrieved dropout, mixed‐methods analysis or imputation methods, as being the closest to OC. </p> </section> <section id="CD003154-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We used standard Cochrane meta‐analysis methods through RevMan 5.3. Data for the meta‐analyses were the reported raw data for each study. The data required for each trial and each outcome for continuous data were the mean change from baseline, the standard deviation of the mean change, and the number of participants for each treatment group. Where changes from baseline were not reported, we extracted the mean, standard deviation and the number of participants for each treatment group at study end. For the global impression of change outcome, the endpoint itself is of clinical relevance as all participants are by definition at the same baseline score. For some studies, we calculated th standard deviation (same for each group) using the P value for the mean difference (MD); this allowed analysis of the data using the standardised mean difference (SMD). </p> <p>The summary statistics calculated by meta‐analysis of the continuous outcomes were (i) the MD, with its 95% confidence interval (CI), used when the pooled trials had the same rating scale or test, and (ii) the SMD ‐ the absolute MD divided by the standard deviation ‐ when the trials used different rating scales to assess a particular domain. Where different scales had different directions, we reversed the signs for the mean change from baseline values before conducting meta‐analysis (for example, in the ADAS‐Cog and SIB scales for cognitive impairment, higher values indicate greater and less impairment, respectively ‐ see <a href="./appendices#CD003154-sec-0136">Appendix 2</a> ‐ so we reversed the signs for results on the SIB scale). </p> <p>At the outset, we conducted separate analyses for dementia of different aetiologies (AD; vascular dementia; Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB); Frontotemporal dementia (FTD) and AIDS Dementia Complex). </p> <p>As described in the section <a href="#CD003154-sec-0049">Dealing with missing data</a>, we used the OC approach to missing data, wherever possible, but otherwise used what was reported by the study authors. </p> <p>We initially combined all trials in AD, regardless of trial duration, severity of dementia or the presence of concomitant cholinesterase inhibitor (ChEI), and then examined these factors in pre‐specified subgroup analyses. </p> </section> <section id="CD003154-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We assessed heterogeneity using the I² statistic (<a href="./references#CD003154-bbs2-0199" title="HigginsJP , GreenS (editors) . Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and by inspecting forest plots. An I² of more than 50% suggests that studies within an analysis may not be sufficiently similar for pooling to be valid. In such circumstances, we conducted sensitivity and subgroup analyses to examine the cause of the heterogeneity. We also examined the variability of the point estimates and the overlap of the confidence intervals, when I² values were less than 50%. Where there was evidence of heterogeneity we explored this further. Where heterogeneity could not be explained and an I² exceeded 35%, we used a random‐effects model instead of a fixed‐effect model. </p> <p>For this update of the review, we explored, in subgroup analyses, the influence of the following characteristics, which were not specified in the original protocol. </p> <p> <ol id="CD003154-list-0005"> <li> <p>Trial duration (&lt; six months; six to seven months; &gt; seven months)</p> </li> <li> <p>Severity or stage of AD (mild versus moderate‐to‐severe)</p> </li> <li> <p>Effect of concomitant ChEI</p> </li> </ol> </p> <p>We also conducted meta‐regression using STATA (<a href="./references#CD003154-bbs2-0238" title="StataCorp LLC. Stata data analysis and statistical software. Version 13. College Station, TX: StataCorp LLC, 2013. ">STATA 2013</a>), considering the factors severity and presence of concomitant ChEIs. </p> <section id="CD003154-sec-0052"> <h5 class="title">Methods for subgroup analysis: mild versus moderate‐to‐severe disease</h5> <p>Only one study in AD investigated the effects of memantine solely in people with mild dementia, but, of our primary outcomes, only cognitive function at 12 months follow‐up was reported (<a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>). Some other studies randomised people with mild‐to‐moderate AD (MMSE 10‐23) but data were also available for separate subgroups of participants, either in the published study report or in a published industry‐produced meta‐analysis (<a href="./references#CD003154-bbs2-0245" title="WinbladB , JonesR , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer's disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitve Disorders2007;24(1):20‐7. ">Winblad 2007</a>). The latter reported OC results separately for the subgroup of participants with moderate dementia, giving results for three mild‐to‐moderate AD studies (<a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>. Comparison of these results with the full mild‐to‐moderate OC results allowed us to estimate the effect of memantine in mild AD. OC data for the three mild‐to‐moderate trials were kindly provided by Forest Laboratories. </p> <p>To obtain the sample sizes and mean effects for the mild AD subgroup (MMSE from 20 to 23), we subtracted values for the moderate AD subgroup (MMSE 11 to 19), weighted by sample size, from the measures for all participants (MMSE from 11 to 23) (<a href="./references#CD003154-bbs2-0231" title="SchneiderLS , DagermanKS , HigginsJP , McShaneR . Lack of evidence for the efficacy of memantine in mild Alzheimer Disease. Archives Neurology2011;68(8):991‐8. ">Schneider 2011b</a>). We calculated standard deviations of the change scores for the mild subgroup using a standard formula for pooling standard deviations (<a href="./references#CD003154-bbs2-0199" title="HigginsJP , GreenS (editors) . Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>).  We also obtained separate results for the <a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a> study for six‐month data for the mild and moderate subgroups (author communication). </p> <p>None of these four trials in people with mild‐to‐moderate dementia stratified the participants by severity before randomising and therefore there may be imbalance in the patient characteristics across the intervention groups for a particular subpopulation (i.e. risk of selection bias). We noted this post‐hoc splitting in the 'Risk of bias' assessments. </p> </section> </section> <section id="CD003154-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted three sensitivity analyses, either to examine assumptions or to investigate risk of bias. </p> <p> <ol id="CD003154-list-0006"> <li> <p>We assessed the impact of using an OC approach, by comparing the results of analyses based on the two main approaches (OC and LOCF). </p> </li> <li> <p>We also examined the effect of high risk of bias, by conducting a sensitivity analysis in which we excluded from the analysis studies with high risk of bias for at least one domain. </p> </li> <li> <p>We also examined the effect of using the results from post‐hoc subgroups for moderate severity AD, investigating the removal of such studies from the analysis of memantine versus placebo in moderate‐to‐severe AD. </p> </li> </ol> </p> <section id="CD003154-sec-0054"> <h5 class="title">'Summary of findings' table</h5> <p>We present the main results of the review in 'Summary of findings' tables. These tables present key information concerning the certainty of the evidence and the magnitude of the effects of the interventions examined for the main outcomes (<a href="./references#CD003154-bbs2-0232" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. The GRADE approach defines the certainty (formerly 'quality') of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The certainty of a body of evidence involves consideration of within‐study risk of bias, directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD003154-bbs2-0233" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We present the following outcomes in the 'Summary of findings' tables, with a separate table for each key comparison or population group. </p> <p> <ol id="CD003154-list-0007"> <li> <p>Clinical global rating</p> </li> <li> <p>Cognitive function</p> </li> <li> <p>Performance on activities of daily living (ADL)</p> </li> <li> <p>Behaviour and mood</p> </li> <li> <p>Discontinuation (all‐cause)</p> </li> <li> <p>Adverse events and serious adverse events</p> </li> <li> <p>Agitation</p> </li> </ol> </p> <section id="CD003154-sec-0055"> <h6 class="title">'Back transformation' for continuous outcomes</h6> <p>Where an SMD analysis was conducted for continuous outcomes, we presented 'back transformed' effect estimates as the MD with its 95% CI: we transformed the overall standardised effect size to an approximate equivalent score on a particular scale for ease of interpretation (<a href="./references#CD003154-bbs2-0199" title="HigginsJP , GreenS (editors) . Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). This involved multiplying the SMD by the median standard deviation for studies using a particular scale, calculated using the method of Hedges adjusted 'g'. We did this separately for each population and outcome. </p> <p>In some cases (for example, ADL), the most appropriate scale was positive (i.e. the maximum score represented a better result), which potentially led to interpretation difficulties, so in the summary tables we report the baseline scores and the change from baseline on the original scales, but give the back‐transformed MD as absolute values representing improvement; the summary statistics from the analyses are also given (as negative outcomes, see <a href="#CD003154-sec-0048">Measures of treatment effect</a>). </p> <p>We analysed all continuous outcomes except clinical global rating using change scores, so for the 'Summary of Findings' Tables, we presented the control group value in two ways: firstly, as the median of the control group baseline scores for studies reporting that scale; and, secondly, as the median change from baseline for the control group. </p> <p>For dichotomous outcomes, we calculated the absolute risk difference (RD) for the appropriate population using the median control group risk for those studies and the risk ratio (RR) for the analysis. For some outcomes (e.g. adverse events), we calculated the RR across studies in all populations because there were no differences between types or severities of dementia; this maximised the precision. </p> </section> <section id="CD003154-sec-0056"> <h6 class="title">Assessing imprecision</h6> <p>Most of the efficacy outcomes are continuous variables, often reported on different scales. Effect estimates are generally small, but in the dementia field even a small improvement is considered important. Therefore, when assessing imprecision, we used a 'default' value of 400 participants as the optimal information size (OIS) (<a href="./references#CD003154-bbs2-0193" title="GuyattGH , OxmanAD , KunzR , BrozekaJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283–93. ">Guyatt 2011</a>). If the evidence was based on fewer than 400 participants, we considered downgrading for imprecision. If there were more than 400 participants, we downgraded only if the 95% CI crossed the null (zero for MD or SMD) and if the CI included what might be an important benefit or harm or both. This decision was made by agreement between two review authors. </p> <p>For assessing imprecision for dichotomous outcomes, we took into account the number of participants, the number of events, whether the CI crossed a risk ratio of 0.75 or 1.25 (GRADE 'default' values) and the CI around the absolute RD (<a href="./references#CD003154-bbs2-0193" title="GuyattGH , OxmanAD , KunzR , BrozekaJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283–93. ">Guyatt 2011</a>). </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003154-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003154-sec-0057"></div> <section id="CD003154-sec-0058"> <h3 class="title">Description of studies</h3> <p>Studies are described in detail in <a href="./references#CD003154-sec-0164" title="">Characteristics of included studies</a>; <a href="./references#CD003154-sec-0165" title="">Characteristics of excluded studies</a>. In the former table, we report one four‐arm study four times: as two comparisons of memantine versus placebo (with or without vitamin E in both arms), and as post‐hoc subgroups for moderate and mild Alzheimer's disease (AD) for each of these comparisons (<a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>). Four other studies reported results for severity subgroups and for these studies we have also extracted data and assessed risk of bias separately for the subgroups (<a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>; <a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>). Summary details of the participants at baseline are given in <a href="#CD003154-tbl-0004">Table 2</a> for the AD studies. Only three studies had fewer than 50% females ((<a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a> ‐ 3%; <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a> ‐ 35%; <a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a> ‐ 38%). Most studies had a mean age between 70 and 80 years, exceptions were older participants in the <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a> study (mean 85 years) and the <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a> study (mean 84 years) and younger participants in the <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a> study (mean 65 years). </p> <div class="table" id="CD003154-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants in the included studies ‐ Alzheimer's disease (AD)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diagnosis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severity of disease</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean MMSE</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% female</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>duration (weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>MODERATE‐TO‐SEVERE AD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderately severe‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜9.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD Nursing home</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜11.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD agitation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD agitation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe MMSE &lt; 20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD agitation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜74.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜58.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>677</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜74.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe MMSE 5‐14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜10.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>295</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> <p>(52% severe 5 to 9)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜14.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE 5‐18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>546</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜78.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜10.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜72.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderately severe‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>404</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜10.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0050" title="European Medicines Evaluation Agency (EMEA). Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/axura/094802en6.pdf2004:16. WinbladB , GrahamSM , LeesGS , MobiüsHJ , RubyJ , McDonaldS . Efficacy and tolerability of memantine in nursing home patients with severe dementia of the Alzheimer's type. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimor. Feb 21‐24, 2004. 2004. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. ">Winblad 1999 (9403) AD</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜74.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>MILD‐TO‐MODERATE AD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>367</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate MMSE 10‐23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐ to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>470</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate 11‐23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜18.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>307</p> <p>and 306 (vit E)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜79.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜3<br/> (97% male) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜27.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜72.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜22.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜63.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>403</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜75.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜16.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0155" title="WangH‐F , YuJ‐T , TangS‐W , JiangT , TanC‐C , MengX‐F , et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta‐analysis and trial sequential analysis. Journal of Neurology, Neurosurgery, and Psychiatry2015;86(2):135‐43. [DOI: 10.1136/jnnp‐2014‐307659] ">Wang 2015</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜12.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> </tbody> </table> </div> <section id="CD003154-sec-0059"> <h4 class="title">Results of the search</h4> <p>The searches generated a total of 3262 results. After de‐duplication and first assessment based on title and abstract screening, we obtained 264 in full text (<a href="#CD003154-fig-0001">Figure 1</a>). We excluded 113 studies (see <a href="./references#CD003154-sec-0165" title="">Characteristics of excluded studies</a>). We added 32 new randomised controlled trials (RCTs) to the 12 studies in the previous 2006 update. Overall, these 44 studies were described in 148 reports. We are also aware of three ongoing studies (see <a href="./references#CD003154-sec-0166" title="">Characteristics of ongoing studies</a>). </p> <div class="figure" id="CD003154-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram of studies identified" data-id="CD003154-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of studies identified</p> </div> </div> </div> </section> <section id="CD003154-sec-0060"> <h4 class="title">Included studies</h4> <p>Forty‐four studies fulfilled the inclusion criteria, comprising 9811 participants (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>; <a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>; <a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>; <a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>; <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a>; <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>; <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>; <a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>; <a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a>; <a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>; <a href="./references#CD003154-bbs2-0028" title="MedinaLD , GilbertP , PirogovskyEV , et al. Memantine in Huntington's disease: a randomized, double blind, placebo‐controlled pilot study. Neurology Vol. 76, issue 9:A544. ">Medina 2011</a>; <a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>; <a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>; <a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>; <a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0041" title="SchifittoG , NaviaBA , YiannoutsosCT , MarraCM , ChangL , ErnstT , et al. Memantine and HIV‐associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 12 Sep 2007;21(14):1877‐86. ZhaoY , NaviaBA , MarraCM , SingerEJ , ChangL , BergerJ , et al. Memantine for AIDS dementia complex: open‐label report of ACTG 301. HIV clinical trials2010; Vol. 11, issue 1:59‐67. ">Schiﬁtto 2007</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>; <a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>; <a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>). The mean sample size was 223 and the median and range were 182.5 (13 to 677); 20 studies had more than 200 participants. Seven studies were reported solely as registry data or via author communication (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a>; <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>; <a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>; <a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>); and we obtained responses to requests for further information from the authors (or companies) of 16 studies (<a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a>; <a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>; <a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>; <a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>; <a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>). </p> <p>We have not been able to identify the results or any associated publications or announcements belonging to four studies: <a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a> was a 12‐week study in Taiwan of 47 people with AD; <a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a> was a 12‐week study in Portugal of 27 people with 'primary dementia'; <a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a> was a 13‐week study in France of 56 people with AD; and <a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a> was a 14‐week study in Sweden of 56 people with vascular dementia. </p> <p>Trial duration varied from six weeks to 2.27 years (mean), with the majority of studies having a duration of six months. Fourteen studies had a duration of less than six months (<a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>; <a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>; <a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a>; <a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>; <a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>; <a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>; <a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>; <a href="./references#CD003154-bbs2-0041" title="SchifittoG , NaviaBA , YiannoutsosCT , MarraCM , ChangL , ErnstT , et al. Memantine and HIV‐associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 12 Sep 2007;21(14):1877‐86. ZhaoY , NaviaBA , MarraCM , SingerEJ , ChangL , BergerJ , et al. Memantine for AIDS dementia complex: open‐label report of ACTG 301. HIV clinical trials2010; Vol. 11, issue 1:59‐67. ">Schiﬁtto 2007</a>; <a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>). Eight studies reported results at 12 months or longer (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>; <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>; <a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>), and of these, one provided interim results at 30 weeks (<a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>); and three at six months (<a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>). </p> <p>Fifteen trials were conducted in North America: including 14 in the USA (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>; <a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>; <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a>; <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>, <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>; <a href="./references#CD003154-bbs2-0028" title="MedinaLD , GilbertP , PirogovskyEV , et al. Memantine in Huntington's disease: a randomized, double blind, placebo‐controlled pilot study. Neurology Vol. 76, issue 9:A544. ">Medina 2011</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0041" title="SchifittoG , NaviaBA , YiannoutsosCT , MarraCM , ChangL , ErnstT , et al. Memantine and HIV‐associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 12 Sep 2007;21(14):1877‐86. ZhaoY , NaviaBA , MarraCM , SingerEJ , ChangL , BergerJ , et al. Memantine for AIDS dementia complex: open‐label report of ACTG 301. HIV clinical trials2010; Vol. 11, issue 1:59‐67. ">Schiﬁtto 2007</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>), and one in Canada (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). Twenty trials were conducted in Europe, including four in the UK (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>; <a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>); four in Germany (<a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>); two in France (<a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>; <a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a>); one each in Austria (<a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008)</a>; Italy (<a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>); Latvia (<a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>); Portugal (<a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>); Sweden (<a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>); and five in more than one European country (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>; <a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>; <a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>). Four trials were conducted in Japan (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>); two in China (<a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>); and one in Taiwan (<a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>). The other two studies were international trials (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>). </p> <section id="CD003154-sec-0061"> <h5 class="title">Funding</h5> <p>All studies had some funding from industry, with one exception (<a href="./references#CD003154-bbs2-0041" title="SchifittoG , NaviaBA , YiannoutsosCT , MarraCM , ChangL , ErnstT , et al. Memantine and HIV‐associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 12 Sep 2007;21(14):1877‐86. ZhaoY , NaviaBA , MarraCM , SingerEJ , ChangL , BergerJ , et al. Memantine for AIDS dementia complex: open‐label report of ACTG 301. HIV clinical trials2010; Vol. 11, issue 1:59‐67. ">Schiﬁtto 2007</a>), although in three trials the only input was the provision of drugs and the main sponsors were the UK Medical Research Council; the US Veterans Affairs Co‐operative Studies Program and the Bundesministerium fűr Bildung und Forschung (respectively, <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a><a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a> and <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>). </p> <p>Eleven trials were sponsored by Merz Pharmaceuticals GmbH, Germany (<a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>; <a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>; <a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>; <a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>; <a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>; <a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>. Fourteen trials were sponsored by Forest Laboratories Inc, US (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>; <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a>; <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>; <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>; <a href="./references#CD003154-bbs2-0028" title="MedinaLD , GilbertP , PirogovskyEV , et al. Memantine in Huntington's disease: a randomized, double blind, placebo‐controlled pilot study. Neurology Vol. 76, issue 9:A544. ">Medina 2011</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>); and this company also provided drugs for one trial (<a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>).<br/> <br/> Twelve trials were sponsored by H. Lundbeck A/S, Denmark (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>; <a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>; <a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>; <a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>; <a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a>; <a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>; <a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>); and this company also provided drugs for one trial (<a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>). One trial was sponsored by both Merz and Lundbeck (<a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>).<br/> <br/> Four trials were sponsored by Daiichi Sankyo Co. Ltd, Japan (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>). </p> </section> <section id="CD003154-sec-0062"> <h5 class="title">Patient characteristics</h5> <section id="CD003154-sec-0063"> <h6 class="title">Diagnosis</h6> <p>The diagnosis of dementia was established using the latest versions of the Diagnostic and Statistical Manual of Mental Disorders (<a href="./references#CD003154-bbs2-0176" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3th edition revised. Washington D.C.: American Psychiatric Association, 1987. ">DSM III‐R</a>; <a href="./references#CD003154-bbs2-0177" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington D.C.: American Psychiatric Association, 1994. ">DSM IV</a>) in 17 studies (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>; <a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>; <a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>; <a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>; <a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>). Eleven other studies included people diagnosed with probable AD (<a href="./references#CD003154-bbs2-0211" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1994;34:939‐44. ">McKhann 1984</a>), according to the criteria of the National Institute of Neurologic, Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS‐ADRDA) (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>; <a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>); and two studies included people diagnosed with probable or possible AD according to the same criteria (<a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>). The other studies did not report diagnosis by these criteria. </p> </section> <section id="CD003154-sec-0064"> <h6 class="title">Type and severity of dementia</h6> <p>Almost all the studies measured severity of dementia as defined by scores on the Mini Mental State Examination (MMSE) (<a href="./references#CD003154-bbs2-0182" title="FolsteinMF , FolsteinSE , McHughPR . Mini‐mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatry Research1975;12:189‐98. ">Folstein 1975</a>). Three exceptions used the Sandoz Clinical Assessment Geriatric Scale (SCAG) (<a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>). </p> <p>Twenty‐eight studies were in people with AD (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>; <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a>; <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>; <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>; <a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a>; <a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>; <a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>). We also included a subpopulation from a further study (<a href="./references#CD003154-bbs2-0050" title="European Medicines Evaluation Agency (EMEA). Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/axura/094802en6.pdf2004:16. WinbladB , GrahamSM , LeesGS , MobiüsHJ , RubyJ , McDonaldS . Efficacy and tolerability of memantine in nursing home patients with severe dementia of the Alzheimer's type. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimor. Feb 21‐24, 2004. 2004. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. ">Winblad 1999 (9403) AD</a>), which reported an AD subgroup from the study <a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>. These studies randomised a total of 7885 participants with AD. </p> <p>Of these AD studies, one was in people with mild AD (<a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>); nine were in people with mild‐to‐moderate AD (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>; <a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>); two were in people with moderate AD (<a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>); 15 were in people with moderate‐to‐severe AD (<a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a>; <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>; <a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>); and we were unable to establish the severity in one study (<a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>). Three of these studies reporting mean MMSE scores at baseline had a mean score of less than 10, suggesting that at least 50% of participants had severe AD (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>); the <a href="./references#CD003154-bbs2-0050" title="European Medicines Evaluation Agency (EMEA). Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/axura/094802en6.pdf2004:16. WinbladB , GrahamSM , LeesGS , MobiüsHJ , RubyJ , McDonaldS . Efficacy and tolerability of memantine in nursing home patients with severe dementia of the Alzheimer's type. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimor. Feb 21‐24, 2004. 2004. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. ">Winblad 1999 (9403) AD</a> subgroup was selected to have a MMSE score below 10. One of the mild‐to‐moderate AD studies had a mean MMSE score of 22, so most people had mild dementia (<a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>). </p> <p>Three studies involved <b>people with vascular dementia</b>, defined by the NINDS‐AIREN criteria (<a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>; <a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>; <a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>); 956 participants were randomised. One of these studies was in people with 'moderately severe' dementia (but reported no results) (<a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>) and the other two studies recruited people with mild‐to‐moderate dementia. </p> <p>Three short, phase II trials of four to six weeks in 213 participants included <b>both AD and vascular dementia i</b>n various proportions (<a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>); the Hachinski score was used to differentiate between AD and vascular dementia. Two further studies included both AD and vascular dementia, but there is no record of an attempt to distinguish the different types of dementia (<a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>). Two studies included people with mild‐to‐moderate dementia (<a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>); participants in one study had severe dementia (<a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>); participants in one study were equally divided between mild, moderate and severe disease (<a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>); and one study reported "mild to‐moderate severe stages of primary dementia" (<a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>). </p> <p>The remaining studies included participants with other types of dementia: four studies in 319 participants with <b>Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB)</b> (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>; <a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>, <a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>); two studies in 133 participants with <b>frontotemporal dementia (FTD)</b> (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>; <a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a>); one study in 140 participants with <b>HIV AIDS dementia complex</b> (<a href="./references#CD003154-bbs2-0041" title="SchifittoG , NaviaBA , YiannoutsosCT , MarraCM , ChangL , ErnstT , et al. Memantine and HIV‐associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 12 Sep 2007;21(14):1877‐86. ZhaoY , NaviaBA , MarraCM , SingerEJ , ChangL , BergerJ , et al. Memantine for AIDS dementia complex: open‐label report of ACTG 301. HIV clinical trials2010; Vol. 11, issue 1:59‐67. ">Schiﬁtto 2007</a>); and one study in 50 participants with <b>Huntingdon's Disease</b> (this study, however, presented no useable data) (<a href="./references#CD003154-bbs2-0028" title="MedinaLD , GilbertP , PirogovskyEV , et al. Memantine in Huntington's disease: a randomized, double blind, placebo‐controlled pilot study. Neurology Vol. 76, issue 9:A544. ">Medina 2011</a>). </p> <p>Three studies stated they selectively included patients with agitation (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>); 556 participants were randomised. One of these studies investigated treatment for those with agitation living in the community (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>); this study was terminated after recruiting only 34 participants, but reported these results. A second study recruited participants living in the community, who were specifically selected for the presence of agitation and aggression at baseline (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>); the trial was prematurely terminated because of difficulty in recruitment (only recruiting 82% of the planned participants), but reported results. The third study of institutionalised patients with agitation specified a primary outcome of Cohen‐Mansfield Agitation Index (CMAI) score at six weeks (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>). </p> </section> </section> <section id="CD003154-sec-0065"> <h5 class="title">Interventions assessed</h5> <p>The majority of studies randomised participants to memantine at its licensed dose of 20 mg daily (or placebo). One study used an extended release preparation of 28 mg/day, equivalent to 20 mg daily (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>). Two studies investigated a dose of 10 mg/day memantine versus placebo (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>); and two other studies included a 10 mg/day arm, alongside 20 mg/day and placebo (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>). </p> <p>Seven studies compared the efficacy and safety of memantine (versus placebo) in people who were already receiving stable treatment with donepezil (<a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>; <a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12);</a><a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>). Five other studies included some participants who were already on cholinesterase inhibitors (ChEIs): 72% (<a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>); 50% (<a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>); 86% for memantine and 67% for placebo (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>); 19% and 23% (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>); and 18% and 14% (<a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>). Two other studies allowed the continuation of stable ChEIs, but did not state the proportions involved (<a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>; <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>). One study was in people who were anti‐dementia drug naive at baseline and were randomised to memantine plus galantamine (a ChEI) versus placebo plus galantamine (<a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>). </p> <p>One study actively discontinued ChEIs before starting memantine or placebo (<a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; another had participants who had ChEIs discontinued because of a lack of efficacy (<a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>). One four‐arm study included 295 participants who were on stable ChEIs, but were being considered for a change of drug treatment; the participants were randomised to discontinue or continue donepezil, as well as randomising to memantine or placebo (<a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>). One study did not permit ChEIs within 30 days of the trial, although 55% had prior use of donepezil (<a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>). Another study reported previous use of drugs for dementia by the participants, but without specifying types (<a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a>). </p> <p>One four‐arm study randomised 613 participants to concurrent vitamin E or placebo, as well as randomising to memantine or placebo (<a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>). </p> </section> <section id="CD003154-sec-0066"> <h5 class="title">Outcome measures</h5> <p>The range of outcome measures used in the studies is summarised in <a href="#CD003154-tbl-0003">Table 1</a>. </p> <p>Adverse events (AEs) were reported in various ways: the number of people with any AE (at least one per person); the number with at least one serious AE (SAE) and results were also given separately for the number of people with specific AEs (agitation, insomnia, confusion (as an AE), depression, headache, hypertension, dizziness, fall, accidental injury, urinary incontinence, diarrhoea and influenza‐like symptoms). For these specific AEs, registry data were commonly presented separately for AEs and SAEs, but it was unclear whether there was overlap between the set of participants with a specific outcome recorded as an AE and the set of participants with that outcome recorded as an SAE. Therefore, we used results for the AE set only unless the outcome was solely reported as SAEs. </p> <p>Adverse events across all diagnoses and durations are reported in <a href="#CD003154-sec-0075">Effects of interventions</a>, section 5 and also separately for each diagnosis. These analyses were restricted to the 20 mg/day or equivalent dose of memantine. </p> </section> </section> <section id="CD003154-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded 115 studies (<a href="#CD003154-fig-0001">Figure 1</a>) at the full‐text stage. Details are given in the <a href="./references#CD003154-sec-0165" title="">Characteristics of excluded studies</a> table, but the main reasons for exclusion were: 15 were not RCTs; 18 were not double‐blinded; the population in 16 studies did not have dementia (or not solely dementia participants); 16 studies were not placebo controlled; 24 were post‐hoc analyses or had inappropriate ways of combining data; and eight studies compared memantine with other interventions. We obtained the full papers for 11 systematic reviews in order to check the references, but there was no new information found (systematic reviews that did provide additional information were added as references to the included studies). </p> </section> </section> <section id="CD003154-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>A detailed analysis of the risks of bias for each study can be found in <a href="./references#CD003154-sec-0164" title="">Characteristics of included studies</a>. 'Risk of bias' domain ratings are shown per study in <a href="#CD003154-fig-0002">Figure 2</a> and percentage contributions for each domain are shown in <a href="#CD003154-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003154-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003154-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003154-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bia's graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003154-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bia's graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD003154-sec-0069"> <h4 class="title">Allocation</h4> <p>We assessed four studies to be at high risk of selection bias because of large differences in outcome at baseline that were as large or larger than the effect size for most outcomes (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>; <a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>); e.g. in one study (<a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>), 15.3 points baseline difference in Severe Impairment Battery (SIB), four points for MMSE, three points for Neuropsychiatric Inventory (NPI). The <a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a> study had baseline differences despite adequate methods of sequence generation and allocation concealment, and this is recorded as 'other' risk of bias. We considered one study to be at high risk of bias because of differences in the levels of concurrent neuroleptic medications: 33% in the placebo group and 28% in the memantine group, and because of a 10‐point difference in activities of daily living (ADL) at baseline (<a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>). </p> <p>Other studies reporting differences at baseline for particular outcomes that are comparable with the effect estimate are considered in the results sections for those outcomes. </p> </section> <section id="CD003154-sec-0070"> <h4 class="title">Blinding</h4> <p>All studies were double blinded ‐ this was an inclusion criterion ‐ and all were at low risk of bias for this domain. </p> </section> <section id="CD003154-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>We considered three studies to have a high risk of attrition bias for the efficacy outcomes of the review: one very small study had missing data of 43% (memantine) and 0% (placebo) (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>); a second study reported a per protocol analysis at 30 weeks for which excluded data were: 45% (memantine), 60% (placebo); 30% (memantine + donepezil) and 32% (placebo + donepezil); sensitivity analyses comparing the per protocol analysis with a 'completed follow‐up' analysis showed some differences in effect estimate (<a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>). The third study also reported a per protocol analysis for which excluded data were 35% (memantine) and 43% (placebo) (<a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>). </p> </section> <section id="CD003154-sec-0072"> <h4 class="title">Selective reporting</h4> <p>We considered four studies to be at high risk of bias for selective reporting of outcomes: one study decided post hoc to reduce the Clinical Global Impression of Change (CGIC) values to three categories (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>); the second did not report the numbers of participants for the observed case (OC) analysis and we had to make assumptions (<a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>); and the third reported missing scores for some participants that were not explained ( Nurse's Observational Scale for Geriatric Patients (NOSGER) outcomes) (<a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>). Where other studies did not report outcomes or did not provide sufficient data to analyse, we included these studies in the appropriate forest plots and estimated their contribution to the whole meta‐analysis, as described in the <a href="#CD003154-sec-0047">Assessment of risk of bias in included studies</a> section. </p> <p>We also assessed the five studies that reported post‐hoc subgroups to be at high risk of outcome reporting bias for those subpopulations (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0050" title="European Medicines Evaluation Agency (EMEA). Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/axura/094802en6.pdf2004:16. WinbladB , GrahamSM , LeesGS , MobiüsHJ , RubyJ , McDonaldS . Efficacy and tolerability of memantine in nursing home patients with severe dementia of the Alzheimer's type. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimor. Feb 21‐24, 2004. 2004. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. ">Winblad 1999 (9403) AD</a>). </p> </section> <section id="CD003154-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>We recorded three other studies as having high risk of bias because they had an outdated diagnosis of AD (<a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>). We considered one study to be at high risk of bias because the trial was terminated early without explanation given (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>). </p> <section id="CD003154-sec-0074"> <h5 class="title">Overall risk of bias</h5> <p>The overall risk of bias for most studies was either unclear or low (<a href="#CD003154-fig-0002">Figure 2</a>). We considered three studies to have low risk of bias for all domains (<a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a>; <a href="./references#CD003154-bbs2-0011" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken VitE 2014</a>; <a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a>). </p> <p>We assessed two studies to be at high risk of bias for at least two domains (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a> for NOSGER outcomes), and 11 other studies to be at high risk of bias for one domain (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>; <a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>; <a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a>; <a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>; <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>; <a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>). We considered post‐hoc subgroups of five studies to be at high risk of bias for one domain (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0050" title="European Medicines Evaluation Agency (EMEA). Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/axura/094802en6.pdf2004:16. WinbladB , GrahamSM , LeesGS , MobiüsHJ , RubyJ , McDonaldS . Efficacy and tolerability of memantine in nursing home patients with severe dementia of the Alzheimer's type. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimor. Feb 21‐24, 2004. 2004. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. ">Winblad 1999 (9403) AD</a>). </p> </section> </section> </section> <section id="CD003154-sec-0075"> <h3 class="title" id="CD003154-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD003154-tbl-0001"><b>Summary of findings for the main comparison</b> Moderate‐to‐severe AD, six to seven months</a>; <a href="./full#CD003154-tbl-0002"><b>Summary of findings 2</b> Vascular dementia ‐ mild‐to‐moderate severity. six months</a> </p> <p>We present the efficacy results according to the aetiology of the dementia in sections 1 to 3 below. We compare effects across different types of dementia in section 4. We describe safety data, including discontinuation (all‐cause and that due to adverse events) and adverse events outcomes in section 5 for all aetiologies of dementia, represented on the same forest plots, with analyses featuring separate subgroups. </p> <p>We conducted the main analyses as observed case (OC), for the reasons discussed in the <a href="#CD003154-sec-0049">Dealing with missing data</a> section, and also tested the OC approach in sensitivity analyses in comparison with the last observation carried forward (LOCF) approach (<a href="./appendices#CD003154-sec-0137">Appendix 3</a>). </p> <p>We produce a 'Summary of findings' table for most sections (<a href="./full#CD003154-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003154-tbl-0002">summary of findings Table 2</a>; <a href="#CD003154-tbl-0005">Table 3</a>; <a href="#CD003154-tbl-0006">Table 4</a>; <a href="#CD003154-tbl-0007">Table 5</a>; <a href="#CD003154-tbl-0008">Table 6</a>; <a href="#CD003154-tbl-0009">Table 7</a>; <a href="#CD003154-tbl-0010">Table 8</a>). We generally analysed the efficacy outcomes as standardised mean difference (SMD), but back‐transformed to a common scale. Similarly, for dichotomous (safety) outcomes, we calculated the absolute risk difference (RD) for the relevant population. In doing so, we reported safety outcomes either for all trials of memantine (across all aetiologies) or for separate sub‐populations, depending on the safety outcome concerned. </p> <div class="table" id="CD003154-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), six to seven months, memantine with concomitant cholinesterase inhibitors (ChEIs)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg or equivalent compared to placebo, with concomitant ChEI, for moderate‐to‐severe AD. 24‐30 week data. OC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: Alzheimer's disease, moderate‐to‐severe</b> <br/> <b>Intervention</b> : memantine 20 mg or equivalent, with concomitant ChEI<br/> <b>Comparison:</b> placebo, with concomitant ChEI </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CIBIC+)<br/> 7‐point Likert scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The median CIBIC+ score was 4.5 <sup>3</sup> (i.e. deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.21 (0.06 to 0.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 (‐0.32 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1125<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference. Random effects (<a href="./references#CD003154-fig-0026" title="">Analysis 2.8</a>) </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>)] </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function (SIB)<br/> 100‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean SIB score at baseline: 77.6.</p> <p>Mean change from baseline (positive scale): ‐1.2 <sup>4</sup> (i.e. slight deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 2.48 (1.45 to 3.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.24 (‐0.33 to ‐0.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1852<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>) </p> <p>Converted to SIB scale (and scale direction inverted); median SD(pooled) = 10.34.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL: (ADCS‐ADL19)<br/> 54‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ADCS‐ADL19 score at baseline: 34.3.</p> <p>Mean change from baseline (positive scale): ‐2.2 <sup>5</sup> (i.e. deterioration over time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.95 (0.22 to 1.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.13 (‐0.24 to ‐0.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1319<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD for decline in ADL as a negative outcome (<a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>) </p> <p>Converted to ADCS‐ADL19 scale (and scale direction inverted); median SD(pooled) = 7.33. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood (NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median baseline NPI score was 16.5.</p> <p>Median change from baseline (negative scale): 2.80 <sup>6</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 2.20 (1.10 to 3.29)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.18 (‐0.27 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1855<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>) </p> <p>Converted to NPI scale; median SD(pooled) = 12.20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 per 1000<br/> (139 to 175) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.83 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5087<br/> (17 RCTs) 924 events </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR for all moderate‐to‐severe AD studies (apart from those with agitation) (<a href="./references#CD003154-fig-0142" title="">Analysis 16.5</a>). </p> <p>Median control group risk for 6 studies in 2089 people with moderate‐to‐severe AD without agitation, receiving ChEIs (<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 12 fewer people per 1000 discontinued treatment for any cause (95% CI 29 fewer to 7 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>639 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>658 per 1000<br/> (639 to 677) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>). </p> <p>Median control group risk for moderate‐to‐severe AD studies in people receiving ChEIs (<a href="./references#CD003154-fig-0029" title="">Analysis 2.11</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 19 more people per 1000 suffered adverse events<br/> (95% CI 0 to 38 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(93 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6482</p> <p>(19 RCTs)</p> <p>918 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control risk from all AD studies (except those with agitation) (from <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 10 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 21 fewer to 2 more)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 per 1000<br/> (27 to 63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.60 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1225<br/> (5 RCTs) </p> <p>3</p> <p>79 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control group risk for studies in people with moderate‐to‐severe AD without agitation, receiving ChEIs (<a href="./references#CD003154-fig-0031" title="">Analysis 2.13</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 4 fewer people per 1000 suffered agitation as an adverse event<br/> (95% CI 18 fewer to 18 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). We adopt the convention that a negative mean difference always means an improvement (i.e. favouring memantine)<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Some inconsistency or variation in the point estimates (downgraded once for inconsistency) </p> <p><sup>2</sup> 79 events; imprecision around relative effect (CI crossing 1.25 and 0.75)(downgraded twice) </p> <p><sup>3</sup> Median control group values for 3 studies reporting CIBIC+ (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>) </p> <p><sup>4</sup> Mean control group baseline scores and mean control group change from baseline for 2 studies reporting SIB (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>) </p> <p><sup>5</sup> Mean control group baseline scores and mean control group change from baseline for the 2 studies reporting ADCS‐ADL19 (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>) </p> <p><sup>6</sup> Median control group baseline scores and median control group change from baseline for the 5 studies reporting NPI (<a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>) </p> </div> </div> <div class="table" id="CD003154-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), six to seven months, monotherapy</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg or equivalent compared to placebo, monotherapy, for moderate‐to‐severe AD. 24‐to 30‐week data observed case (OC)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: Alzheimer's disease, moderate‐to‐severe</b> <br/> <b>Intervention</b> : memantine 20 mg or equivalent, as monotherapy<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global<br/> (CIBIC+) </p> <p>7‐point Likert scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The median CIBIC+ score was 4.64 <sup>3</sup> (i.e. deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.22 (0.11 to 0.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.30 to ‐0.10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1672<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>). </p> <p>Converted to CIBIC+ scale; median SD(pooled) = 1.09.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function<br/> (SIB) </p> <p>100‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median SIB score at baseline: 68.3.</p> <p>Median change from baseline (positive scale): ‐5.6 <sup>4</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 3.97 (2.77 to<br/> 5.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.33 (‐0.43 to ‐0.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1485<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>) </p> <p>Converted to SIB scale (and scale direction inverted); median SD(pooled) = 12.04.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL<br/> (ADCS‐ADL19)<br/> 54‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ADCS‐ADL19 score at baseline: 30.5.</p> <p>Mean change from baseline (positive scale): ‐4.1<sup>5</sup> (i.e. deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 1.33 (0.20 to 2.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.30 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1368<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD for decline in ADL as a negative outcome (<a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>) </p> <p>Converted to ADCS‐ADL19 scale (and scale direction inverted); median SD(pooled) = 6.67. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood</p> <p>(NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median baseline NPI score was 18.5.</p> <p>Median change from baseline (negative scale): 1.95 <sup>6</sup> </p> <p>(i.e. slight deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 1.57 (0.16 to 2.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.10 (‐0.19 to ‐0.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1819<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>) </p> <p>Converted to NPI scale; median SD(pooled) = 15.70.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175 per 1000<br/> (156 to 196) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.83 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5087<br/> (17 RCTs) </p> <p>924 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR for all studies in people with moderate‐to‐severe AD (apart from those with agitation) (<a href="./references#CD003154-fig-0142" title="">Analysis 16.5</a>). </p> <p>Median control group risk for 10 studies in 2459 people with moderate‐to‐severe AD without agitation, receiving monotherapy (<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 13 fewer people per 1000 discontinued treatment for any cause (95% CI 32 fewer to 8 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>760 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>783 per 1000<br/> (760 to 806) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>).Median control group risk for moderate‐to‐severe AD studies in people receiving monotherapy (<a href="./references#CD003154-fig-0029" title="">Analysis 2.11</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 23 more people per 1000 suffered adverse events<br/> (95% CI 0 to 46 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(93 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6482</p> <p>(19 RCTs)</p> <p>918 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control risk from all AD studies (except those with agitation) (from <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 10 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 21 fewer to 2 more)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 per 1000<br/> (84 to 149) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/> (0.51 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1016<br/> (4 RCTs) </p> <p>154 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control group risk for studies in people with moderate‐to‐severe AD without agitation, receiving monotherapy (<a href="./references#CD003154-fig-0031" title="">Analysis 2.13</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 52 fewer people per 1000 suffered agitation as an adverse event<br/> (95% CI 80 to 15 fewer) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Some inconsistency in point estimates, but insufficient to downgrade </p> <p><sup>2</sup> Some imprecision (193 events and borderline for CI crossing 1; CI crossed 0.75) and some inconsistency in point estimates ‐ downgrade once overall </p> <p><sup>3</sup> Median control group values for 4 studies reporting CIBIC+ (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>) </p> <p><sup>4</sup> Median control group baseline scores and mean control group change from baseline for 3 studies reporting SIB (<a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>) </p> <p><sup>5</sup> Mean control group baseline scores and mean control group change from baseline for the 2 studies reporting ADCS‐ADL19 (<a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>) </p> <p><sup>6</sup> Median control group baseline scores and median control group change from baseline for the 4 studies reporting NPI (<a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>) </p> </div> </div> <div class="table" id="CD003154-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), selected for agitation</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg or equivalent compared to placebo, for moderate‐to‐severe AD, selected for agitation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: Alzheimer's disease, moderate‐to‐severe, selected for agitation</b> <br/> <b>Intervention</b> : memantine 20 mg or equivalent<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global<br/> (CIBIC+) </p> <p>7‐point Likert scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The CIBIC+ score from one study was 4.63 <sup>5</sup> (i.e. deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.14 (‐0.17 to 0.44)</p> <p>(random effects)</p> <p>24 week study only:</p> <p>MD: ‐0.05 (‐0.35 to 0.25) (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.11 (‐0.34 to 0.13) (random effects)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>443<br/> (3 RCTs) </p> <p>24 week study: 275 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0037" title="">Analysis 3.5</a>). </p> <p>Heterogeneity between 12 weeks (2 studies) and 24 weeks.</p> <p>Converted to CIBIC+ scale; SD(pooled) = 1.29 (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function<br/> (SIB) </p> <p>100‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean SIB score at baseline: 68.1.</p> <p>Median change from baseline (positive scale): ‐5.23 <sup>6</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 4.34 (‐5.89 to<br/> 14.58) (random effects) </p> <p>24 week study only:</p> <p>MD: ‐0.48 (‐2.57 to 1.61) (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.24 (‐0.84 to 0.36)</p> <p>(random effects)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0038" title="">Analysis 3.6</a>). </p> <p>[SMD as a negative outcome]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL<br/> (ADCS‐ADL19)<br/> 54‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ADCS‐ADL19 score at baseline: 32.5.</p> <p>Mean change from baseline (positive scale): ‐1.08<sup>7</sup> (i.e. slight deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: ‐1.48 (‐3.15 to 0.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (‐0.02 to 0.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0039" title="">Analysis 3.7</a>) </p> <p>[SMD for decline in ADL as a negative outcome]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood</p> <p>(NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median baseline NPI score was 33.3.</p> <p>Median change from baseline (negative scale): ‐8.6 <sup>8</sup> </p> <p>(i.e. improvement with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 1.51 (‐5.03 to 8.05)</p> <p>(random effects)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.07 (‐0.41 to 0.27)</p> <p>(random effects)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (random effects) (<a href="./references#CD003154-fig-0040" title="">Analysis 3.8</a>) </p> <p>[SMD as a negative outcome]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> <p>(Cohen Mansfield Agitation Inventory)</p> <p>range 29 ‐ 203 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean baseline CMAI score was 57.7</p> <p>Mean change from baseline (negative score) was ‐6.1<sup>9</sup> (i.e. improvement with time) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD: 0.50 (‐3.71 to 4.71)</p> <p>(random effects)</p> <p>2 studies in 422 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (‐0.12 to 0.33)</p> <p>2 studies in 306 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>455</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD and SMD as negative outcomes</p> <p>(<a href="./references#CD003154-fig-0033" title="">Analysis 3.1</a>; <a href="./references#CD003154-fig-0034" title="">Analysis 3.2</a>). </p> <p>One study reported final scores (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>), so not included in SMD. One study reported CMAI‐C (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>), so not included in MD meta‐analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188 per 1000<br/> (135 to 260) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10 (0.79 to 1.52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>555<br/> (3 RCTs) </p> <p>113 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR for all 3 studies in people with moderate‐to‐severe AD selected for agitation (<a href="./references#CD003154-fig-0041" title="">Analysis 3.9</a>). </p> <p>Median control group risk for 3 studies in 555 people with moderate‐to‐severe AD selected for agitation (<a href="./references#CD003154-fig-0041" title="">Analysis 3.9</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 17 more people per 1000 discontinued treatment for any cause (95% CI 36 fewer to 89 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>618 per 1000<br/> (600 to 636) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>).Mean control group risk for 2 moderate‐to‐severe AD studies in people selected for agitation (<a href="./references#CD003154-fig-0043" title="">Analysis 3.11</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 18 more people per 1000 suffered adverse events<br/> (95% CI 0 to 36 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Inconsistency in point estimates between 24 week and 12 week studies (downgrade once); imprecision (crossed null and SMD 0.30) (downgrade once) </p> <p><sup>2</sup> Inconsistency between 24 week and 12 week studies (I² =90%) (downgrade twice); imprecision (very wide CI crossing SMD +0.30 and ‐0.30 (downgrade twice) </p> <p><sup>3</sup> Imprecision (crossed null and SMD 0.40) (downgrade once); some inconsistency in point estimates and risk of bias from baseline differences (downgrade once across the two domains) </p> <p><sup>4</sup> Inconsistency (I² = 62%, P = 0.07) (downgrade once); risk of bias (due to baseline differences) (downgrade once); imprecision (wide CI: SMD crossing ‐0.2 and 0.4) (downgrade twice) </p> <p><sup>5</sup> Control group value for 1 study reporting CIBIC+ (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>)) </p> <p><sup>6</sup> Mean control group baseline scores and mean control group change from baseline for 2 studies reporting SIB (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> <p><sup>7</sup> Mean control group baseline scores and mean control group change from baseline for the 2 studies reporting ADCS‐ADL19 (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> <p><sup>8</sup> Median control group baseline scores and median control group change from baseline for the 3 studies reporting NPI (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> <p><sup>9</sup> Mean control group baseline scores and mean control group change from baseline for the 2 studies reporting CMAI (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> <p><sup>10</sup> Some inconsistency for two studies reporting CMAI and some imprecision (SMD crossing 0.3 and null) (downgrade once overall) </p> <p><sup>11</sup> Imprecision (113 events) (downgrade once) </p> </div> </div> <div class="table" id="CD003154-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of findings: mild Alzheimer's disease (AD) (MMSE 20 to 23) observed case (OC) ‐ six‐month studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg compared to placebo for mild AD (MMSE 20‐23) observed case (OC) ‐ six‐month studies for dementia</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: mild Alzheimer's disease</b> <br/> <b>Intervention</b> : memantine 20 mg<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo<br/> (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CIBIC+)<br/> 7‐point Likert scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median CIBIC+ score<br/> was 4.1 <sup>5</sup> (i.e. no change with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.09 (‐0.12 to 0.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.08 (‐0.27 to 0.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0045" title="">Analysis 4.1</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0138" title="">Analysis 16.1</a>)] </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function (ADAS‐Cog)<br/> 70‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline ADAS‐Cog scores not reported.</p> <p>Median change from baseline in ADAS‐Cog score (negative scale): ‐1.7 <sup>6</sup> (i.e. improvement with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.21 (‐0.95 to 1.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03 (‐0.19 to 0.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>619<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0046" title="">Analysis 4.2</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0139" title="">Analysis 16.2</a>).] </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL (ADCS‐ADL23)<br/> 78‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline ADL scores not reported.</p> <p>Median change from<br/> baseline in ADCS‐ADL23<br/> (positive scale) was ‐0.34 <sup>7</sup> (i.e. no change with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: ‐0.07 (‐1.80 to 1.66)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (‐0.14 to 0.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference for decline in ADL (<a href="./references#CD003154-fig-0047" title="">Analysis 4.3</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0140" title="">Analysis 16.3</a>)] </p> <p>Direction of scale reversed for ADL outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and mood: (NPI)<br/> 144‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline NPI scores not reported.</p> <p>Median change from baseline in NPI was ‐2.4</p> <p>(i.e. slight improvement with time) <sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: ‐0.29 (‐2.16 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (‐0.14 to 0.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference.</p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0141" title="">Analysis 16.4</a>)]. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174 per 1000<br/> (108 to 281) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.74<br/> (1.08 to 2.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>528<br/> (4 RCTs) </p> <p>72 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control group risk for mild AD studies (<a href="./references#CD003154-fig-0142" title="">Analysis 16.5</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 74 more people per 1000 discontinued treatment for any cause (95% CI 8 to 181 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442 per 1000<br/> (429 to 455) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>).Control group risk taken from <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a> study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Difference: 13 more people per 1000 suffered adverse events<br/> (95% CI 0 to 26 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(93 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6482</p> <p>(19 RCTs)</p> <p>918 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control risk from all AD studies (except those with agitation) (from <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 10 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 21 fewer to 2 more)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported by any study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> All studies are post‐hoc subgroups (downgrade once on risk of bias); imprecision ‐ 427 patients and SMD estimate crosses null and is consistent with appreciable benefit and no benefit (downgrade once) </p> <p><sup>2</sup> All studies are post‐hoc subgroups (downgrade once on risk of bias) </p> <p><sup>3</sup> All studies are post‐hoc subgroups (downgrade once on risk of bias) and some inconsistency in the point estimates (but not sufficient to downgrade) </p> <p><sup>4</sup> Majority of the information from post‐hoc subgroups (downgrade once on risk of bias); imprecision: 72 events, and CI crossed 1.25 (downgrade once); inconsistency (I² = 49%) downgrade once </p> <p><sup>5</sup> Median control group values for 3 studies reporting CIBIC+ (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>) </p> <p><sup>6</sup> Median control group change from baseline for 4 studies reporting ADAS‐Cog (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>) </p> <p><sup>7</sup> Median control group change from baseline for the 4 studies reporting ADCS‐ADL23 (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>) </p> <p><sup>8</sup> Median control group change from baseline for the 4 studies reporting NPI (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>) </p> </div> </div> <div class="table" id="CD003154-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of findings: Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine compared to placebo for Parkinson's disease dementia (PDD) and Dementia with Lewy Bodies (DLB)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB)<br/> <b>Intervention</b> : memantine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CIBIC+)</p> <p>7‐point Likert scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIBIC+ score from 1 study was 4.1 (i.e. no change)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.49 (0.13 to 0.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.35 (‐0.60 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0058" title="">Analysis 6.1</a>) </p> <p>Back transformed to CIBIC+ scale using SD(pooled) = 1.39 (from 1 study (<a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>)). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function: (MMSE)</p> <p>30‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE score: 20.0 (at 24 weeks).</p> <p>Change from baseline (positive scale): ‐0.5 (i.e. slight deterioration with time)</p> <p>(one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 1.9 (0.07 to 3.73)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.50(‐1.00 to 0.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study at 24 weeks and one at 16 weeks only for this outcome; highly heterogeneous.</p> <p>So 24 week study reported only (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>). MMSE scale direction was reversed (<a href="./references#CD003154-fig-0059" title="">Analysis 6.2</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL (ADCS‐ADL23)</p> <p>78‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADCS‐ADL23 score at baseline: 48</p> <p>Change from baseline (positive scale): ‐0.1 (i.e. no change with time)</p> <p>(one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 3.07 (‐1.25 to 7.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.27 (‐0.67 to 0.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD decline in ADL as a negative outcome (<a href="./references#CD003154-fig-0060" title="">Analysis 6.3</a>). Random effects. </p> <p>Back transformed to ADCS‐ADL23 scale, using results from one study (<a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>). SD(pooled) = 11.38. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood</p> <p>(NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median NPI score at baseline: 13.0</p> <p>Median change from baseline (negative scale): 1.4<br/> (i.e. slight deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 2.18 (‐1.21 to 5.57)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.18 (‐0.43 to 0.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random effects. Analysed as mean difference (<a href="./references#CD003154-fig-0061" title="">Analysis 6.4</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0076" title="">Analysis 8.4</a>)] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause</p> <p>discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169 per 1000<br/> (111 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.55 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>312<br/> (4 RCTs) </p> <p>64 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from PDD or DLB studies (<a href="./references#CD003154-fig-0062" title="">Analysis 6.5</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 32 fewer people per 1000 discontinued treatment for any cause<br/> (95% CI 90 fewer to 56 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at</p> <p>least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>515 per 1000<br/> (500 to 530) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>). Median control group risk for PDD or DLB studies (<a href="./references#CD003154-fig-0064" title="">Analysis 6.7</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 15 more people per 1000 suffered adverse events<br/> (95% CI 0 to 30 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at</p> <p>least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> <p>(59 to 255)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.43<br/> (0.69 to 2.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220</p> <p>(2 RCTs)</p> <p>26 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from PDD or DLB studies (<a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 37 more people per 1000 suffered serious adverse events</p> <p>(95% CI 27 fewer to 169 more)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number suffering agitation as an adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported for either study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Majority of the information at high risk of bias and number of patients estimated (downgrade once); imprecision ‐ 243 patients (below optimal information size) (downgrade once) </p> <p><sup>2</sup> Reporting bias (2 larger studies did not report outcome) and high risk of bias for remaining study (downgrade once), inconsistency with 16 weeks study high (I² = 75%) (downgrade once), imprecision (only 63 patients, wide CI) (downgrade once) </p> <p><sup>3</sup> Majority of information at high risk of bias (downgrade once), inconsistency in point estimates (I² = 40%) (downgrade once) and imprecision (243 participants and CI crossed null and consistent with both benefit and no difference) (downgrade once) </p> <p><sup>4</sup> Majority of information at high risk of bias (downgrade once), some inconsistency in point estimates (I² = 20%) (not downgraded) and imprecision (243 patients; CI crossed null and included benefit and no difference) (downgrade once) </p> <p><sup>5</sup> Imprecision: CI crossed both 1.25 and 0.75, and CI fairly wide around absolute effect (downgrade twice) </p> </div> </div> <div class="table" id="CD003154-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Summary of findings: frontotemporal dementia (FTD)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine compared to placebo for Frontotemporal dementia (FTD)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : frontotemporal dementia<br/> <b>Intervention</b> : memantine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CGIC)</p> <p>7‐point Likert scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGIC score from 1 study was 4.8</p> <p>(i.e. deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.56 (‐0.11 to 1.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.31 (‐0.67 to 0.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0065" title="">Analysis 7.1</a>) </p> <p>Back transformed to CGIC scale using SD (pooled) = 1.80 (from 1 study (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive Function: (MMSE)</p> <p>30‐point scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE score: 25.1 (at 26 weeks).</p> <p>Change from baseline (positive scale): ‐0.9 (i.e. deterioration with time)</p> <p>(one study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐0.30 (‐1.83 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09 (‐0.35 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study at 6 months and one at 12 months for this outcome; some heterogeneity so 6‐month study reported only (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>) </p> <p>(<a href="./references#CD003154-fig-0066" title="">Analysis 7.2</a>). MMSE scale direction was reversed.<br/> [SMD as a negative outcome (<a href="./references#CD003154-fig-0074" title="">Analysis 8.2</a>)] </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL</p> <p>% DAD score = yes at 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline score: 58.3%. Change from baseline (positive scale): ‐19.5% (i.e. deterioration)</p> <p>(one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 12.10% (‐1.40 to 25.60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decline in ADL not reported in either study. Percentage with DAD score = yes reported in <a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a> at 12 months. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood</p> <p>(NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI score at baseline: 21.5.</p> <p>Change from baseline (negative scale): 0.3<br/> (i.e. no difference) (one study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 3.16 (‐3.61 to 8.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.17 (‐0.62 to 0.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0067" title="">Analysis 7.3</a>). </p> <p>Baseline score and change from baseline for 26‐week study (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0076" title="">Analysis 8.4</a>)] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause</p> <p>discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109 per 1000<br/> (38 to 288) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.54 (0.54 to 4.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>133<br/> (2 RCTs) </p> <p>15 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from FTD studies; control group risk from 26 week study (<a href="./references#CD003154-fig-0068" title="">Analysis 7.4</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 38 more people per 1000 discontinued treatment for any cause (95% CI 33 fewer to 217 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at</p> <p>least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>687 per 1000<br/> (667 to 707) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>).Control group risk for 26‐week FTD study </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 20 more people per 1000<br/> suffered adverse events<br/> (95% CI 0 to 40 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one severe adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> <p>(14 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.30 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>133</p> <p>(2 RCTs)</p> <p>17 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from FTD study at 26 weeks (<a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 14 fewer people per 1000<br/> suffered adverse events<br/> (95% CI 34 fewer to 32 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000 (0.5 to 208)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21<br/> (0.01 to 4.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>81 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from FTD study at 26 weeks (<a href="./references#CD003154-fig-0072" title="">Analysis 7.8</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 38 fewer people per 1000<br/> suffered adverse events<br/> (95% CI 48 fewer to 160 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Majority of the information at high risk of bias (downgrade once); imprecision ‐ 117 patients (below optimal information size) (downgrade once) </p> <p><sup>2</sup> Inconsistency in point estimates (I² = 23%) (downgrade once) and Imprecision (122 patients and wide confidence interval) (downgrade twice) </p> <p><sup>3</sup> Imprecision (39 participants and CI crossed null and consistent with both benefit and no difference) (downgrade twice); indirect outcome (percentage DAD score at 12 months) and borderline high risk of bias (differential missing data) (downgrade once) </p> <p><sup>4</sup> Some inconsistency in point estimates and Imprecision (122 patients and wide confidence interval) (downgrade twice overall) </p> <p><sup>5</sup> Inconsistency in point estimates (downgrade once); Imprecision: 15 events and CI crossed both 1.25 and 0.75 (downgrade twice) </p> <p><sup>6</sup> Imprecision: 17 events and wide CI (downgrade twice) </p> <p><sup>7</sup> Imprecision: 2 events and very wide CI (downgrade twice): high risk of bias ‐ number discontinuing treatment greater than number of events (downgrade twice) </p> </div> </div> <section id="CD003154-sec-0076"> <h4 class="title">1. Alzheimer's disease (AD)</h4> <section id="CD003154-sec-0077"> <h5 class="title">1.1. Results for all studies in people with AD: trial selection</h5> <p>Twenty‐nine studies reported the effect of memantine in people with AD, however, we did not include five of these studies in the main analyses: three studies concerned participants selected for agitation or aggression and we treated this group separately because we considered this to be a different sub‐population (see section 1.4) (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>. Secondly, it was necessary to analyse the main efficacy outcomes using the SMD because the studies employed different scales; therefore, we had to exclude from the efficacy analyses two studies reporting only final values (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>). In addition, in a post‐hoc decision, we excluded from the analyses results for two of the four arms in one study: the comparison of memantine versus placebo, in the presence of vitamin E (<a href="./references#CD003154-bbs2-0011" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken VitE 2014</a>). This was because a negative interaction between memantine and vitamin E was identified by the authors for their primary outcome (decline in activities of daily living (ADL), P = 0.03), which persisted at all time points in the four‐arm study. Finally, for one study, there was a discrepancy in the one‐year results between the unpublished poster (which reported standard deviations) and the full paper (which did not) for their ADL outcome, so we also omitted this study for the outcome, decline in ADL (<a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>). </p> <p>We therefore included data from 24 trials in 7102 randomised participants with AD, using the OC approach to missing data, whenever possible. For most outcomes, there was too much heterogeneity to make overall statements of effect, therefore we investigated the heterogeneity in sensitivity and subgroup analyses, examining risk of bias, trial duration, memantine dose, concomitant cholinesterase inhibitors (ChEIs) and severity of AD. Details are reported in <a href="./appendices#CD003154-sec-0138">Appendix 4</a> . </p> <p>In a sensitivity analysis, we found that exclusion of the trials at high risk of bias for one or more domains generally made little difference to the heterogeneity, so all 24 studies were included in subgroup analyses (<a href="./appendices#CD003154-sec-0138">Appendix 4</a>.1). </p> <p>Following subgroup analyses (<a href="./appendices#CD003154-sec-0138">Appendix 4</a>), we firstly restricted the main analyses (below) to those with the licensed memantine dose of 20 mg per day or a daily 28 mg extended release tablet, and to a duration of six to seven months. This meant that some studies were excluded from the analyses: four short‐term studies in 658 participants (<a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>; <a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a>; <a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>; <a href="./references#CD003154-bbs2-0050" title="European Medicines Evaluation Agency (EMEA). Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/axura/094802en6.pdf2004:16. WinbladB , GrahamSM , LeesGS , MobiüsHJ , RubyJ , McDonaldS . Efficacy and tolerability of memantine in nursing home patients with severe dementia of the Alzheimer's type. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimor. Feb 21‐24, 2004. 2004. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. ">Winblad 1999 (9403) AD</a>); and three longer‐term studies in 334 participants that did not report interim results at six to seven months (<a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a>; <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>); these studies only reported results for the cognitive function outcome. Additionally, we did not include in the main analyses the 10 mg/day arms from two studies (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>). This left 17 studies in 5813 randomised participants. </p> <p>Secondly, on the basis of subgroup analyses and meta‐regression addressing both severity and the presence or absence of ChEIs, we concluded that it was necessary to stratify the studies by severity of AD, and to later investigate residual heterogeneity in the moderate‐to‐severe population (<a href="./appendices#CD003154-sec-0138">Appendix 4</a>; <a href="./appendices#CD003154-sec-0151">Appendix 5</a>; <a href="./appendices#CD003154-sec-0152">Appendix 6</a>). In the test for subgroup differences, there were large differences relating to disease severity, both between mild‐to‐moderate and moderate‐to‐severe AD and between mild and moderate‐to‐severe AD. We analysed and reported separately results for mild dementia and moderate‐to‐severe dementia because these represent the categories for the licensed indications. These analyses include post‐hoc subgroups for mild and moderate AD obtained from studies in people with mild‐to‐moderate AD. We had to omit from the main analyses three studies in 468 participants with mild‐to‐moderate AD because they did not report separately results for mild and moderate populations (<a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>). Subgroup analyses also showed that any impact from the presence of ChEIs was small. </p> <p>All subgroup analyses investigated the impact of different study factors on the effect estimate (i.e. the difference in mean change‐from‐baseline scores between memantine and placebo). However, we also observed differences according to severity in the change from baseline for the placebo group alone; this was found for all outcomes except clinical global (which appeared to be independent of severity). There was increased efficacy of memantine (versus placebo) with increasing severity of disease, but this occurred alongside deterioration in the placebo group for the moderate and severe populations and improvement for the mild population. </p> <p>In the rest of this section, we report results for the following sub‐populations: Section 1.2 reports the results for all participants with moderate‐to‐severe AD, with the exception of studies in patients selected for agitation. Section 1.3 examines the effect of concomitant ChEIs in people with moderate‐to‐severe AD. Section 1.4 covers the effect of memantine versus placebo in patients with agitation (who also had moderate‐to‐severe AD). Finally, section 1.5 summarises the evidence for people with mild dementia. We do not discuss separately results for moderate and severe AD in the main section, but analyses based on post‐hoc subgroups are given in <a href="./appendices#CD003154-sec-0138">Appendix 4</a>. Each sub‐section includes the individual results for the efficacy outcomes, GRADE certainty ratings and a summary. </p> </section> <section id="CD003154-sec-0078"> <h5 class="title">1.2. Effect of memantine in people with moderate‐to‐severe AD at six to seven months; OC </h5> <section id="CD003154-sec-0079"> <h6 class="title">1.2.1. Effect of memantine (20 mg to 28 mg/day) versus placebo (irrespective of whether additionally taking a cholinesterase inhibitor) </h6> <p>Fifteen studies met the inclusion criteria and contributed data from approximately 3700 analysed participants (<a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>). Four of these studies provided post‐hoc data for moderate severity AD participants (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>). </p> <p>Not all studies reported all the outcomes: for the efficacy outcomes,10 studies contributed data to the clinical global outcome, 13 to cognitive function, 11 to decline in ADL and 14 to the behaviour and mood outcome. Thirteen studies reported all‐cause discontinuation and 12 withdrawal due to adverse events, but considerably fewer studies reported adverse events: nine studies (72% of all participants) reported the proportion of participants with at least one adverse event; nine studies (77% of all participants) reported the proportion with serious adverse events and six studies (61% of all participants) reported the proportion with agitation. </p> <p>The evidence for this section is summarised in <a href="./full#CD003154-tbl-0001">summary of findings Table for the main comparison</a>, which covers both efficacy and safety outcomes; a negative SMD (or MD value means that the effect favours memantine. </p> <p> <ul id="CD003154-list-0008"> <li> <p>Clinical global rating (<a href="./references#CD003154-fig-0010" title="">Analysis 1.1</a>): high‐certainty evidence: meta‐analysis of 10 studies in 2797 participants gave an SMD of ‐0.20 (95% CI ‐0.28 to ‐0.13), favouring memantine. </p> </li> <li> <p>Cognitive function (<a href="./references#CD003154-fig-0011" title="">Analysis 1.2</a>): high‐certainty evidence: meta‐analysis of 13 studies in 3337 participants gave an SMD of ‐0.27 (95% CI ‐0.34 to ‐0.21); there was some variation in the point estimates (I² = 30%, P = 0.14). </p> </li> <li> <p>Decline in ADL (<a href="./references#CD003154-fig-0012" title="">Analysis 1.3</a>): high‐certainty evidence: meta‐analysis of 11 studies in 2687 participants gave an SMD ‐0.16 (95% CI ‐0.24 to ‐0.09). </p> </li> <li> <p>Behaviour and mood (<a href="./references#CD003154-fig-0013" title="">Analysis 1.4</a>) high‐certainty evidence: meta‐analysis of 14 studies in 3674 participants gave an SMD of ‐0.14 (95% CI ‐0.21 to ‐0.08); there was some variability in the point estimates (but I² = 8%, P = 0.36). </p> </li> <li> <p>All‐cause discontinuation, discontinuation due to adverse events, adverse events and serious adverse events are reported in section 5. </p> </li> </ul> </p> <p>Funnel plots for the primary outcomes are shown in <a href="#CD003154-fig-0004">Figure 4</a>; <a href="#CD003154-fig-0005">Figure 5</a>; <a href="#CD003154-fig-0006">Figure 6</a>; <a href="#CD003154-fig-0007">Figure 7</a> and for all‐cause discontinuation in <a href="#CD003154-fig-0008">Figure 8</a>. There appeared to be no suggestion of publication bias. There may be some asymmetry in the funnel plot for the number of people with at least one adverse event (<a href="#CD003154-fig-0009">Figure 9</a>), but probably not sufficient to downgrade the evidence on the basis of publication bias. </p> <div class="figure" id="CD003154-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.1 Clinical Global." data-id="CD003154-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.1 Clinical Global. </p> </div> </div> </div> <div class="figure" id="CD003154-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.2 Cognitive Function." data-id="CD003154-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.2 Cognitive Function. </p> </div> </div> </div> <div class="figure" id="CD003154-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.3 Decline in ADL." data-id="CD003154-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.3 Decline in ADL. </p> </div> </div> </div> <div class="figure" id="CD003154-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.4 Behaviour and Mood." data-id="CD003154-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.4 Behaviour and Mood. </p> </div> </div> </div> <div class="figure" id="CD003154-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.5 All‐cause discontinuation." data-id="CD003154-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.5 All‐cause discontinuation. </p> </div> </div> </div> <div class="figure" id="CD003154-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 12 Adverse reactions ‐ Memantine vs placebo for mild to severe dementia. All diagnoses, all durations, outcome: 12.3 Number suffering at least one adverse event." data-id="CD003154-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 12 Adverse reactions ‐ Memantine vs placebo for mild to severe dementia. All diagnoses, all durations, outcome: 12.3 Number suffering at least one adverse event. </p> </div> </div> </div> </section> <section id="CD003154-sec-0080"> <h6 class="title">1.2.2. Summary of results transformed to an appropriate scale</h6> <p>High‐certainty evidence from up to 14 studies in around 3700 participants shows a small clinical benefit for memantine versus placebo in each of the following outcomes: clinical global rating (MD benefit: 0.21 Clinician's Interview‐Based Impression of Change (CIBIC)+ points, 95% CI 0.14 to 0.30); cognitive function (MD benefit: 3.11 SIB points, 95% CI 2.42 to 3.92); performance on ADL (MD benefit: 1.09 ADL19 points, 95% CI 0.62 to 1.64); and behaviour and mood (MD benefit: 1.84 NPI points, 95% CI 1.05 to 2.76). (<a href="./full#CD003154-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>There are similar numbers of people with adverse events in both groups, and memantine (compared with placebo) shows little difference in the number of people discontinuing treatment: RR 0.93 (95% CI 0.83 to 1.04), which corresponds to 13 fewer people discontinuing per 1000, 95% CI 31 fewer to 7 more. There is probably a reduction in the number with agitation as an adverse event (25 fewer per 1000; 95% CI 1 to 44 fewer). </p> </section> </section> <section id="CD003154-sec-0081"> <h5 class="title">1.3. Effect of memantine 20 mg or equivalent versus placebo in people with moderate‐to‐severe AD six to seven months, receiving concomitant ChEI or receiving monotherapy </h5> <p>An important objective of this review was to determine whether memantine (versus placebo) gave additional benefits for people already on ChEIs. In this section, firstly, we report the results of pre‐specified subgroup analyses by concomitant ChEI for the moderate‐to‐severe AD population. Statistically, there were no significant differences between the results for the two subgroups (with and without ChEI) ‐ see section 1.3.1, but, for the interested reader, we also report results separately for the population receiving ChEIs in section 1.3.2 and results for the monotherapy subgroup in section 1.3.3. </p> <section id="CD003154-sec-0082"> <h6 class="title">1.3.1. Effect of memantine 20 mg or equivalent: subgroup analysis according to the presence or absence of concomitant ChEI </h6> <p>We conducted subgroup analyses for the four efficacy outcomes to investigate any differences in the effect of memantine (versus placebo) between memantine as monotherapy or with concomitant ChEI. We examined both between‐trial and within‐trial subgroup analyses (see <a href="./appendices#CD003154-sec-0152">Appendix 6</a>). The results for patients receiving monotherapy and for those receiving concomitant ChEI are summarised in <a href="#CD003154-tbl-0011">Table 9</a> for all outcomes (<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>; <a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>; <a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>; <a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>; <a href="./references#CD003154-fig-0023" title="">Analysis 2.5</a>; <a href="./references#CD003154-fig-0024" title="">Analysis 2.6</a>; <a href="./references#CD003154-fig-0025" title="">Analysis 2.7</a>). </p> <div class="table" id="CD003154-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Subgroup analysis: concomitant ChEI therapy versus monotherapy; six to seven month studies in moderate‐to‐severe Alzheimer's disease (AD)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Number of Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Number of Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Standardised Effect Estimate</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Heterogeneity (I²)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Test for<br/> subgroup differences</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Domain</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>with ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>no ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>with ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>no ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>with ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>no ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>with ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>no ChEI</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical Global</p> <p>(<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1125</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20<br/> (‐0.28 to ‐0.13) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.21</p> <p>(‐0.32 to ‐0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20</p> <p>(‐0.30 to ‐0.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.99</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive Function</p> <p>(<a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3337</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1852</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1485</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28</p> <p>(‐0.35 to ‐0.21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24</p> <p>(‐0.33 to ‐0.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33</p> <p>(‐0.43 to ‐0.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 44%, P = 0.18</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decline in<br/> Activities of Daily </p> <p>Living (<a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2687</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1319</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1368</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.17</p> <p>(‐0.24 to ‐0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.13</p> <p>(‐0.24 to ‐0.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20</p> <p>(‐0.30 to ‐0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.43</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Behaviour and Mood</p> <p>(<a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3674</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1855</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1819</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.14</p> <p>(‐0.21 to ‐0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.18</p> <p>(‐0.27 to ‐0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10</p> <p>(‐0.19 to ‐0.01)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 35%, P = 0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause discontinuation</p> <p>(<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4548</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2089</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2459</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.93</p> <p>(0.82 to 1.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.94</p> <p>(0.78 to 1.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.92</p> <p>(0.78 to 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%,</p> <p>P = 0.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> <p>(<a href="./references#CD003154-fig-0029" title="">Analysis 2.11</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3390</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1625</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1765</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.02</p> <p>(0.98 to 1.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05</p> <p>(0.98 to 1.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.99</p> <p>(0.94 to 1.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 46%,</p> <p>P = 0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation as an</p> <p>adverse event</p> <p>(<a href="./references#CD003154-fig-0031" title="">Analysis 2.13</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3854</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1965</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1889</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.79</p> <p>(0.64 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.93</p> <p>(0.65 to 1.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72</p> <p>(0.55 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 25.1%,</p> <p>P = 0.25</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Six studies were conducted on patients with moderate‐to‐severe disease receiving ChEI therapy, these were: </p> <p><a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>: patients were on ongoing ChEI therapy with any ChEI (donepezil, rivastigmine or galantamine), as maintenance dosage for at least 4 weeks </p> <p><a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>: patients were on ongoing ChEI therapy with a stable dose of any ChEI for 3 months or longer, patients must remain on the same dose throughout the study. </p> <p><a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>: patients were on ongoing ChEI therapy with donepezil for at least 3 months and had received a dose of 10 mg for at least the previous<br/> 6 weeks. Patients were randomised to continue or discontinue donepezil. The patient’s prescribing clinician was considering a change in drug treatment. </p> <p><a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>: patients had been on donepezil for at least four weeks when recruited and then had 12 weeks single blind observation period on donepezil. Only those stable continued to the double blind period. </p> <p><a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>: patients were on ongoing ChEI therapy with any ChEI for 6 months or longer, and a stable dosing regimen for 3 months or longer (donepezil 5‐10 mg/day; rivastigmine 6, 9 or 12 mg/day; galantamine 16 or 24 mg/day) </p> <p><a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>: patients were on ongoing ChEI therapy with donepezil for more than 6 months before entry into the trial and at a stable dose (5‐10mg/day) for at least 3 months. </p> </div> </div> <p>The test for subgroup differences showed no significant difference between memantine monotherapy and memantine with concomitant ChEI (for the comparison of memantine versus placebo) for any of the primary efficacy outcomes, although there was a non‐significant difference between subgroups for the behaviour and mood outcome (I² = 35.2%, P = 0.21), and for the cognitive function outcome (I² = 44.2%, P = 0.18). For the behaviour and mood outcome, the subgroup results suggested a slightly larger effect of memantine versus placebo in the presence of concomitant ChEI (SMD ‐0.18, 95% CI ‐0.27 to ‐0.09) than in its absence (SMD ‐0.10, 95% CI ‐0.19 to ‐0.01), whereas for the cognitive function outcome, there was a slightly smaller effect in the presence of ChEI (SMD ‐0.24, 95% CI ‐0.33 to ‐0.14) compared with monotherapy (SMD ‐0.33, 95% CI ‐0.43 to ‐0,23). The forest plots for these analyses (<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>; <a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>; <a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>; <a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>) are ordered within subgroups in decreasing order of mean study severity (MMSE) and we note that for the behaviour and mood outcome, an alternative explanation for the heterogeneity could be severity of disease (<a href="./appendices#CD003154-sec-0138">Appendix 4</a>.5). </p> <p>The safety outcomes showed no significant impact of concomitant ChEI (<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>; <a href="./references#CD003154-fig-0028" title="">Analysis 2.10</a>; <a href="./references#CD003154-fig-0029" title="">Analysis 2.11</a>; <a href="./references#CD003154-fig-0030" title="">Analysis 2.12</a>; <a href="./references#CD003154-fig-0031" title="">Analysis 2.13</a>). There was a non‐significant result in the test for subgroup differences for adverse events overall (I² = 46% and P = 0.17), however, this is likely to occur because the confidence intervals for the subgroups are small; the numerical difference is minimal: the ChEI subgroup is RR 1.05 (95% CI 0.98 to 1.12) and monotherapy is RR 0.99 (95%CI 0.94 to 1.04), both indicating no difference between memantine and placebo. For agitation as an adverse event, the test for subgroup differences was I² = 20.9% and P = 0.26, there was probably no difference between memantine and placebo for the ChEI subgroup (RR 0.92, 95% CI 0.60 to 1.40), but for the monotherapy subgroup there was probably a reduction in agitation (RR 0.68, 95% CI 0.51 to 0.91). </p> <p>The within‐trial subgroup analyses suffered from large and differential levels of missing data and it was uncertain whether there was a difference between subgroups with and without ChEIs (<a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>). Low‐certainty evidence (downgraded for risk of bias and imprecision) from one study, which randomised 149 participants to memantine plus continued donepezil versus memantine plus placebo and donepezil discontinued, suggested there may be a larger effect for the two drugs together compared with memantine monotherapy for cognitive function: MD benefit: 1.34 MMSE points (95% CI 0.19 to 2.49), i.e. it may be better to add memantine than to switch to memantine (<a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>). </p> </section> <section id="CD003154-sec-0083"> <h6 class="title">1.3.2. Effect of memantine versus placebo in people with moderate‐to‐severe AD, receiving concomitant ChEIs </h6> <p>We report results of analyses restricted to studies in participants receiving ChEIs. Six studies analysed results from 1855 participants (<a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>). Two of these studies were reported as post‐hoc subgroups for moderate AD, taken from trials in people with mild‐to‐moderate AD (<a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>). </p> <p>The evidence for this section is summarised in the additional 'Summary of findings' <a href="#CD003154-tbl-0005">Table 3</a>, which covers both efficacy and safety outcomes. </p> <p>Results were as follows. We analysed one outcome (clinical global) as the mean difference (MD) (rather than SMD) because all studies used the same scale; a negative SMD (or MD) value means that the effect favours memantine. In the forest plots, studies are shown in decreasing order of severity (MMSE). </p> <p> <ul id="CD003154-list-0009"> <li> <p>Clinical global rating, CIBIC+ (<a href="./references#CD003154-fig-0026" title="">Analysis 2.8</a>): moderate‐certainty evidence (downgraded for inconsistency): meta‐analysis of three studies in 1125 participants gave an MD (random effects) of ‐0.21 (95% CI ‐0.36 to ‐0.06), favouring memantine. There was some heterogeneity in the point estimates (and I² = 32%, P = 0.23). </p> </li> <li> <p>Cognitive function (<a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>): high‐certainty evidence: meta‐analysis of 6 studies in 1852 participants gave an SMD of ‐0.24 (95% CI ‐0.33 to ‐0.14). </p> </li> <li> <p>Decline in ADL (<a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>): high‐certainty evidence: meta‐analysis of 5 studies in 1319 participants gave an SMD of ‐0.13 (95% CI ‐0.24 to ‐0.03). </p> </li> <li> <p>Behaviour and mood (<a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>): high‐certainty evidence : meta‐analysis of 6 studies in 1855 participants gave an SMD of ‐0.18 (‐0.27 to ‐0.09). There was unimportant heterogeneity (I² = 10%, P = 0.35). </p> </li> <li> <p>All‐cause discontinuation, discontinuation due to adverse events, adverse events and serious adverse events are reported in section 5 and <a href="#CD003154-tbl-0005">Table 3</a>. </p> </li> </ul> </p> </section> <section id="CD003154-sec-0084"> <h6 class="title">1.3.3. Effect of memantine versus placebo in people with moderate‐to‐severe AD, receiving monotherapy </h6> <p>In this section, we report results of analyses restricted to studies in participants receiving monotherapy. Nine studies analysed results from 2215 participants (<a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a>; <a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>). Two of these studies were reported as post‐hoc subgroups for moderate AD, taken from trials in people with mild‐to‐moderate AD (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>). </p> <p>The evidence for this section is summarised in the additional 'Summary of findings' <a href="#CD003154-tbl-0006">Table 4</a>, which covers both efficacy and safety outcomes. Results were as follows. Forest plots show studies in decreasing order of severity; a negative SMD (or MD) value means that the effect favours memantine. </p> <p> <ul id="CD003154-list-0010"> <li> <p>Clinical global rating, CIBIC+ (<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>): high‐certainty evidence: meta‐analysis of 7 studies in 1672 participants gave an SMD of ‐0.20 (95% CI ‐0.30 to ‐0.10), favouring memantine. </p> </li> <li> <p>Cognitive function (<a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>): high‐certainty evidence: meta‐analysis of 8 studies in 1485 participants gave an SMD of ‐0.33 (95% CI ‐0.43 to ‐0.23). There is some heterogeneity in the point estimates, but apart from one study, the results are consistent with a benefit for memantine and were not downgraded for inconsistency (I² = 41%, P = 0.11). </p> </li> <li> <p>Decline in ADL (<a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>): high‐certainty evidence: meta‐analysis of 7 studies in 1368 participants gave an SMD of ‐0.20 (95% CI ‐0.30 to ‐0.09). </p> </li> <li> <p>Behaviour and mood, NPI (<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>): high‐certainty evidence: meta‐analysis of 9 studies in 1819 participants gave an SMD of ‐0.10 (95% CI ‐0.19 to ‐0.01). </p> </li> <li> <p>All‐cause discontinuation, discontinuation due to adverse events, adverse events and serious adverse events are reported in section 5 and <a href="#CD003154-tbl-0006">Table 4</a>. </p> </li> </ul> </p> </section> <section id="CD003154-sec-0085"> <h6 class="title">1.3.4. Summary of results transformed to an appropriate scale</h6> <section id="CD003154-sec-0086"> <p><b>For people receiving concomitant ChEI</b></p> <p>Mainly high‐, and moderate‐certainty evidence from up to six studies in around 1850 participants taking cholinesterase inhibitors shows a small clinical benefit for memantine versus placebo in cognitive function (MD benefit: 2.48 SIB points, 95% CI 1.45 to 3.41), performance on ADL (MD benefit: 0.95 ADL19 points, 95% CI 0.22 to 1.76) and behaviour and mood (MD benefit: 2.20 NPI points, 95% CI 1.10 to 3.29); and probably a small clinical benefit in clinical global rating (MD benefit: 0.21 CIBIC+ points, 95% CI 0.06 to 0.36) (<a href="#CD003154-tbl-0005">Table 3</a>). </p> <p>There are similar numbers of people with adverse events in both groups. Memantine (compared with placebo) shows little difference in the number of people discontinuing treatment for any cause (12 fewer per 1000, 95% CI 29 fewer to 7 more), and there is probably no difference between interventions in the number with agitation as an adverse event (4 fewer per 1000, 95% CI 18 more to 18 fewer). </p> </section> <section id="CD003154-sec-0087"> <p><b>For people receiving monotherapy</b></p> <p>High‐certainty evidence from up to nine studies in around 1800 participants shows a small clinical benefit for memantine versus placebo in all efficacy outcomes: clinical global rating (MD benefit:0.22 CIBIC+ points, 95% CI 0.11 to 0.33); cognitive function (MD benefit: 3.97 SIB points, 95% CI 2.77 to 5.18); performance on ADL (MD benefit:1.33 ADL19 points, 95% CI 0.20 to 2.00) and behaviour and mood (MD benefit:1.57 NPI points, 95% CI 0.16 to 2.98) (<a href="#CD003154-tbl-0006">Table 4</a>). </p> <p>There are similar numbers of people with adverse events in both groups. Memantine (compared with placebo) shows little difference in the number of people discontinuing treatment for any cause (13 fewer per 1000, 95% CI 32 fewer to 8 more), and there is probably also a reduction in the number with agitation as an adverse event (52 fewer per 1000, 95% CI 15 to 80 fewer) (compare agitation in people receiving concomitant ChEI). </p> </section> <section id="CD003154-sec-0088"> <p><b>Test for subgroup differences</b></p> <p>The test for subgroup differences between trials in which participants did and did not receive concomitant ChEI showed no significant differences, but three outcomes had non‐significant differences: cognitive function (I² = 44%), behaviour and mood (I² = 35%), and agitation as an adverse event (I² = 21%). For behaviour and mood, the effect of memantine appeared to be larger in people receiving ChEI, and for cognitive function the effect appeared larger in the monotherapy group. However, it was not clear that these differences could be attributed to concomitant ChEI, and severity may still play a role. For agitation as an adverse event, memantine monotherapy appeared to effect a reduction in the number of people with agitation, but memantine did not appear to add anything to existing effects with cholinesterase inhibitors. </p> </section> </section> </section> <section id="CD003154-sec-0089"> <h5 class="title">1.4. Effect of memantine in people with moderate‐to‐severe AD with agitation; OC</h5> <section id="CD003154-sec-0090"> <h6 class="title">1.4.1. Effect of memantine versus placebo in people with moderate‐to‐severe AD, with agitation </h6> <p>Three studies investigated the effect of memantine versus placebo in 556 randomised participants with agitation (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>); one study was unpublished (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>). Agitation was defined variously as: NPI &gt; 12 with a score on the NPI agitation–aggression item of at least 1 (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>); at least two weeks history of behavioural disturbance, and agitation judged by their clinical team to require intervention, with a Cohen Mansfield Agitation Inventory (CMAI) score ≥ 45 (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>); and a score on the NPI agitation–aggression item of at least 4 (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>). All studies recruited people with moderate‐to‐severe AD, although the mean MMSE scores differed: one study had a mean score of 7.5 (inclusion ≤ 19) (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>); the second had a mean of 11.9 (range 5 to 15) (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>); and the third did not state the mean, but the range was 3 to 18 (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>). Two studies included participants on ChEIs (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>); and the other had about 20% participants on ChEIs (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>). One of the three studies was in institutionalised patients (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>). </p> <p>Two studies had a duration of 12 weeks (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>); and the other was 24 weeks. Two of these studies were terminated prematurely, one after recruiting only 34 participants (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>); and the other because of difficulties in recruitment (the 369 participants formed 82% of the planned recruited sample) (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). One study had the primary aim of reducing agitation (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>), and the other two aimed to investigate the efficacy of memantine in an agitated population (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). All three studies reported the effect of memantine on agitation using the CMAI, but one used the community version (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>). </p> <p>We did not extract data from two reviews reporting on post‐hoc agitated subgroups because the data for individual trials were not available in a useful format (<a href="./references#CD003154-bbs2-0190" title="GauthierS , WirthY , MöbiusHJ . Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20:459‐64. ">Gaultier 2005</a>; <a href="./references#CD003154-bbs2-0241" title="WilcockGK , BallardCG , CooperJA , LoftH . Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry2008;69(3):341‐8. ">Wilcock Post‐Hoc 3RCTs 2008</a>). However, we discuss the findings from these studies in the <a href="#CD003154-sec-0128">Agreements and disagreements with other studies or reviews</a>) and note the disagreement. </p> <p>We analysed all efficacy outcomes except clinical global rating as the mean difference (rather than SMD) because all studies used the same scale; a negative SMD (or MD) value means that the effect favours memantine (<a href="#CD003154-tbl-0007">Table 5</a>). </p> <p>Two main outcome measures were used to investigate agitation: the CMAI score (range 29 to 203) (or the CMAI‐community score in the <a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>) study; and the agitation–aggression subscale of the NPI. Analyses were subgrouped by time point (12 weeks and 24 weeks); we reported both the results for the pooled analysis and the 24‐week study alone, in order both to be consistent with the approach to duration in AD, and also to avoid reducing the analysis to only one study; a negative SMD (or MD) value means that the effect favours memantine. </p> <p> <ul id="CD003154-list-0011"> <li> <p>CMAI: the three studies varied in the CMAI scale used and how they reported the results (one only reported final values), so we did not combine all studies in either an SMD analysis or as the MD. Instead, we meta‐analysed the two CMAI studies using the MD (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) (<a href="./references#CD003154-fig-0033" title="">Analysis 3.1</a>) and also carried out meta‐analysis for the two studies reporting change scores using the SMD (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) (<a href="./references#CD003154-fig-0034" title="">Analysis 3.2</a>). </p> <ul id="CD003154-list-0012"> <li> <p>Meta‐analysis of 2 studies in 306 participants: moderate‐certainty evidence (downgraded once for imprecision) gave an SMD of 0.11 (‐0.12 to 0.33). </p> </li> <li> <p>Meta‐analysis of 2 studies in 422 participants: moderate‐certainty evidence (downgraded once for inconsistency; I² = 48% and P = 0.16) gave a mean difference of ‐0.50 (‐4.71 to 3.71) (random effects). </p> </li> <li> <p>The 24‐week study (1 study in 273 participants): low‐certainty evidence (downgraded once for imprecision and once for inconsistency with the other studies) gave an MD of 0.90 (95% CI ‐1.29 to 3.09) on the CMAI long form scale (range 29 ‐ 203, with a clinically important difference of about 40), i.e. no difference between interventions (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). </p> </li> <li> <p>Baseline levels were: 43.3 and 41.3 (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>); 68.3 for both groups (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>); and 46.8 and 47.0 (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). </p> </li> <li> <p>There was no inconsistency between the two studies in people receiving concomitant ChEI. </p> </li> </ul> </li> <li> <p>NPI subscale for agitation–aggression (<a href="./references#CD003154-fig-0035" title="">Analysis 3.3</a>); this outcome was only reported for the short‐term studies ‐ very low‐certainty evidence (downgraded once each for risk of bias, imprecision and indirectness): meta‐analysis of 2 studies in 146 participants gave an MD of ‐0.39 (95% CI ‐1.90 to 1.13) (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>). </p> </li> </ul> </p> <p>Two studies also reported the proportion with agitation as a treatment emergent adverse event (TEAE); a risk ratio (RR) less than 1 means the effect favours memantine. </p> <p> <ul id="CD003154-list-0013"> <li> <p>Proportion with agitation as a TEAE (<a href="./references#CD003154-fig-0036" title="">Analysis 3.4</a>). </p> <ul id="CD003154-list-0014"> <li> <p>Meta‐analysis of 2 studies in 403 participants, 24 events, participants in both studies receiving concomitant ChEI: low‐certainty evidence (downgraded for imprecision twice) gave a RR of 2.39 (95% CI 1.04 to 5.50). This effect was consistent across the two studies (I² = 0%, P = 0.60). </p> </li> <li> <p>The 24‐week study (369 participants, 22 events): low‐certainty evidence (downgraded on imprecision twice) gave a RR of 2.20 (95% CI 0.92 to 5.27), i.e. about twice as many participants on memantine and ChEI had agitation compared with participants on ChEI plus placebo. </p> </li> </ul> </li> </ul> </p> <p>Results for the four other efficacy outcomes are shown below. All are reported as negative outcomes; a negative SMD (or MD) value means that the effect favours memantine. </p> <p> <ul id="CD003154-list-0015"> <li> <p>Clinical global rating (<a href="./references#CD003154-fig-0037" title="">Analysis 3.5</a>). </p> <ul id="CD003154-list-0016"> <li> <p>Meta‐analysis of 3 studies in 443 participants: low‐certainty evidence (downgraded for inconsistency and imprecision) gave an SMD (random effects) of ‐0.11 (95% CI ‐0.34 to 0.13). There is heterogeneity in the point estimates between the 12‐week and 24‐week studies (although I² = 25%, P = 0.26). </p> </li> <li> <p>The 24‐week study (275 participants): low‐certainty evidence (downgraded on inconsistency with other studies and imprecision) gave an MD of 0.05 (95% CI ‐0.25 to 0.35) for the CIBIC+ scale. </p> </li> </ul> </li> <li> <p>Cognitive function; SIB (<a href="./references#CD003154-fig-0038" title="">Analysis 3.6</a>). </p> <ul id="CD003154-list-0017"> <li> <p>The two studies gave very different results.There is substantial heterogeneity (I² = 90%, P = 0.002), and therefore results are reported separately. </p> </li> <li> <p>At 12 weeks (1 study, 129 participants): the MD is ‐10.00 (95% CI ‐16.15 to ‐3.85).</p> </li> <li> <p>The 24‐week study (324 participants): very low‐certainty evidence (downgraded twice on inconsistency with the other study and imprecision) gave an MD of 0.48 (95% CI ‐1.61 to 2.57). </p> </li> </ul> </li> <li> <p>Decline in ADL; ADCS‐ADL19 (<a href="./references#CD003154-fig-0039" title="">Analysis 3.7</a>). </p> <ul id="CD003154-list-0018"> <li> <p>Meta‐analysis of 2 studies in 309 participants receiving ChEI: low‐certainty evidence (downgraded once for imprecision and once overall for some inconsistency and risk of bias (baseline difference)): gave an MD of 1.48 (95% CI ‐0.19 to 3.15). There was heterogeneity in the point estimates (although I² = 0%, P = 0.40). </p> </li> <li> <p>The 24‐week study (276 participants): low‐certainty evidence (downgraded for risk of bias and imprecision) gave an MD of 1.80 (95% CI ‐0.03 to 3.63). The difference at baseline for that study (276 participants) was 1.10 units lower for memantine (i.e. memantine more severe) (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>), </p> </li> </ul> </li> <li> <p>Behaviour and mood, NPI total (<a href="./references#CD003154-fig-0040" title="">Analysis 3.8</a>). </p> <ul id="CD003154-list-0019"> <li> <p>Meta‐analysis of 3 studies in 470 participants: very low‐certainty evidence (downgraded once each for risk of bias (baseline difference), inconsistency and imprecision): gave a random effects MD of ‐1.51 (95% CI ‐8.05 to 5.03). There was heterogeneity in both the 12‐week studies' subgroup (I² = 57%, P = 0.13) and overall (I² = 62%, P = 0.07), but no differences between durations. In each study there were large baseline differences between the values for memantine and placebo, which for two studies were comparable with the effect estimate. </p> </li> <li> <p>The 24‐week study (324 participants): very low‐certainty evidence (downgraded on imprecision, inconsistency and risk of bias) gave an MD of 1.23 (95% CI ‐2.19 to 4.65). The difference in NPI at baseline for that study was 1.70 units higher for memantine (i.e. more severe), which is larger than the effect estimate. </p> </li> </ul> </li> <li> <p>All‐cause discontinuation, discontinuation due to adverse events, adverse events and serious adverse events are reported in section 5. </p> </li> </ul> </p> <p>The results for studies with and without patients with agitation are compared in <a href="#CD003154-tbl-0012">Table 10</a>. </p> <div class="table" id="CD003154-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Comparison of analyses in people with moderate‐to‐severe AD, selected versus not selected for agitation at six to seven months</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Patients not selected for agitation (with moderate‐to‐severe AD)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Patients selected for agitation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With / without ChEI<br/> (24‐28 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No ChEI<br/> (24‐28 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With ChEI<br/> (24‐28 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With / without ChEI, mainly with<br/> (12 &amp; 24 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With ChEI<br/> (24 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With / without ChEI ‐<br/> majority without<br/> (12 weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical</p> <p>global</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.28 to ‐0.13)</p> <p>n = 10 studies;</p> <p>2797 patients</p> <p>I² = 0%, P = 0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.30 to ‐0.10)</p> <p>n = 7; 1672 patients</p> <p>I² = 0%, P = 0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.21 (‐0.32 to ‐0.09)</p> <p>n = 3; 1125 patients</p> <p>I² = 13%, P = 0.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.11 (‐0.34 to 0.13)</p> <p>n = 3; 443 patients</p> <p>I² = 25%, P = 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (‐0.20 to 0.28)</p> <p>n = 1; 324 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.59 to 0.02)</p> <p>n = 2; 168 patients</p> <p>I² = 0%, P = 0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive</p> <p>function</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.35 to ‐0.21)</p> <p>n = 13; 3337 patients</p> <p>I² = 30%, P = 0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33 (‐0.43 to ‐0.23)</p> <p>n = 8; 1485 patients</p> <p>I² = 41%, P = 0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24 (‐0.33 to ‐0.14)</p> <p>n = 6; 1852 patients</p> <p>I² = 13%, P = 0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not pooled</p> <p>I² = 90%, P = 0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.17 to 0.27)</p> <p>n = 1, 324 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.56 (‐0.92 to ‐0.21)</p> <p>n = 1; 129 patients</p> <p>(with ˜20% ChEI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decline</p> <p>in ADL</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.17 (‐0.24 to ‐0.09)</p> <p>n = 11; 2687 patients</p> <p>I² = 0%, P = 0.582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.30 to ‐0.09)</p> <p>n = 7; 1368 patients</p> <p>I² = 10%, P = 0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.13 (‐0.24 to ‐0.03)</p> <p>n = 5; 1319 patients</p> <p>I² = 0%, P = 0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (‐0.02 to 0.43)</p> <p>n = 2; 309 patients</p> <p>I² = 0%, P = 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (‐0.01 to 0.47)</p> <p>n = 1; 276 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.02 (‐0.70 to 0.67)</p> <p>n = 1; 33 patients</p> <p>(with ChEI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour</p> <p>and mood</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.14 (‐0.21 to ‐0.08)</p> <p>n = 14; 3674 patients</p> <p>I² =6%, P = 0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10 (‐0.19 to ‐0.01)</p> <p>n = 9; 1819 patients</p> <p>I² = 0%, P = 0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.18 (‐0.27 to ‐0.09)</p> <p>n = 6; 1855 patients</p> <p>I² = 10%, P = 0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.07 (‐0.41 to 0.27)</p> <p>n = 3; 470 patients</p> <p>I² = 62%, P = 0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (‐0.14 to 0.30)</p> <p>n = 1; 324 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.69 to 0.29)</p> <p>n = 2; 146 patients</p> <p>I² = 43%, P = 0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.21 (‐0.45 to 0.04)</p> <p>n = 1; 261 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (‐0.12 to 0.33)</p> <p>n = 2; 306 patients</p> <p>I² = 0%, P = 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (‐0.14 to 0.33)</p> <p>n = 1; 273 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI (final values):</p> <p>SMD: ‐0.19 (‐0.52 to 0.13) <br/> n = 1; 149 patients </p> <p>CMAI (community):</p> <p>SMD: 0.21 (‐0.48 to 0.89)</p> <p>n = 1; 33 patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion</p> <p>with</p> <p>agitation (RR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.601 to 0.96)</p> <p>6 studies; 2 241 patients</p> <p>I² = 0%, P = 0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.51, 0.91)</p> <p>4 studies; 1016 patients</p> <p>I² = 0%, P = 0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.54 to 1.31)</p> <p>3 studies; 1225 patients</p> <p>I² = 0% and 0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.39 (1.04 to 5.50)</p> <p>2 studies; 403 patients</p> <p>I² = 0%, P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.20 (0.92 to 5.27)</p> <p>1 study; 369 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.26 to 97.00)</p> <p>1 study; 34 patients (with ChEI)</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003154-sec-0091"> <h6 class="title">1.4.2. Summary of results transformed to an appropriate scale</h6> <p>The evidence was mainly of low or very low certainty for this patient group. Three studies in around 550 participants compared memantine and placebo in people with moderate‐to‐severe disease with agitation, but only one of these studies had a duration of six to seven months (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). One of the short‐term studies had more severe agitation at baseline compared with the other two studies, and this same study only had 20% of participants on ChEIs (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>), whereas the other two studies had all on ChEIs. For the outcomes of CMAI, clinical global and cognitive function, there is inconsistency between the 24‐week and 12‐week studies. For these outcomes, we reported the meta‐analysis results and also gave the results for the 24‐week study alone, with the evidence for the latter downgraded due to inconsistency with the other study results. The results are summarised below in terms of relative improvement for memantine versus placebo for consistency with the other summary sections. </p> <p>Low‐certainty evidence from one study in 275 people suggested there may have been no difference between memantine and placebo, either for clinical global rating: MD (relative improvement) = ‐0.05 CIBIC+ points, 95% CI ‐0.35 to 0.25; or for cognitive function: MD (relative improvement) = ‐0.48, 95% CI ‐2.57 to 1.61. For performance on ADL, there may be no difference between memantine (with ChEI) and placebo (with ChEI): MD (relative improvement) = ‐1.48 ADL19 points, 95% CI ‐3.15 to 0.19 (2 studies in 309 people). It is very uncertain whether there is a difference between memantine and placebo for the behaviour and mood outcome: MD (relative improvement) = +1.51 NPI points, 95% CI ‐5.03 to 8.05. </p> <p>Regarding agitation, there is moderate‐certainty evidence from two studies (422 participants) to suggest there is probably no difference between memantine and placebo on the agitation CMAI scale: MD (relative improvement) = 0.50 CMAI points, 95% CI ‐3.71 to 4.71: this is a very small change for the CMAI scale. The evidence on the NPI agitation–aggression subscale was not reported (although measured) for the 24 week study and the remaining evidence is of very low certainty. </p> <p>The proportion reporting agitation as a TEAE in two studies (403 participants) may be doubled in those receiving memantine (plus ChEI) compared with placebo (plus ChEI) (RR 2.39, 95% CI 1.04 to 5.50). We assume that the proportion with agitation reflects increases in the severity of agitation in this patient group; baseline levels were not reported, but the proportions at 24 weeks in the two groups in the larger study were relatively small (8% for memantine and 4% placebo) (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). These proportions are similar to the ranges for the moderate‐to‐severe AD groups (0% to18% memantine and 3% to 22% placebo). Additionally, the larger study reported differences at baseline ‐ the memantine group had higher levels of antipsychotic medication (24% versus 20%) and there was a centre effect (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). </p> <p>There are similar numbers of people with adverse events in both groups, and memantine (compared with placebo) probably shows little difference in the number of people discontinuing treatment (RR 1.10, 95% CI 0.79 to 1.52, which corresponds to 17 fewer per 1000, 95% CI 36 fewer to 89 more). </p> </section> </section> <section id="CD003154-sec-0092"> <h5 class="title">1.5. Effect of memantine 20 mg in people with mild AD at six months</h5> <section id="CD003154-sec-0093"> <h6 class="title">1.5.1. Effect of memantine versus placebo in people with mild AD</h6> <p>Four studies contributed data from post‐hoc subgroups (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>); (see section <a href="#CD003154-sec-0051">Subgroup analysis and investigation of heterogeneity</a>). Of the 1396 participants analysed in the four mild‐to‐moderate AD trials, 621 (44%) had mild AD. Two studies gave concomitant ChEIs (<a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>, <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>). One additional study recruited 26 participants with mild AD and reported cognitive function at 12 months ((<a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>)). One further study in 195 participants was considered in sensitivity analyses because it had a mean MMSE score of around 22 and the participants were anti‐dementia treatment naive (<a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>). The addition of this study reinforced the efficacy results (see <a href="./appendices#CD003154-sec-0138">Appendix 4</a>.5.2). </p> <p>The evidence for this section is summarised in the additional summary of findings <a href="#CD003154-tbl-0008">Table 6</a>. Results are shown below; a negative SMD (or MD) value means that the effect favours memantine. </p> <p> <ul id="CD003154-list-0020"> <li> <p>Clinical global rating, CIBIC+ (<a href="./references#CD003154-fig-0045" title="">Analysis 4.1</a>): low‐certainty evidence (downgraded once on risk of bias because post‐hoc subgroups and once on imprecision): meta‐analysis of 3 studies in 427 participants gave an MD of ‐0.09 (95% CI ‐0.30 to 0.12). </p> </li> <li> <p>Cognitive function, ADAS‐Cog (<a href="./references#CD003154-fig-0046" title="">Analysis 4.2</a>): moderate‐certainty evidence (downgraded once on risk of bias): meta‐analysis of 4 studies in 619 participants gave an MD of ‐0.21 (95% CI ‐1.38 to 0.95). </p> </li> <li> <p>Decline in ADL, ADCS‐ADL23 (<a href="./references#CD003154-fig-0047" title="">Analysis 4.3</a>): moderate‐certainty evidence (downgraded once on risk of bias): meta‐analysis of 4 studies in 621 participants gave an MD of 0.07 (95% CI ‐1.66 to 1.80). There was some heterogeneity in point estimates (but I² = 3%, P = 0.38). </p> </li> <li> <p>Behaviour and mood, NPI (<a href="./references#CD003154-fig-0048" title="">Analysis 4.4</a>): moderate‐certainty evidence (downgraded once on risk of bias): meta‐analysis of 4 studies in 621 participants gave an MD of 0.29 (95% CI ‐1.58 to 2.16). </p> </li> </ul> </p> <p>One additional trial was conducted in 26 participants with mild AD, but only gave data for MMSE ‐ and only final values were reported at 12 months (<a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>). Very low‐certainty evidence (downgraded for imprecision (twice) and indirectness) gave an MD (negative outcome) of ‐1.15 (95% CI ‐3.47 to 1.17), favouring memantine, however, the baseline difference was ‐0.46. Addition of the <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a> study to the meta‐analyses for cognitive function and decline in ADL showed very similar SMD results, but narrower CIs (<a href="./appendices#CD003154-sec-0138">Appendix 4</a>.5.2). </p> <p>All‐cause discontinuation, discontinuation due to adverse events and adverse events are reported in section 5. Serious adverse events were not reported separately for people with mild dementia. </p> </section> <section id="CD003154-sec-0094"> <h6 class="title">1.5.2. Summary of results transformed to an appropriate scale</h6> <p>The results are summarised in terms of the relative improvement for memantine versus placebo, for consistency with the other summary sections. Mainly moderate‐certainty evidence based on post‐hoc subgroups from up to four studies in around 600 participants suggests there is probably no difference between memantine and placebo for three of the efficacy outcomes: cognitive function: MD (relative improvement) = 0.21 ADAS‐Cog points, 95% CI ‐0.95 to 1.38; performance on ADL: MD (relative improvement): ‐0.07 ADL 23 points, 95% CI ‐1.80 to 1.66; and behaviour and mood: MD (relative improvement) = ‐0.29 NPI points, 95% CI ‐2.16 to 1.58, and there may be no difference for clinical global rating: MD (relative improvement) = 0.09 CIBIC+ points, 95% CI ‐0.12 to 0.30 (low‐certainty evidence) (<a href="#CD003154-tbl-0008">Table 6</a>). </p> <p>For the cognitive function and behaviour and mood outcomes, we observed an average <i>improvement</i> over time for the placebo groups, but little or no change over time for the decline in ADL and clinical global outcomes (<a href="./appendices#CD003154-sec-0138">Appendix 4</a>.5.2.2): for placebo, the median of the standardised mean change from baseline was: cognitive function ‐0.20, range ‐0.38 to 0.11 and behaviour and mood ‐0.16, range ‐0.33 to ‐0.10). This improvement with placebo is in contrast to the results for people with moderate‐to‐severe disease (see section 1.2.2 and <a href="./appendices#CD003154-sec-0138">Appendix 4</a>.5.2.2). </p> <p>There are similar numbers of people with adverse events in both groups, but memantine (compared with placebo) may give an increase in the number of people discontinuing treatment because of adverse events: RR 2.12 (95% CI 1.03 to 4.39), which corresponds to 33 more per 1000 (95% CI 1 to 100 more). The evidence is of very low certainty regarding all‐cause discontinuation (74 more people per 1000 discontinued treatment, 95% CI 8 to 181 more), and agitation was not reported in these studies. </p> </section> </section> </section> <section id="CD003154-sec-0095"> <h4 class="title">2. Vascular dementia</h4> <section id="CD003154-sec-0096"> <h5 class="title">2.1. Effect of memantine in people with mild‐to‐moderate vascular dementia at six to seven months; OC or per protocol </h5> <section id="CD003154-sec-0097"> <h6 class="title">2.1.1 Effect of memantine (20 mg/day) versus placebo</h6> <p>Three studies randomised 956 participants with vascular dementia (<a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>; <a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>; <a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>); but only two of these contributed data (<a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>; <a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202);</a> 900 randomised participants). Both studies were in people with mild‐to‐moderate dementia, and neither study appeared to allow concurrent ChEIs. Participants were randomised to 20 mg/day memantine versus placebo for 28 weeks. The two studies used different scales for each outcome except cognitive function (for which both studies used ADAS‐Cog). The decline in ADL, and the behaviour and mood outcomes used the Nurse's Observational Scale for Geriatric Patients (NOSGER) subscales (<a href="./appendices#CD003154-sec-0136">Appendix 2</a>), but one study used the revised version (NOSGER II) and were presented as per protocol analyses (<a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>). Consequently, we analysed all outcomes as SMD, with the exception of cognitive function. </p> <p>The evidence for this section is summarised in <a href="./full#CD003154-tbl-0002">summary of findings Table 2</a>, which covers both efficacy and safety outcomes. </p> <p>Results are shown below; a negative SMD (or MD) value means that the effect favours memantine. </p> <p> <ul id="CD003154-list-0021"> <li> <p>Clinical Global (<a href="./references#CD003154-fig-0049" title="">Analysis 5.1</a>): moderate‐certainty evidence (downgraded for inconsistency): meta‐analysis of 2 studies in 757 analysed participants gave a random effects SMD of ‐0.02 (95% CI ‐0.23 to 0.19). There is some heterogeneity (I² = 48%, P = 0.16). </p> </li> <li> <p>Cognitive function, ADAS‐Cog (<a href="./references#CD003154-fig-0050" title="">Analysis 5.2</a>): moderate‐certainty evidence (downgraded for risk of bias): meta‐analysis of 2 studies in 569 participants gave an MD of ‐2.15 (95% CI ‐3.25 to ‐1.05). There is some heterogeneity in the point estimates (and I² = 12%, P = 0.29), but this was insufficient to downgrade on inconsistency. </p> </li> <li> <p>Decline in ADL on the NOSGER self‐care subscale (<a href="./references#CD003154-fig-0051" title="">Analysis 5.3</a>): low‐certainty evidence (downgraded twice overall for risk of bias and unclear scale direction for one study): meta‐analysis of 2 studies in 542 participants gave an SMD of ‐0.04 (95% CI ‐0.20 to 0.13). </p> </li> <li> <p>Behaviour and mood on the NOSGER disturbing behaviour subscale (<a href="./references#CD003154-fig-0052" title="">Analysis 5.4</a>): low‐certainty evidence (downgraded twice for risk of bias): meta‐analysis of 2 studies in 541 participants gave an SMD of ‐0.20 (95% CI ‐0.37 to ‐0.03). </p> </li> </ul> </p> <p>Post‐hoc subgroup analyses by severity were also conducted for an FDA report for the cognitive function outcome: results were reported for both trials, separated at an MMSE score of 14 into mild‐to‐moderate and moderate‐to‐severe. <a href="./references#CD003154-fig-0053" title="">Analysis 5.5</a> (fixed effect) shows the test for subgroup differences to be significant (I² = 72.5, P = 0.06), with a bigger effect in the moderate‐to‐severe subgroup (ADAS‐Cog MD ‐4.51, 95% CI ‐7.21 to ‐1.81) than in the mild‐to‐moderate subgroup (MD ‐1.64, 95% CI ‐2.83 to ‐0.45). </p> </section> <section id="CD003154-sec-0098"> <h6 class="title">2.1.2. Summary of results transformed to an appropriate scale</h6> <p>Moderate‐ and low‐certainty evidence from two studies in around 750 participants with vascular dementia gave mixed results for the comparison of memantine and placebo. There is probably a small clinical benefit for cognitive function: MD benefit = 2.15 ADAS‐Cog points, 95% CI 1.05 to 3.25, and there may be a small clinical benefit on the NOSGER disturbing behaviour outcome: MD benefit = 0.47 NOSGER points, 95% CI 0.07 to 0.87. However, there is probably no difference between memantine and placebo in clinical global rating: MD benefit = 0.03 CIBIC+ points, 95% CI ‐0.28 to 0.34, and there may be no difference in performance on ADL: MD benefit = 0.11 NOSGER II self‐care subscale points, 95% CI ‐0.35 to 0.54. </p> <p>There are similar numbers of people with adverse events in both groups, and there may be no difference in the numbers of people discontinuing treatment RR 1.05 (95% CI 0.83 to 1.34), which corresponds to 11 fewer people per 1000 (95% CI 37 fewer to 74 more). There may be fewer people with agitation as an adverse event for memantine compared with placebo RR 0.57 (95% CI 0.33 to 0.97) (i.e., 33 fewer per 1000, 95% CI 2 to 52 fewer). </p> <p>A post‐hoc subgroup analysis by severity suggested that memantine (versus placebo) may have had a bigger effect for cognitive function in people with moderate‐to‐ severe vascular dementia (MMSE ≥14) than in people with mild‐to‐moderate vascular dementia. The test for subgroup differences was significant (I² = 72.5%, P = 0.06), although this was a post‐hoc analysis. </p> </section> </section> </section> <section id="CD003154-sec-0099"> <h4 class="title">3. Other forms of dementia</h4> <section id="CD003154-sec-0100"> <h5 class="title">3.1. Effect of memantine in people with Parkinson’s disease dementia (PDD) or dementia Lewy bodies (DLB) </h5> <section id="CD003154-sec-0101"> <h6 class="title">3.1.1. Effect of memantine (20 mg/day) versus placebo</h6> <p>Four studies in 319 randomised participants with PDD or DLB met the inclusion criteria (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>; <a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>; <a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>; <a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>); two studies were solely in participants with PDD (<a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009;</a><a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD)</a>; and the other two were in a mixed PDD–DLB population: one study had more PDD participants (memantine group 50%, placebo 61%) (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>); and the other had 65% with PDD in the memantine group and 59% in the placebo group (<a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>). The severity of dementia was mild‐to‐moderate, with mean MMSE scores of ˜22 (<a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>); ˜21 (<a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>); ˜20 (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>); and ˜19 (<a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>). Some studies gave the participants concomitant ChEIs: one study had 47% in the memantine group and 63% for placebo (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>); one did not permit ChEIs (<a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>); one had 18.2% (memantine) and 14.2% (placebo) (<a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>); and the other did not state the proportions (<a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>). Only one study reported OC results (<a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>). All outcomes were analysed as SMD apart from cognitive function and behaviour–mood. One study reported results at 16 weeks (<a href="./references#CD003154-bbs2-0023" title="LeroiI , AtkinsonR , OvershottR . Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry2014;29(9):899‐905. [DOI: 10.1002/gps.4077] LeroiI , OvershottR , ByrneJ , DanielE , BurnsA . Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders2009;24(8):1217‐21. ">Leroi 2009</a>); the others were at 24 weeks. We report results for the 24‐week studies, unless there was only one 24‐week study, in which case the 16‐week study was considered. </p> <p>The evidence for this section is summarised in 'Summary of findings' <a href="#CD003154-tbl-0009">Table 7</a>, which covers both efficacy and safety outcomes. Results are shown below; a negative SMD (or MD) value means that the effect favours memantine. </p> <p> <ul id="CD003154-list-0022"> <li> <p>Clinical Global (<a href="./references#CD003154-fig-0058" title="">Analysis 6.1</a>): low‐certainty evidence (downgraded once each for risk of bias and imprecision): meta‐analysis of 3 studies in 243 participants gave an SMD of ‐0.35 (95% CI ‐0.60 to ‐0.09). There was a little heterogeneity in the point estimates (I² = 15%, P = 0.31). </p> </li> <li> <p>Cognitive function, MMSE (<a href="./references#CD003154-fig-0059" title="">Analysis 6.2</a>): very low‐certainty evidence (downgraded once each for risk of bias, inconsistency with the 16‐week study and imprecision): one study in 63 participants gave an MD of ‐1.90 (95% CI ‐3.73 to ‐0.07). There was substantial heterogeneity between this study and the study reporting results at 16 weeks (I² = 75%, P = 0.05). </p> </li> <li> <p>Decline in ADL (<a href="./references#CD003154-fig-0060" title="">Analysis 6.3</a>): very low‐certainty evidence (downgraded once each on risk of bias, inconsistency and imprecision): meta‐analysis of 3 studies in 243 participants gave a random effects SMD of ‐0.27 (95% CI ‐0.65 to 0.11). There was some heterogeneity (I² = 40%, P = 0.19). </p> </li> <li> <p>Behaviour and mood, NPI (<a href="./references#CD003154-fig-0061" title="">Analysis 6.4</a>): low‐certainty evidence (downgraded once on each of risk of bias and imprecision or inconsistency): meta‐analysis of 3 studies in 242 participants) gave a random effects MD of ‐2.18 (95% CI ‐5.57 to 1.21). There was some heterogeneity in the point estimates (I² = 20%, P = 0.29). </p> </li> <li> <p>All‐cause discontinuation, discontinuation due to adverse events, adverse events and serious adverse events are reported in section 5. </p> </li> </ul> </p> </section> <section id="CD003154-sec-0102"> <h6 class="title">3.1.2. Summary of results transformed to an appropriate scale</h6> <p>Low‐ and very low‐certainty evidence from up to 3 studies in around 250 participants suggested that, for memantine versus placebo in people with PDD or DLB, there may be a small clinical benefit in clinical global rating (MD benefit: 0.49 CIBIC+ points, 95% CI 0.13 to 0.83) and in behaviour and mood (although the confidence interval was consistent with both no effect and benefit) (MD benefit: 2.18 NPI points, 95% CI ‐1.21 to 5.57). Evidence for all other efficacy outcomes is of very low certainty. There may be fewer people discontinuing treatment RR 0.84 (95% CI 0.55 to 1.28), which corresponds to 32 fewer per 1000 (95% CI 90 fewer to 56 more). </p> </section> </section> <section id="CD003154-sec-0103"> <h5 class="title">3.2. Effect of memantine in people with frontotemporal dementia (FTD)</h5> <section id="CD003154-sec-0104"> <h6 class="title">3.2.1. Effect of memantine (20 mg/day) versus placebo in people with FTD</h6> <p>Two studies in 133 randomised participants with FTD were included (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>; <a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a>). Both studies were in people with mild dementia and both prohibited the use of ChEIs. One study (52 participants) reported at 52 weeks (<a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a>), and the other (81 participants) at 26 weeks (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>); both are included in the meta‐analyses, but where there was heterogeneity, we reported only the 26‐week (single study) results. </p> <p>The evidence for this section is summarised in 'Summary of findings' <a href="#CD003154-tbl-0010">Table 8</a>, which covers both efficacy and safety outcomes. Results are shown below; a negative SMD (or MD) value means that the effect favours memantine. </p> <p> <ul id="CD003154-list-0023"> <li> <p>Clinical global rating (<a href="./references#CD003154-fig-0065" title="">Analysis 7.1</a>): low‐certainty evidence (downgraded once each for risk of bias and imprecision): meta‐analysis of 2 studies in 117 participants gave an SMD of ‐0.31 (95% CI ‐0.67 to 0.06). The single study at 26 weeks (76 participants) had an MD (CGIC) of ‐0.40 (95% CI ‐1.23 to 0.43) (low‐certainty evidence). </p> </li> <li> <p>Cognitive function, MMSE (<a href="./references#CD003154-fig-0066" title="">Analysis 7.2</a>): very low‐certainty evidence (downgraded twice for imprecision and once for inconsistency): meta‐analysis of 2 studies in 122 participants gave a random effects MD (negative outcome is an improvement) of ‐0.23 (95% CI ‐2.03 to 1.56). The single study at 26 weeks (81 participants) had an MD of 0.30 (95% CI ‐1.23 to 1.83), low‐certainty evidence (downgraded twice for imprecision). </p> </li> <li> <p>Decline in ADL ‐ outcome reported only for one study (<a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a>), as the percentage DAD score = yes </p> </li> <li> <p>Behaviour and mood, NPI (<a href="./references#CD003154-fig-0067" title="">Analysis 7.3</a>): low‐certainty evidence (downgraded twice overall for imprecision and some inconsistency): meta‐analysis of 2 studies in 115 participants gave an MD of ‐3.16 (95% CI ‐8.06 to 1.74). For the single study at 26 weeks: MD (NPI) = ‐2.20 (95% CI ‐8.01 to 3.61) (low‐certainty evidence (downgraded twice on imprecision)). </p> </li> <li> <p>All‐cause discontinuation, discontinuation due to adverse events, adverse events and serious adverse events are reported in section 5. </p> </li> </ul> </p> </section> <section id="CD003154-sec-0105"> <h6 class="title">3.2.2 Summary of results transformed to an appropriate scale</h6> <p>Mainly low‐certainty evidence from 2 studies in around 120 participants suggests there may be a small clinical benefit in clinical global rating (MD benefit: 0.56 CGIC points, 95% CI ‐1.21 to 0.11) and in behaviour and mood (MD benefit: 3.16 NPI points, 95% CI ‐3.61 to 8.01) for memantine versus placebo in people with FTD. There may be no difference in cognitive function (MD benefit for one study: ‐0.30 MMSE points, 95% CI ‐1.83 to 1.23). However, for all of the efficacy outcomes, there is uncertainty and the confidence interval is consistent with more than one conclusion. There may be more discontinuation in the memantine group (compared with placebo) for this population (RR 1.54, 95% CI 0.54 to 4.06). </p> </section> </section> <section id="CD003154-sec-0106"> <h5 class="title">3.3. Effect of memantine in people with AIDS‐related dementia complex (ADC)</h5> <p>Only one study currently fulfilled the inclusion criteria of this review with regard to the use of memantine in ADC ((<a href="./references#CD003154-bbs2-0041" title="SchifittoG , NaviaBA , YiannoutsosCT , MarraCM , ChangL , ErnstT , et al. Memantine and HIV‐associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 12 Sep 2007;21(14):1877‐86. ZhaoY , NaviaBA , MarraCM , SingerEJ , ChangL , BergerJ , et al. Memantine for AIDS dementia complex: open‐label report of ACTG 301. HIV clinical trials2010; Vol. 11, issue 1:59‐67. ">Schiﬁtto 2007</a>)). The study randomised a total of 140 participants to 40 mg/day memantine or placebo. Only the cognitive function outcome was reported for 48 and 45 participants, respectively, as measured by a summary neuropsychological test score, averaged over eight measures (NPZ‐8). The authors reported the percentage improvement from baseline at 16 weeks: MD 43.0% (95% CI ‐19.2 to 105.2), in favour of memantine (low‐certainty evidence because of imprecision). </p> <p>The number of adverse events (not the number of participants with adverse events) were similar in each arm: 116 in the memantine arm and 106 in the placebo arm. low‐certainty evidence (downgraded twice for imprecision) suggested that for all‐cause discontinuation, there may be no difference between memantine and placebo (1 study 140 participants, 28 events) RR 1.00 (95% CI 0.52 to 1.94). Similarly for discontinuation due to adverse events (1 study 140 participants, 14 events) RR 1.00 (95% CI 0.37 to 2.70). Further investigation into the use of memantine in ADC would be warranted. </p> </section> </section> <section id="CD003154-sec-0107"> <h4 class="title">4. Comparison of effects in different types of dementia</h4> <section id="CD003154-sec-0108"> <h5 class="title">4.1 Memantine versus placebo, all severities ‐ efficacy analyses at six‐seven months</h5> <p>The results of the efficacy analyses for six to seven months for each type of dementia, separated by severity are summarised in <a href="./references#CD003154-fig-0073" title="">Analysis 8.1</a>; <a href="./references#CD003154-fig-0074" title="">Analysis 8.2</a>; <a href="./references#CD003154-fig-0075" title="">Analysis 8.3</a>; <a href="./references#CD003154-fig-0076" title="">Analysis 8.4</a>. These analyses only include studies with a duration of six to seven months, so some types of dementia are represented only by single studies: AD with agitation (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>); FTD (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>); and, for cognitive function, PDD or DLB (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>). </p> <p>The evidence for AD (apart from the studies in people with agitation) was mainly of high certainty and moderate for the mild subpopulation. The evidence certainty was moderate to low for vascular dementia and mainly low for FTD. For PDD or DLB and AD participants with agitation, the evidence certainty was low or very low. </p> <p>Within these limitations, the following observations can be made for the efficacy outcomes; this section does not further address evidence certainty. </p> <p><b>Clinical global</b> rating (<a href="./references#CD003154-fig-0073" title="">Analysis 8.1</a>): memantine (versus placebo) gives a small improvement in clinical global rating in all types and severities of dementia, with the exception of AD with agitation (single study) and vascular dementia. In the latter two types, there seems to be no difference between memantine and placebo. There may be a smaller effect in people with mild AD than in people with moderate‐to‐severe AD, but severity does not seem very important for this outcome. </p> <p><b>Cognitive function</b>: memantine (versus placebo) gives an improvement in cognitive function for AD (moderate‐to‐severe), vascular dementia and PDD or DLB (single study). Single studies in people with AD plus agitation and FTD suggested there may have been no difference between interventions. There is a significantly larger effect of memantine (versus placebo) in the moderate‐to‐severe AD population compared with that in mild AD ‐ such that memantine probably has no effect on cognitive function in people with mild AD, whereas an effect is observed in the moderate‐to‐severe population. The effect size in <i>mild‐to‐moderate</i> DLB or PDD (single study) and in <i>mild‐to‐moderate</i> vascular dementia appears to be similar to that in <i>moderate‐severe AD</i> (<a href="./references#CD003154-fig-0074" title="">Analysis 8.2</a>). Further trends towards increased efficacy with severity are indicated in <a href="./references#CD003154-fig-0053" title="">Analysis 5.5</a> for vascular dementia and (<a href="./appendices#CD003154-sec-0138">Appendix 4</a>) for AD. </p> <p><b>Decline in</b> ADL (<a href="./references#CD003154-fig-0075" title="">Analysis 8.3</a>): memantine (versus placebo) gives an improvement in performance on ADL in AD (moderate‐to‐severe) and PDD or DLB, but there may be no effect in vascular dementia and a deterioration in ADL performance for AD with agitation (single study). There is a significantly larger effect of memantine (versus placebo) in participants with moderate‐to‐severe AD compared with mild AD ‐ such that memantine probably has no effect on ADL in people with mild AD, but a small effect in people with moderate‐to‐severe AD. The effect in <i>mild‐to‐moderate</i> DLB or PDD again appears to be similar to that in <i>moderate‐to‐severe AD</i>. </p> <p><b>Behaviour and mood</b> (<a href="./references#CD003154-fig-0076" title="">Analysis 8.4</a>): memantine (versus placebo) appears to give an improvement in behaviour and mood for all types of dementia, with the exception of mild AD and AD with agitation (single study), for which there may be no difference between interventions. There is a significantly larger effect of memantine (versus placebo) in participants with moderate‐to‐severe AD versus mild AD ‐ such that memantine probably has no effect on behaviour and mood in people with mild AD. The effect in each of the other types of dementia (vascular dementia, DLB or PDD and FTD (one study) for <i>mild‐to‐moderate</i> dementia appears to be similar to that in <i>moderate‐to‐severe AD</i> (<a href="./references#CD003154-fig-0076" title="">Analysis 8.4</a>). There appears to be a trend towards increased efficacy with increased severity (<a href="./appendices#CD003154-sec-0138">Appendix 4</a>), but this was an aggregate level subgroup analysis. </p> <p><b>Agitation:</b> the CMAI score has been compared in a limited way between AD patients, with versus without agitation at baseline (<a href="#CD003154-tbl-0012">Table 10</a>). Memantine (versus placebo) appears to result in fewer people with agitation in most types of dementia, with the exception of AD patients with agitation, for which memantine may give more severe agitation (<a href="./references#CD003154-fig-0077" title="">Analysis 8.5</a>) (see section 5.2.3 below). The effect on agitation of memantine versus placebo appears to be larger in people with moderate‐to‐severe AD compared with mild‐to‐moderate AD (<a href="./references#CD003154-fig-0077" title="">Analysis 8.5</a>), and also seems more effective in monotherapy compared with concomitant ChEI (<a href="./references#CD003154-fig-0078" title="">Analysis 8.6</a>). Results for this outcome were not given for the mild post‐hoc subgroup. </p> </section> </section> <section id="CD003154-sec-0109"> <h4 class="title">5. Adverse effects</h4> <p>We report results for all types of dementia and all durations for the 20 mg/day dose or equivalent. Forty‐one studies met these dose inclusion criteria in 8960 randomised participants. However, not all studies reported all outcomes and four of these remaining studies did not report any safety outcomes (<a href="./references#CD003154-bbs2-0026" title="Lundbeck . Personal communication 21 June 2006. ">Lundbeck 2006 (99817)</a>; <a href="./references#CD003154-bbs2-0029" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9104)</a>; <a href="./references#CD003154-bbs2-0030" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9105)</a>; <a href="./references#CD003154-bbs2-0031" title="BoehmG . FDA new drug application 21‐487: safety review. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA‐Safety%20Review.pdfAugust 2003:71. ">Merz 2003 (MRZ‐9206)</a>). </p> <section id="CD003154-sec-0110"> <h5 class="title">5.1. All‐cause discontinuation and discontinuation due to adverse events</h5> <p>The results of the discontinuation analyses for all studies are shown in <a href="./references#CD003154-fig-0084" title="">Analysis 9.1</a> and <a href="./references#CD003154-fig-0085" title="">Analysis 9.2</a>, regardless of study duration, but split by dementia type and severity in <a href="./references#CD003154-fig-0079" title="">Analysis 8.7</a> and <a href="./references#CD003154-fig-0080" title="">Analysis 8.8</a> (three studies in mild‐to‐moderate disease were excluded from this analysis: <a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a>; <a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a>; <a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a>. Differences between studies in participants with or without ChEI are shown in <a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a> and <a href="./references#CD003154-fig-0028" title="">Analysis 2.10</a> (for which three studies were excluded from the analysis because a proportion of participants were treated with ChEI ‐ <a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a>; <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a>; <a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>); all study durations were permitted. </p> <section id="CD003154-sec-0111"> <h6 class="title">5.1.1. All‐cause discontinuation</h6> <p>All‐cause discontinuation was reported in 36 studies that included 8752 participants (1600 events). Overall, there is no difference between memantine and placebo: RR 0.99 (95% CI 0.91 to 1.08) (<a href="./references#CD003154-fig-0084" title="">Analysis 9.1</a>). There may be slight heterogeneity in the point estimates, but I² = 0%, P = 0.79. However, <a href="./references#CD003154-fig-0079" title="">Analysis 8.7</a> suggests there are differences across dementia types and severities, and this is reinforced in AD, which shows a highly significant result in the test for subgroup differences (I² = 83.8% and P = 0.01) when comparing mild disease (RR 1.74, 95% CI 1.08 to 2.81) and moderate‐to‐severe disease (RR 0.93, 0.83 to 1.04). </p> <p>We therefore report the results for this outcome separately for each dementia type and severity in the 'Summary of findings' tables for sections 1 to 3. For the moderate‐to‐severe AD group, there was no significant difference between the results for monotherapy and those for concomitant ChEI (<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>) and so we report the combined moderate‐to‐severe results (test for subgroup differences I² = 0%, P = 0.83). </p> </section> <section id="CD003154-sec-0112"> <h6 class="title">5.1.2. Discontinuation due to adverse events</h6> <p>Discontinuation due to adverse events was reported in 32 studies that included 8271 participants (779 events). Overall, there is little difference between memantine and placebo: RR 1.06 (95% CI 0.92 to 1.21) (<a href="./references#CD003154-fig-0085" title="">Analysis 9.2</a>). There is some heterogeneity in the point estimates, but I² = 0%, P = 0.64. <a href="./references#CD003154-fig-0080" title="">Analysis 8.8</a> suggests there may be differences in discontinuation due to adverse events across dementia types and severities, and for AD there is a significant result in the test for subgroup differences between mild and moderate‐to‐severe disease (I² = 78.5% and P = 0.03). For the moderate‐to‐severe subgroup, there is no difference between the results for monotherapy and those for concomitant ChEI (<a href="./references#CD003154-fig-0028" title="">Analysis 2.10</a>; test for subgroup differences: I² = 0%, P = 0.65). </p> <p>A previous finding of this review was that all‐cause discontinuation appeared to be less in participants taking memantine. This is only partially supported in this update by the six‐month trials of moderate‐to‐severe AD, which suggest a slight benefit (<a href="./references#CD003154-fig-0014" title="">Analysis 1.5</a>). However, for populations in which memantine has little effectiveness, there may be more people discontinuing the drug compared with placebo. </p> </section> </section> <section id="CD003154-sec-0113"> <h5 class="title">5.2. Adverse events</h5> <p>The adverse effects profile and tolerability were good.</p> <section id="CD003154-sec-0114"> <h6 class="title">5.2.1. Number with at least one adverse event</h6> <p>Twenty‐nine studies (of 41 possible) in 8033 participants reported the number of participants with at least one adverse event (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>); this is 90% of the available participants. Meta‐analysis showed no difference between memantine and placebo, which appeared consistent across studies: RR 1.03 (95% CI 1.00 to 1.06), I² = 0%, P = 0.60 (5371 events). </p> <p><a href="./references#CD003154-fig-0081" title="">Analysis 8.9</a> shows a subgroup analysis by severity (mild‐to‐moderate and moderate‐to‐severe) and type of dementia and there are no significant differences between subgroups. Sensitivity analysis, excluding studies at overall high risk of bias had little effect. An analysis of studies in AD patients with moderate‐to‐severe disease and without agitation at baseline showed there is no significant difference between the results for monotherapy (RR 0.99, 95% CI 0.94 to 1.04) and those for concomitant ChEI (RR 1.05, 95% CI 0.98 to 1.12). (<a href="./references#CD003154-fig-0029" title="">Analysis 2.11</a>). The test for subgroup differences was I² = 46.0%, P = 0.17), but this is probably due to the narrow confidence intervals as a consequence of a large number of participants, On the basis of the similarity of the different subgroup findings, we used AE results for the full dataset for every type and severity of dementia. </p> </section> <section id="CD003154-sec-0115"> <h6 class="title">5.2.2. Number with at least one serious adverse event</h6> <p>Twenty‐seven studies in 8138 participants reported the number with at least one serious adverse event (<a href="./references#CD003154-fig-0087" title="">Analysis 9.4</a>); this was 93% of all available participants. Meta‐analysis shows little difference between memantine and placebo: RR 0.92 (95% CI 0.83 to 1.02), I² = 0%, P = 0.71 (1157 events). <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a> shows subgroups by both type and severity of dementia. There appear to be some differences by type of dementia, but no dependence on severity amongst the AD studies without agitation. Additionally, there is no significant difference between the results for monotherapy and those for concomitant ChEI in people with moderate‐to‐severe disease (<a href="./references#CD003154-fig-0030" title="">Analysis 2.12</a>). Therefore, in sections 1 to 4 we report this outcome separately for the different types of dementia, but combine the results for the AD studies (apart from those with agitation). </p> </section> <section id="CD003154-sec-0116"> <h6 class="title">5.2.3. Number with agitation as an adverse event</h6> <p>Nineteen studies in 5933 participants reported the number of participants with agitation (<a href="./references#CD003154-fig-0088" title="">Analysis 9.5</a>); this was 68% of all available participants. Data on agitation were mainly reported as 'serious adverse events' or 'adverse events' in ClinicalTrials.gov or as registry data (see footnotes to the forest plots). Meta‐analysis suggests that fewer participants have agitation if they are taking memantine compared with placebo: RR 0.84 (95% CI 0.71 to 1.01) (424 events). There is some heterogeneity, I² = 32%, P = 0.09. Subgrouping by severity and type of dementia in <a href="./references#CD003154-fig-0077" title="">Analysis 8.5</a> showed there were some differences by type of dementia, but the subdivision into mild‐to‐moderate and moderate‐to‐severe AD is not warranted, particularly because it was dependent on one study in people with moderate AD ((<a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a>). There are no agitation data for the post‐hoc subgroups of mild and moderate AD. </p> <p>In the AD population with agitation at baseline, there may be twice as many participants with agitation as a treatment emergent adverse event at six months for memantine compared with those on placebo, whereas memantine appears to be protective for agitation in people with AD without agitation at baseline (test for subgroup differences I² = 84%, P = 0.01) (<a href="./references#CD003154-fig-0077" title="">Analysis 8.5</a>) (low‐certainty evidence). </p> <p>There may be different effects in the presence compared with the absence of ChEIs (<a href="./references#CD003154-fig-0031" title="">Analysis 2.13</a>; test for subgroup differences: I² = 20.9, P = 0.26). The results suggest less agitation for memantine (versus placebo) for the monotherapy subgroup (RR 0.68, 95% CI 0.51 to 0.91) and some heterogeneity, but little difference for concurrent therapy with ChEI (RR 0.92, 95% CI 0.60 to 1.40). Therefore, we reported this outcome separately in the summary of findings tables for sections 1 to 3 for other types of dementia; we combined the results for the AD studies across all severities (apart from those with agitation), but reported separately the results for studies in people receiving concomitant ChEI. </p> <p>The collection of 'agitation as an adverse event' is not a good way to assess the impact of interventions on incident agitation, particularly for the studies in patients with agitation at baseline. Nevertheless, we have included these results in <a href="./references#CD003154-fig-0083" title="">Analysis 8.11</a> for completeness, but have reported agitation as an efficacy outcome in section 1.4. </p> </section> <section id="CD003154-sec-0117"> <h6 class="title">5.2.4. Number with specific adverse events</h6> <p>Results for other adverse events are shown in <a href="#CD003154-tbl-0013">Table 11</a> and in <a href="./references#CD003154-fig-0089" title="">Analysis 9.6</a> (insomnia); <a href="./references#CD003154-fig-0090" title="">Analysis 9.7</a> (confusion); <a href="./references#CD003154-fig-0091" title="">Analysis 9.8</a> (depression); <a href="./references#CD003154-fig-0092" title="">Analysis 9.9</a> (headache); <a href="./references#CD003154-fig-0093" title="">Analysis 9.10</a> (hypertension); <a href="./references#CD003154-fig-0094" title="">Analysis 9.11</a> (dizziness); <a href="./references#CD003154-fig-0095" title="">Analysis 9.12</a> (falls); <a href="./references#CD003154-fig-0096" title="">Analysis 9.13</a> (accidental injury); <a href="./references#CD003154-fig-0097" title="">Analysis 9.14</a> (urinary incontinence); <a href="./references#CD003154-fig-0098" title="">Analysis 9.15</a> (diarrhoea) and <a href="./references#CD003154-fig-0099" title="">Analysis 9.16</a> (influenza‐type symptoms). </p> <div class="table" id="CD003154-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies (participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity (I²)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GRADE rating</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia (<a href="./references#CD003154-fig-0089" title="">Analysis 9.6</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (5354), 221 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.73 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 14%, P = 0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW (downgraded on imprecision and reporting bias &lt; 70% patients had AE data)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confusion (<a href="./references#CD003154-fig-0090" title="">Analysis 9.7</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (4509), 167 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.91 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW (downgraded on imprecision and reporting bias &lt; 70% patients had AE data)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression (<a href="./references#CD003154-fig-0091" title="">Analysis 9.8</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3052), 83 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.70 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (twice), inconsistency in point estimates (once) and reporting bias &lt;40% patients had AE data (twice)) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache (<a href="./references#CD003154-fig-0092" title="">Analysis 9.9</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (4889), 240 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (1.00 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 9%,P = 0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW (downgraded on imprecision (once) and reporting bias &lt;70% patients had AE data)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (<a href="./references#CD003154-fig-0093" title="">Analysis 9.10</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (3175), 87 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 (1.14 to 2.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 1%, P = 0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (twice), inconsistency in point estimates (once) and reporting bias &lt;40% patients had AE data (twice)) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness (<a href="./references#CD003154-fig-0094" title="">Analysis 9.11</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (6395), 323 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59 (1.28 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MODERATE (downgraded on inconsistency in point estimates)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Falls (<a href="./references#CD003154-fig-0095" title="">Analysis 9.12</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (6743), 589 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.84 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIGH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Accidental injury (<a href="./references#CD003154-fig-0096" title="">Analysis 9.13</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3813), 214 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.62 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (once) and twice on reporting bias (&lt; 50% patients and 1 in 4 studies) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary incontinence (<a href="./references#CD003154-fig-0097" title="">Analysis 9.14</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (2724), 76 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.73 to 1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (twice), inconsistency in point estimates (once) and reporting bias &lt;4 0% patients had AE data (twice)) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea (<a href="./references#CD003154-fig-0098" title="">Analysis 9.15</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (6186), 318 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.66 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW (downgraded on imprecision (once), some inconsistency in point estimates and reporting bias &lt;70% patients had AE data (once further)) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Influenza‐like symptoms (<a href="./references#CD003154-fig-0099" title="">Analysis 9.16</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2836), 129 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.87 to 1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (once), and reporting bias &lt; 40% patients and 1/6 studies had AE data (twice)) </p> </td> </tr> </tbody> </table> </div> <p>The evidence on specific adverse events was generally of low‐ or very low‐certainty, mainly because relatively few studies reported the outcomes and we felt there was risk of reporting bias (<a href="#CD003154-tbl-0013">Table 11</a>). </p> <p>Memantine is probably 1.6 times more likely than placebo to result in dizziness (RR 1.59, 95% CI 1.28 to 1.98) (moderate‐certainty) and may be 1.2 times more likely to result in confusion (RR 1.23, 95% CI 0.91 to 1.65) and 1.3 times more likely to give headache (RR 1.29, 95% CI 1.00 to 1.66) (low certainty). Memantine may be 1.2 times less likely than placebo to result in diarrhoea (RR 0.82, 95% CI 0.66 to 1.02) (low certainty). There is no difference between interventions for the incidence of falls (RR 0.98, 95% CI 0.84 to 1.13) (high‐certainty evidence). There is uncertainty about the other adverse events recorded. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003154-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003154-sec-0118">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003154-sec-0194">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003154-sec-0118"></div> <section id="CD003154-sec-0119"> <h3 class="title" id="CD003154-sec-0119">Summary of main results</h3> <p>We discuss in this section the findings in relation to the two objectives of the review: to assess the efficacy and safety of memantine for the treatment of dementia of different aetiologies, and secondly, to assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs). </p> <section id="CD003154-sec-0120"> <h4 class="title">A) Efficacy and safety of memantine</h4> <p>Memantine shows a small important clinical benefit over placebo in some populations, but not others. In particular, there is benefit for moderate‐to‐severe Alzheimer's disease (AD) for the four efficacy outcomes, and for some outcomes for vascular dementia. There is probably no benefit in mild AD and it is uncertain whether there is any effect in people with agitation in moderate‐to‐severe disease. A summary of the efficacy results are given below. </p> <p>Throughout the review, we found no difference between memantine and placebo in the number of people with at least one adverse event, regardless of aetiology of dementia or severity (risk ratio (RR) 1.03, 95% confidence interval (CI) 1.00 to 1.06). The evidence on specific adverse events is generally of low‐ or very low‐certainty, mainly because relatively few studies reported the outcomes and we felt there was risk of reporting bias. That said, memantine is probably 1.59 (95% CI 1.28 to 1.98) times more likely than placebo to result in dizziness (6.1% versus 3.9%) and may be 1.29 (95% CI 1.00 to 1.66) times more likely to result in headache (5.5% versus 4.3%). Memantine may be 1.2 times less likely than placebo to result in diarrhoea (RR 0.82, 95% CI 0.66 to 1.02) . There is no difference between interventions for the incidence of falls. </p> <p>Discontinuation (all‐cause) varies according to severity of disease and may have an inverse relationship with effectiveness. For example, discontinuation in mild AD participants (RR 1.74, 95% CI 1.08 to 2.81) is very different from that in moderate‐to‐severe AD: (RR 0.93, 95% CI 0.83 to 1.04). </p> <section id="CD003154-sec-0121"> <h5 class="title">1. Alzheimer's disease (AD)</h5> <p>The efficacy of memantine varies according to the severity of disease.</p> <p>For moderate‐to‐severe AD, evidence from up to 14 studies in around 3700 participants shows there is a small clinical benefit for memantine relative to placebo in each of the main efficacy outcomes. Approximately similar numbers of people taking memantine and placebo discontinue treatment and there is probably a reduction in the number with agitation as an adverse event. These differences between memantine and placebo are small but important benefits and we know them with confidence (see <a href="#CD003154-sec-0126">Quality of the evidence</a>). They are accompanied by similar numbers of people discontinuing treatment and there is probably a reduction in those with agitation. </p> <p>For people with mild AD, we used evidence from post‐hoc subgroups within four studies in people with mild‐to‐moderate disease. Although the trials were conducted in the mild‐to‐moderate population, licensing and treatment of AD is stratified into mild and moderate‐to‐severe categories, and we had to isolate evidence on the mild population in this way. There was one small study conducted solely in people with mild disease, but this did not give sufficient information to investigate the effect of memantine in this population (and was concerned with driving abilities). Evidence from up to four studies in around 600 participants suggested there may be no difference between memantine and placebo for clinical global rating and there is probably no difference for the other three efficacy outcomes. There may be an increase in the number of people discontinuing treatment because of adverse events, which may not be surprising given the lack of efficacy. For the population with mild AD, we observed an average improvement over time in cognitive function and in behaviour and mood for the placebo groups (median change from baseline). We are uncertain whether this improvement is a real effect or a statistical regression to the mean; it is possible that the improvement could be related to participants being in a trial. </p> <p>We also investigated separately the effect of memantine in people with moderate‐to‐severe AD, who were selected for agitation. Only one study had results at six months, but we also analysed two other studies with three months' follow‐up, in order to probe whether the six‐month study was an outlier. This evidence was mainly of low or very low certainty, and within these limitations, suggested there may be little or no effect of memantine in this population for the outcomes of clinical global rating, cognitive function and performance on activities of daily living (ADL); the evidence for behaviour and mood was of very low certainty. There was moderate‐certainty evidence for the Cohen‐Mansfield Agitation Index (CMAI) score for agitation, which suggested there was probably no difference between memantine and placebo. The proportion reporting agitation as a treatment emergent adverse events (AEs) in two studies (403 participants) may be doubled in patients selected for agitation receiving memantine (plus ChEI) compared with placebo (plus ChEI). This is in contrast with AD patients with moderate‐to‐severe disease who were not selected for agitation, and in whom the proportion reporting agitation is reduced by memantine. We do not generally have confidence in these results, but consider that further research is needed to determine if memantine is indeed ineffective in an agitation population, appreciating that trials in this agitated population are difficult to conduct. </p> </section> <section id="CD003154-sec-0122"> <h5 class="title">2. Vascular dementia</h5> <p>Moderate‐ and low‐certainty evidence from two studies in around 750 participants with vascular dementia gave mixed results for the comparison of memantine and placebo. There is probably a small clinical benefit for cognitive function and there may be a small clinical benefit on the Nurse's Observational Scale for Geriatric Patients (NOSGER) disturbing behaviour outcome. However, there is probably no difference between memantine and placebo in clinical global rating and there may be no difference in performance on ADL. There may be no difference in the numbers of people discontinuing treatment and there may be fewer people with agitation as an adverse event for memantine compared with placebo. </p> <p>A post‐hoc subgroup analysis by severity suggested that memantine (versus placebo) may have a bigger effect for cognitive function in people with moderate‐to‐severe vascular dementia ( Mini Mental State Examination (MMSE) ≥14) than in people with mild‐to‐moderate vascular dementia. The test for subgroup differences was significant (I² = 72.5%, P = 0.06), although this was a post‐hoc analysis. </p> </section> <section id="CD003154-sec-0123"> <h5 class="title">3. Other forms of dementia</h5> <p>Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB): low‐ and very low‐certainty evidence from up to three studies in around 250 participants suggests that, for memantine versus placebo in people with PDD or DLB, there may be a small clinical benefit in clinical global rating and in behaviour and mood (although the confidence interval was consistent with both no effect and benefit). Evidence for all other efficacy outcomes was of very low certainty. There may be fewer people discontinuing treatment. </p> <p>Frontotemporal dementia (FTD): mainly low‐certainty evidence from two studies in around 120 participants suggests there may be a small clinical benefit in clinical global function and in behaviour and mood for memantine versus placebo in people with FTD. There may be no difference in cognitive function. However, for all of the efficacy outcomes, there is uncertainty and the confidence interval is consistent with more than one conclusion. There may be more discontinuation in the memantine group (compared with placebo) for this population, but again the CI is wide. </p> <p>AIDS‐related Dementia Complex (ADC): only one study in 140 participants was identified and suggested there may be an improvement in cognitive score ( Neuropsychological Z score (NPZ)‐8) at 16 weeks and that all‐cause discontinuation may be similar for memantine and placebo. </p> </section> </section> <section id="CD003154-sec-0124"> <h4 class="title">B) Benefit of memantine for those already taking cholinesterase inhibitors (ChEIs)</h4> <p>For our second objective, we examined whether memantine could give incremental benefit for people already taking ChEIs. We examined this by investigating whether there were different effects according to the presence or absence of concomitant ChEIs in those for whom memantine was more efficacious than placebo (i.e. moderate‐to‐severe AD). </p> <p>Moderate‐to‐severe AD, with concomitant ChEIs: six trials in around 1850 people showed a small clinical benefit for memantine versus placebo in cognitive function, performance on ADL and behaviour and mood; and there is probably a small clinical benefit in clinical global rating. There are similar numbers of people with adverse events in both groups (RR 1.03, 95% CI 1.00 to 1.06). Similar numbers of people taking memantine and a ChEI discontinue their treatment compared to those taking placebo and a ChEI, and there may be little or no difference between interventions in the number with agitation as an adverse event. </p> <p>There were similar efficacy findings for people receiving memantine monotherapy, except that the benefit compared with placebo is smaller in monotherapy for the behaviour and mood outcome and larger for the cognitive function outcome (<a href="#CD003154-tbl-0012">Table 10</a>). In contrast to people receiving concomitant ChEI, people receiving memantine monotherapy probably have less agitation than those receiving placebo. </p> <p>Between‐trial subgroup analyses comparing the presence and absence of concomitant ChEIs suggest there is no significant difference between monotherapy and concurrent therapy with concomitant ChEI (for the comparison of memantine versus placebo) for any of the primary efficacy outcomes, although there is a non‐significant difference between subgroups for the cognitive function outcome (I² = 44%, P = 0.18) and for the behaviour and mood outcome (I² = 35%, P = 0.21). These subgroup analyses are non‐randomised comparisons between different groups of studies and do not investigate possible confounding factors, such as severity of disease. The only head‐to‐head randomised evidence was of low certainty: one study randomised 149 participants to memantine plus continued donepezil versus memantine plus placebo and donepezil discontinued. The study suffered from differential missing data, but there may be a benefit in using both drugs compared with memantine monotherapy for cognitive function, i.e. it may be better to add memantine than to switch to memantine. </p> </section> </section> <section id="CD003154-sec-0125"> <h3 class="title" id="CD003154-sec-0125">Overall completeness and applicability of evidence</h3> <p>People with dementia who are recruited into drugs trials are often not representative of typical clinical populations. Those recruited typically lack physical comorbidities, have better psychosocial support, and are less likely to have neuropsychiatric symptoms, all of which may mitigate against decline and its functional impact. </p> <p>The studies were too short and small to be expected to show any effect of memantine on life expectancy. It is possible that the drug extends the total time of deterioration without reducing the personal or social burden of the disease (<a href="./references#CD003154-bbs2-0175" title="DresserR . Weighing the benefits of new Alzheimer's treatments. Science2000;289:869. ">Dresser 2000</a>).The benefits of slowing Alzheimer's disease progression in the later stages can be controversial (<a href="./references#CD003154-bbs2-0220" title="PostSG . Slowing the progression of Alzheimer disease: ethical issues. Alzheimer Disease and Associated Disorders1997;11(suppl 5):S34‐9. ">Post 1997</a>). </p> <p>The reliability of the distinction between vascular and Alzheimer's dementia is not high: most patients with vascular dementia, especially those with severe dementia have additional Alzheimer's pathology. This limits the applicability of results from trials of mild‐to‐moderate vascular dementia to those with severe vascular dementia. </p> <p>Responder analyses are not routinely presented although the data are available from all trials. However, a meta‐analysis of responders based on six trials found that 10% more placebo‐treated than memantine‐treated patients showed any clinical worsening (<a href="./references#CD003154-bbs2-0242" title="WilkinsonD , AndersenHF . Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dementia &amp; Geriatric Cognitive Disorders2007;24(2):138‐45. ">Wilkinson Post‐Hoc 6RCTs 2007</a>). There was a similar difference in rates of marked clinical worsening. </p> <p>Measures of executive function are difficult to assess in those with more advanced dementia and in general are not well covered in AD trials which use the Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) and were not included in the vascular dementia trials (<a href="./references#CD003154-bbs2-0226" title="RomanGC , RoyallDR . Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Disease and Associated Disorders1999;13(suppl 3):S69‐S80. ">Roman 1999</a>). </p> <p>Comprehensive lists of adverse drug reactions are infrequently reported so there is a theoretical possibility of publication bias. Regulators require comprehensive reporting. Whilst the details of these reports to regulators remain confidential, changes in the 'Summary of Product Characteristics' are likely to be a more reliable source of information on rare adverse effects than pooled data in systematic reviews. </p> </section> <section id="CD003154-sec-0126"> <h3 class="title" id="CD003154-sec-0126">Quality of the evidence</h3> <p>The evidence for AD is mainly of high certainty (with the exception of studies in people selected for agitation), which means we can be very confident of the results, which we summarised across many studies in large numbers of participants. The evidence for mild AD was obtained from within‐trial post‐hoc subgroups, with data provided by drug companies, but this evidence is still of moderate certainty. </p> <p>The evidence certainty is moderate to low for vascular dementia and mainly low for FTD. For PDD or DLB and AD participants with agitation, the evidence certainty is mainly low or very low. </p> <p>The authors of this review have gone to great lengths to obtain data for studies that have not been fully published, or for which there have been delays in publication. This work has much increased the volume of evidence available, nevertheless the results of some studies are still not in the public domain and there could be publication bias. Funnel plots for the main efficacy outcomes and for all‐cause discontinuation did not appear to suggest small studies' bias. There may be some asymmetry found for the adverse events outcome. Nearly all the trials were funded by drug companies. </p> </section> <section id="CD003154-sec-0127"> <h3 class="title" id="CD003154-sec-0127">Potential biases in the review process</h3> <p>In analysing the data, we have carried out a series of subgroup analyses and stratifications. At the outset, we stratified the studies by type of dementia, but later compared across aetiologies as a check. Stratification seemed appropriate for the efficacy outcomes and some safety outcomes, but we combined the results for adverse events across all studies because we found no differences in adverse events between diagnostic subgroups. We investigated duration of study, dose of memantine and type of analysis (observed case (OC) versus last observation carried forward (LOCF)) and restricted the main analyses to a duration of six months and licensed dose, also preferring to analyse OC data. We have documented our reasoning for all these decisions, but they could be a source of bias. </p> <p>We split the data by severity into mild and moderate‐to‐severe AD, on the basis of subgroup analyses and pragmatism connected with current licensing requirements. These subgroup analyses seemed to provide convincing evidence, but are still non‐randomised comparisons, and there could have been confounding by some other factor. We then split the moderate‐to‐severe dataset further in our investigation of the effect of concomitant ChEI, and this further splitting could have led to random error. For this reason (and the lack of evidence of a difference between monotherapy and dual therapy), we prefer to use results for all studies regardless of their use of ChEI. </p> <p>We calculated data for mild AD from published trial data in people with mild‐to‐moderate disease and drug company‐provided subgroup data for people with moderate disease. These data are from post‐hoc subgroups and so there may be differences between intervention groups in baseline characteristics. It would have been preferable to stratify patients by severity and then randomise to treatments, but this was not done by the trialists. Having said this, there are large numbers of participants and the split into mild and moderate disease is pre‐defined, so this is probably a minor limitation. </p> <p>We also made some post‐hoc decisions, namely to treat separately studies in AD patients selected for agitation and to exclude from the analysis two randomised arms from one study because of a study‐reported interaction of memantine with Vitamin E. In the first instance, we considered the patients selected for agitation to be sufficiently dissimilar from other AD patients that they should not be included in the same analyses, and in the second case we thought the effect modification could have introduced unwarranted heterogeneity. These decisions could have meant that our findings for AD were overestimated. </p> <p>We have been transparent about the approaches taken in this review, and do not consider the potential for bias is high. </p> </section> <section id="CD003154-sec-0128"> <h3 class="title" id="CD003154-sec-0128">Agreements and disagreements with other studies or reviews</h3> <p>This updated Cochrane Review has mainly similarities, but some differences with previous work. We focus here on clinical guidelines or technology appraisals for dementia, and recent systematic reviews of memantine. We mainly focus on AD, considering the number of studies included, the approach to monotherapy and concurrent therapy, ways of dealing with missing data, the effects of severity and the impact of agitation. </p> <p>We have included 32 new studies (in comparison with 2006), several of which had unpublished data provided by the study authors or drug companies. We also included results for post‐hoc subgroups, which have informed analyses for both the mild and moderate‐to‐severe AD categories. We have meta‐analysed results from considerably more AD studies than were included in the NICE technology appraisal, which had four monotherapy and two dual therapy trials (<a href="./references#CD003154-bbs2-0215" title="National Institute for Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. Technology appraisal guidance 217 (Review of NICE technology appraisal guidance 111). http://guidance.nice.org.uk/TA217/Guidance/pdf/English2011. ">NICE 2011</a>); and consequently our review has more precise summary statistics. For moderate‐to‐severe AD, this has meant that all the main efficacy outcomes show small benefits that are statistically significant, in contrast to the largely non‐significant findings of TA 217 ‐ which were equated with no effect (see <a href="#CD003154-sec-0034">Why it is important to do this review</a>). </p> <p>Our analyses have shown that the benefit obtained for monotherapy versus placebo in moderate‐to‐severe AD is very similar to that obtained in dual therapy trials, and the test for subgroup differences is not significant. Therefore, we have included all trials in the meta‐analyses, regardless of the presence or absence of ChEIs. This conclusion about the efficacy of dual therapy contrasts with the conclusion of the NICE appraisal, which stated there was a lack of evidence of additional clinical efficacy (of concurrent therapy with ChEIs) compared with memantine monotherapy (<a href="./references#CD003154-bbs2-0215" title="National Institute for Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. Technology appraisal guidance 217 (Review of NICE technology appraisal guidance 111). http://guidance.nice.org.uk/TA217/Guidance/pdf/English2011. ">NICE 2011</a>). Since 2011, there have been many new studies of memantine in AD, leading to more up‐to‐date systematic reviews, and NICE has now published an update to its dementia guideline in June 2018 (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>). We discuss this recent literature below. </p> <p>Three systematic reviews in AD have been published in the past three years, two of memantine monotherapy (<a href="./references#CD003154-bbs2-0073" title="ChenR , ChanPT , ChuH , LinYC , ChangPC , ChenCY , et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a metaanalysis. PLOS One2017;12(8):e0183586. doi: 10.1371/journal.pone.0183586. eCollection 2017. ">Chen 2017</a>; <a href="./references#CD003154-bbs2-0209" title="MatsunagaS , KishiT , IwataN . Memantine for Alzheimer’s Disease: systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. ">Matsunaga 2015</a>, and one of dual therapy (<a href="./references#CD003154-bbs2-0210" title="MatsunagaS , KishiT , IwataN . Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta‐analysis. International Journal of Neuropsychopharmacology2015;18(5):pyu115. doi:10.1093/ijnp/pyu115. ">Matsunaga 2015b</a>). These gave similar conclusions to our review for most outcomes, even though the authors included studies reporting participants with mild AD and studies that did not have a placebo comparator, and also used LOCF approaches for missing data. A further systematic review included three studies of dual therapy and showed significant benefits when the analysis was restricted to moderate‐to‐severe AD (<a href="./references#CD003154-bbs2-0213" title="MuayqilT , CamicioliR . Systematic review and meta‐analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer’s disease and other dementias. Dementia and Geriatric Cognitive Disorders Extra2012;2(1):546‐72. ">Muayqil 2012</a>). We also identified a recent review of predominantly Chinese studies, which compared concurrent therapy with donepezil, however the majority of studies did not include a placebo (<a href="./references#CD003154-bbs2-0073" title="ChenR , ChanPT , ChuH , LinYC , ChangPC , ChenCY , et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a metaanalysis. PLOS One2017;12(8):e0183586. doi: 10.1371/journal.pone.0183586. eCollection 2017. ">Chen 2017</a>). We note that the FDA granted a license for combination therapy in patients stabilised on 10 mg donepezil once daily in December 2014 and a combined formulation product was launched in 2015. </p> <p>The effect of severity was also identified in two other systematic reviews (<a href="./references#CD003154-bbs2-0174" title="DiSantoSG , PrinelliF , AdorniF , CaltagironeC , MusiccoM . A meta‐analysis of the efficacy of donepezil, rivastigmine, galantamine and memantine in relation to severity of Alzheimer’s Disease. Journal of Alzheimer’s Disease2013;35:349–61. ">Di Santo 2013;</a><a href="./references#CD003154-bbs2-0205" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. ">Kishi 2017</a>): one of these showed greater efficacy as severity increased in a similar way to our review, but only included six trials (<a href="./references#CD003154-bbs2-0174" title="DiSantoSG , PrinelliF , AdorniF , CaltagironeC , MusiccoM . A meta‐analysis of the efficacy of donepezil, rivastigmine, galantamine and memantine in relation to severity of Alzheimer’s Disease. Journal of Alzheimer’s Disease2013;35:349–61. ">Di Santo 2013</a>). The other review of 30 AD studies (including those without a placebo comparator) reached similar conclusions to ours regarding severity, but did not probe the effect of memantine in mild AD disease (<a href="./references#CD003154-bbs2-0205" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. ">Kishi 2017</a>). </p> <p>The NICE dementia guideline has been updated concurrently with the update of this Cochrane Review (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>); we have shared data with the guideline developers and the Cochrane Dementia and Cognitive Improvement review group is a registered stakeholder for the guideline. The guideline is a major update of the original guideline and updates some aspects of TA 217. The guideline preserved the TA's original stratification for analyses of monotherapy and dual therapy, and has updated the dual therapy analyses by including additional studies; however, the monotherapy analyses have not been updated (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>). The update has revised recommendations for 'people who are already taking a ChEI', for whom clinicians should now consider adding memantine to ChEIs for people with moderate disease and offer memantine in addition to ChEI to people with severe disease (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>). The evidence in this Cochrane Review supports (and indeed has informed) recommendations to offer dual therapy, but we consider that the monotherapy recommendations should also have been examined, especially because there are many new studies and memantine is now off‐patent. We are also concerned that the conflation of the old and new recommendations in the new guideline may lead to confusion for clinicians. For example, in severe disease, the unchanged monotherapy recommendation is to offer memantine (and not ChEIs), yet the new dual therapy recommendation is for people who are 'already taking a ChEI'. Additionally, the 2018 guideline is not explicit on whether combination therapy should be offered as first line therapy for people presenting with moderate or severe disease. </p> <p>A systematic review of clinical guidelines reported the recommendations from 12 moderate‐ to high‐quality guidelines (<a href="./references#CD003154-bbs2-0214" title="NgoJ , Holroyd‐LeducJM . Systematic review of recent dementia practice guidelines. Age and Ageing (https://doi.org/10.1093/ageing/afu143)2015;44(1):25‐33. ">Ngo 2015</a>). The authors noted there was disagreement between two guidelines on the benefit of memantine in mild AD, but agreement in its use in moderate‐to‐severe dementia.They noted conflicting recommendations amongst four guidelines to support combining ChEI therapy with memantine in moderate–to‐severe dementia. </p> <p>France's Minister for Health has recently de‐listed memantine and the ChEIs, donepezil, galantamine and rivastigmine (<a href="./references#CD003154-bbs2-0197" title="Haute Autorité deSanté . Care Pathway Guide for Patients with Neurocognitive Disorders Associated with Alzheimer's Disease or Related Disease [Guide parcours de soins des patients présentant un trouble neurocognitif associé à la maladie d’Alzheimer ou à une maladie apparentée]. https://www.has‐sante.fr/portail/upload/docs/application/pdf/2018‐05/parcours_de_soins_alzheimer.pdf (accessed 28 October 2018). ">HAS 2018</a>), stating that "it is better to concentrate on helping to organise daily activities, maintain activity, support and help from those around you", This de‐listing was based on work by the Haute Autorité de Santé (HAS), which stated in 2016 following evidence review, "The new data confirms that the efficacy of drugs for the symptomatic treatment of Alzheimer's disease is, at best, modest. It is established only in the short term, mainly on cognitive disorders, in placebo controlled clinical studies whose clinical relevance and transposability in real life are not ensured. Patients in these studies are indeed younger than those who are managed in real practice, and unlike these they have no comorbidities, nor risks of drug interactions. In addition, the effects on behavioral disorders, quality of life, time to enter an institution, mortality, burden of illness for carers are still not established... However, the data accumulated since the commercialization of the drugs confirm the risk of occurrence of undesirable side effects (digestive, cardiovascular or neuropsychiatric disorders for the most notable) potentially serious, which can alter the quality of life" (<a href="./references#CD003154-bbs2-0196" title="Haute Autorité deSanté . Drugs of Alzheimer's disease: insufficient medical interest to justify their support by national solidarity. https://translate.google.com/translate?hl=en&amp;sl=fr&amp;u=https://www.has‐sante.fr/portail/jcms/c_2679466/fr/medicaments‐de‐la‐maladie‐d‐alzheimer‐un‐interet‐medical‐insuffisant‐pour‐justifier‐leur‐prise‐en‐charge‐par‐la‐solidarite‐nationale&amp;prev=search (accessed 8 November 2018)2016. ">HAS 2016</a>, translation). The 2018 statement was less measured, stating that, "None of the available drugs has been shown to slow down progression toward dependence, yet all carry a risk of life‐threatening adverse effects and severe drug interactions" (<a href="./references#CD003154-bbs2-0222" title="Drugs for Alzheimer's disease: finally delisted in France. http://english.prescrire.org/en/81/168/55126/0/NewsDetails.aspx (accessed 28 October 2018). ">Prescrire 2018</a>) (see <a href="#CD003154-sec-0034">Why it is important to do this review</a>). </p> <p>The HAS based its conclusions for the efficacy of memantine on the <a href="./references#CD003154-bbs2-0209" title="MatsunagaS , KishiT , IwataN . Memantine for Alzheimer’s Disease: systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. ">Matsunaga 2015</a> review for monotherapy and an earlier review authored by some of us for dual therapy (<a href="./references#CD003154-bbs2-0181" title="FarrimondLE , RobertsE , McShaneR . Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open2012;2:e000917.doi:10.1136/bmjopen‐2012‐000917. ">Farrimond 2012</a>), both of which broadly agree with the conclusions of our memantine review, but there are differences for ADL for both reviews (<a href="./references#CD003154-bbs2-0198" title="Haute Autorité deSanté . Assessment report of drugs indicated in the symptomatic treatment of Alzheimer's disease [Rapport d'évaluation des médicaments indiqués dans le traitement symptomatique de la maladie d'Alzheimer]. http://docreader.readspeaker.com/docreader/?jsmode=1&amp;cid=brvzc&amp;lang=fr_fr&amp;voice=Thomas&amp;url=https%3A%2F%2Fwww.has‐sante.fr%2Fportail%2Fupload%2Fdocs%2Fapplication%2Fpdf%2F2016‐10%2Fannexe_‐_rapport_devaluation_des_medicaments.pdf&amp;v= 2016 (accessed 8 November 2018). ">HAS Annexe 2016</a>). The HAS considered the benefits to be 'clinically irrelevant' and stated there is no difference in ADL for dual therapy. These conclusions are not supported either by our current memantine review or by the review and cost‐effectiveness analysis of the NICE guideline (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>). We consider that the small incremental benefits from each of ChEI and memantine for all outcomes at six months follow‐up, each having an effect size that may be less than the minimum clinically important difference, do not equate to clinical irrelevance. As stated above, we do agree that participants recruited into drugs trials are often not representative of typical clinical populations. </p> <p>Second, the French authorities examined adverse effect data in detail for the ChEIs and memantine, using meta‐analyses of clinical trials, summary of products characteristics (SPC) and (for uncommon AEs) observational studies and analyses of pharmacovigilance databases (<a href="./references#CD003154-bbs2-0198" title="Haute Autorité deSanté . Assessment report of drugs indicated in the symptomatic treatment of Alzheimer's disease [Rapport d'évaluation des médicaments indiqués dans le traitement symptomatique de la maladie d'Alzheimer]. http://docreader.readspeaker.com/docreader/?jsmode=1&amp;cid=brvzc&amp;lang=fr_fr&amp;voice=Thomas&amp;url=https%3A%2F%2Fwww.has‐sante.fr%2Fportail%2Fupload%2Fdocs%2Fapplication%2Fpdf%2F2016‐10%2Fannexe_‐_rapport_devaluation_des_medicaments.pdf&amp;v= 2016 (accessed 8 November 2018). ">HAS Annexe 2016</a>). The HAS reported that in placebo‐controlled clinical trials, more people discontinued donepezil 10 mg than placebo due to adverse effects, but the HAS did not report this for other ChEIs or memantine. In our current memantine review, however, we have noted a significant subgroup difference for this outcome between people with mild disease (greater discontinuation on memantine) and those with moderate‐to‐severe disease (no difference compared with placebo) (see section A above). The HAS report included some observational studies, one of which compared memantine and the three ChEIs (but had no data on untreated patients) (<a href="./references#CD003154-bbs2-0188" title="FosbølEL , PetersonED , HolmE , GislasonGH , ZhangY , CurtisLH , et al. Comparative cardiovascular safety of dementia medications: a cross‐national study. Journal of the American Geriatric Society2012;60:2283–9. ">Fosbøl 2012</a>). This very large study in the USA and Denmark reported for the Danish cohort a greater risk (in adjusted analyses) of myocardial infarction and cardiac death for memantine (compared with donepezil) and a smaller risk for syncope and atrioventricular block, but no differences in the USA cohort on hospitalisation for cardiac events. In both cohorts, all‐cause mortality was greater for patients receiving memantine. The authors concluded that the greater risk of cardiovascular events in the Danish cohort in users of memantine and dual therapy is probably related to selection of sicker participants, because these therapies are reserved for individuals with more severe dementia in Denmark. They also noted the lack of comparative data (with placebo/no treatment) and stated that "no clinical studies has found cardiovascular signals of clinical concern" (<a href="./references#CD003154-bbs2-0188" title="FosbølEL , PetersonED , HolmE , GislasonGH , ZhangY , CurtisLH , et al. Comparative cardiovascular safety of dementia medications: a cross‐national study. Journal of the American Geriatric Society2012;60:2283–9. ">Fosbøl 2012</a>). The HAS also gives pharmacovigilance data (as case reports) and indicates changes made to the SPCs of the various drugs: data on donepezil versus placebo was inconsistent for mortality in people with vascular dementia; there may be an increased risk of QT interval prolongation for galantamine and there may be an increased risk of myocardial infarction, stroke and torsade de pointes for rivastigmine. A very large pharmacovigilance study of the WHO database, VigiBase, over 58 countries, investigated all ChEIs and noted that serious cardiovascular events were frequently reported, suggesting that their significance has probably been previously underestimated, and encouraging caution when prescribing these drugs, especially as patients with Alzheimer's disease are frequently frail and receive other drugs (<a href="./references#CD003154-bbs2-0207" title="KrögerE , MoulsM , WilcheskyM , BerkersM , CarmichaelP‐H , vanMarumR , et al. Adverse drug reactions reported with cholinesterase Inhibitors: an analysis of 16 years of individual case safety reports from VigiBase. Annals of Pharmacotherapy2015;49(11):1197‐206. ">Krӧger 2015</a>). The HAS has little to say about memantine pharmacovigilance except that hepatitis has been added to the SPC, but does agree with our review on the results for adverse effects from clinical trials. Instead of treating memantine separately from ChEIs, the HAS statements on safety apply to the dementia drugs as a whole (<a href="./references#CD003154-bbs2-0198" title="Haute Autorité deSanté . Assessment report of drugs indicated in the symptomatic treatment of Alzheimer's disease [Rapport d'évaluation des médicaments indiqués dans le traitement symptomatique de la maladie d'Alzheimer]. http://docreader.readspeaker.com/docreader/?jsmode=1&amp;cid=brvzc&amp;lang=fr_fr&amp;voice=Thomas&amp;url=https%3A%2F%2Fwww.has‐sante.fr%2Fportail%2Fupload%2Fdocs%2Fapplication%2Fpdf%2F2016‐10%2Fannexe_‐_rapport_devaluation_des_medicaments.pdf&amp;v= 2016 (accessed 8 November 2018). ">HAS Annexe 2016</a>). Overall, we consider there is insufficient evidence to support the strong statement on adverse events (<a href="./references#CD003154-bbs2-0196" title="Haute Autorité deSanté . Drugs of Alzheimer's disease: insufficient medical interest to justify their support by national solidarity. https://translate.google.com/translate?hl=en&amp;sl=fr&amp;u=https://www.has‐sante.fr/portail/jcms/c_2679466/fr/medicaments‐de‐la‐maladie‐d‐alzheimer‐un‐interet‐medical‐insuffisant‐pour‐justifier‐leur‐prise‐en‐charge‐par‐la‐solidarite‐nationale&amp;prev=search (accessed 8 November 2018)2016. ">HAS 2016</a>) and think that memantine, which has a different mode of action from ChEIs, should be considered separately. </p> <p>The HAS recommends care and support for the individual <i>instead </i> of the drug treatments, rather than including drug treatments as a part of a general care package. They do not appear to have reviewed the evidence on this. </p> <p>Overall, our view is that the evidence in our review and our examination of the French adverse effects data raises questions about the appropriateness of the de‐listing policy taken by the French government. We note that de‐listing means the drugs are no longer reimbursed by the national health insurance system (<a href="./references#CD003154-bbs2-0222" title="Drugs for Alzheimer's disease: finally delisted in France. http://english.prescrire.org/en/81/168/55126/0/NewsDetails.aspx (accessed 28 October 2018). ">Prescrire 2018</a>), but that the drugs can be prescribed in line with their summary of product characteristics (<a href="./references#CD003154-bbs2-0197" title="Haute Autorité deSanté . Care Pathway Guide for Patients with Neurocognitive Disorders Associated with Alzheimer's Disease or Related Disease [Guide parcours de soins des patients présentant un trouble neurocognitif associé à la maladie d’Alzheimer ou à une maladie apparentée]. https://www.has‐sante.fr/portail/upload/docs/application/pdf/2018‐05/parcours_de_soins_alzheimer.pdf (accessed 28 October 2018). ">HAS 2018</a>). This may mean confusion for clinicians and potential for inequalities in the healthcare system. </p> <p>Our review of the evidence on the effect on memantine in people with moderate‐to‐severe AD selected for agitation suggested that memantine may be ineffective in this population, but this is low‐ or very low‐certainty evidence. Our findings contrast with two post‐hoc analyses (<a href="./references#CD003154-bbs2-0190" title="GauthierS , WirthY , MöbiusHJ . Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20:459‐64. ">Gaultier 2005</a>; <a href="./references#CD003154-bbs2-0241" title="WilcockGK , BallardCG , CooperJA , LoftH . Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry2008;69(3):341‐8. ">Wilcock Post‐Hoc 3RCTs 2008</a>); the latter analysed individual participant data (IPD) from three randomised controlled trials (RCTs) in our review (<a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>); selecting only those from a 'behaviourally disturbed population', defined as a score &gt; 0 on any of the three NPI symptoms of agitation–aggression, delusion, and hallucinations at baseline. Data were integrated in a single dataset and then analysed; meta‐analysis was not reported and the data were said to be 'pooled', indicating that the randomisation was not maintained. The study found a significant benefit for memantine for each of the efficacy outcomes at six months, but its reliability is unclear. A second review (<a href="./references#CD003154-bbs2-0190" title="GauthierS , WirthY , MöbiusHJ . Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20:459‐64. ">Gaultier 2005</a>); reported separately data from two RCTs in our review (<a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>), and, for one of the studies with memantine monotherapy (<a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>) gave results for post‐hoc subgroups of participants with agitation and no agitation at baseline. Results were not reported for the other study (which had dual therapy). The review stated that for people with agitation at baseline (defined as in <a href="./references#CD003154-bbs2-0241" title="WilcockGK , BallardCG , CooperJA , LoftH . Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry2008;69(3):341‐8. ">Wilcock Post‐Hoc 3RCTs 2008</a>, and comprising about 60% of the population); there was a significant improvement in agitation symptoms for memantine compared with placebo, which does not agree with our review's findings, but we note this is a different outcome to that in our review (improvement versus worsening of symptoms). In people without agitation at baseline, there were stated to be significantly fewer emergent agitation symptoms for memantine. Overall, there may be some differences with earlier findings, but all the efficacy evidence is of low or very low certainty and there is a need for further research of alternative therapies in this important patient group. </p> <p>Finally, we note some differences between this Cochrane Review and the 2018 NICE guideline for types of dementia other than AD (<a href="./references#CD003154-bbs2-0216" title="Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97 (accessed 10 September 2018). ">NICE 2018</a>). For people with vascular dementia, the NICE guideline recommends that ChEIs or memantine should be considered only if they have comorbid AD or PDD/DLB. However, this Cochrane Review has identified small clinical benefits in cognitive function and in behaviour and mood in people diagnosed with vascular dementia, and there is a post‐hoc analysis indicating there may be greater benefits in people with more severe disease. For people with FTD, the guideline recommends that ChEIs and memantine should not be offered (a strong recommendation), stating that there is not usually a cholinergic deficit in people with FTD, that there was no evidence of benefit and also citing the potential for adverse effects, whilst noting no difference between memantine and placebo. It may be that the guideline has conflated the findings for ChEIs with those for memantine, and we note that memantine has a non‐cholinergic mechanism of action and may have potential for benefit, albeit from low‐ or very low‐certainty evidence. For people with PDD or DLB, the guideline reviewed the evidence for PDD and DLB separately, and appeared to draw conclusions on the basis of a lack of statistical significance. The guideline recommended that memantine should be considered only if ChEIs are not tolerated or contraindicated, which, while consistent with our review findings of low‐ or very lo‐ certainty evidence in this patient group, has a strength which goes beyond the evidence. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003154-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of studies identified" data-id="CD003154-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram of studies identified</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003154-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bia's graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003154-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bia's graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.1 Clinical Global." data-id="CD003154-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.1 Clinical Global. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.2 Cognitive Function." data-id="CD003154-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.2 Cognitive Function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.3 Decline in ADL." data-id="CD003154-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.3 Decline in ADL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.4 Behaviour and Mood." data-id="CD003154-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.4 Behaviour and Mood. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.5 All‐cause discontinuation." data-id="CD003154-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease. 24‐30 week data. OC, outcome: 1.5 All‐cause discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 12 Adverse reactions ‐ Memantine vs placebo for mild to severe dementia. All diagnoses, all durations, outcome: 12.3 Number suffering at least one adverse event." data-id="CD003154-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 12 Adverse reactions ‐ Memantine vs placebo for mild to severe dementia. All diagnoses, all durations, outcome: 12.3 Number suffering at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 1 Clinical Global." data-id="CD003154-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 1 Clinical Global. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 2 Cognitive Function." data-id="CD003154-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 2 Cognitive Function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 3 Decline in ADL." data-id="CD003154-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 3 Decline in ADL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 4 Behaviour and Mood." data-id="CD003154-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 4 Behaviour and Mood. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 5 All‐cause discontinuation." data-id="CD003154-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 5 All‐cause discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 6 Discontinuations due to adverse events." data-id="CD003154-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 6 Discontinuations due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 7 Number suffering at least one adverse event." data-id="CD003154-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 7 Number suffering at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 8 Number suffering serious adverse events." data-id="CD003154-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 8 Number suffering serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 9 Number suffering agitation as an adverse event." data-id="CD003154-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC, Outcome 9 Number suffering agitation as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 1 Clinical Global: subgroup analysis by +/‐ ChEI." data-id="CD003154-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 1 Clinical Global: subgroup analysis by +/‐ ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 2 Cognitive Function subgroup analysis by +/‐ ChEI." data-id="CD003154-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 2 Cognitive Function subgroup analysis by +/‐ ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 3 Decline in ADL: subgroup analysis by +/‐ ChEI." data-id="CD003154-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 3 Decline in ADL: subgroup analysis by +/‐ ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 4 Behaviour and Mood: subgroup analysis by +/‐ ChEI." data-id="CD003154-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 4 Behaviour and Mood: subgroup analysis by +/‐ ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 5 Cognitive function (sMMSE):subgroup analysis within randomised study ‐ per protocol." data-id="CD003154-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 5 Cognitive function (sMMSE):subgroup analysis within randomised study ‐ per protocol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 6 Decline in ADL (BADL): subgroup analysis within randomised study ‐ per protocol." data-id="CD003154-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 6 Decline in ADL (BADL): subgroup analysis within randomised study ‐ per protocol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 7 NPI: subgroup analysis within randomised study ‐ per protocol." data-id="CD003154-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 7 NPI: subgroup analysis within randomised study ‐ per protocol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 8 Clinical Global: CIBIC+ mean difference; ChEI subgroup." data-id="CD003154-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 8 Clinical Global: CIBIC+ mean difference; ChEI subgroup. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 9 All‐cause discontinuation ‐ by ChEI." data-id="CD003154-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 9 All‐cause discontinuation ‐ by ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 10 Discontinuations due to adverse events ‐ by ChEI." data-id="CD003154-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 10 Discontinuations due to adverse events ‐ by ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 11 Adverse events ‐ by ChEI." data-id="CD003154-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 11 Adverse events ‐ by ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 12 Serious adverse events ‐ by ChEI." data-id="CD003154-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 12 Serious adverse events ‐ by ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 13 Number suffering agitation as an adverse event ‐ by ChEI." data-id="CD003154-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 13 Number suffering agitation as an adverse event ‐ by ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 14 Memantine + donepezil vs memantine + placebo." data-id="CD003154-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data, Outcome 14 Memantine + donepezil vs memantine + placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 1 Cohen Mansfield Agitation Inventory (MD)." data-id="CD003154-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 1 Cohen Mansfield Agitation Inventory (MD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 2 Cohen Mansfield Agitation Inventory (SMD)." data-id="CD003154-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 2 Cohen Mansfield Agitation Inventory (SMD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 3 NPI agitation subscale." data-id="CD003154-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 3 NPI agitation subscale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 4 Number suffering agitation." data-id="CD003154-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 4 Number suffering agitation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 5 Clinical Global." data-id="CD003154-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 5 Clinical Global. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 6 Cognitive Function: SIB." data-id="CD003154-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 6 Cognitive Function: SIB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 7 Decline in ADL: ADCS‐ADL19." data-id="CD003154-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 7 Decline in ADL: ADCS‐ADL19. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 8 Behaviour and Mood." data-id="CD003154-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 8 Behaviour and Mood. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 9 All‐cause discontinuation." data-id="CD003154-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 9 All‐cause discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 10 Discontinuations due to adverse events." data-id="CD003154-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 10 Discontinuations due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 11 Number suffering at least one adverse event." data-id="CD003154-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 11 Number suffering at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 12 Number suffering serious adverse events." data-id="CD003154-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation, Outcome 12 Number suffering serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies, Outcome 1 Clinical global: CIBIC+." data-id="CD003154-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies, Outcome 1 Clinical global: CIBIC+. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies, Outcome 2 Cognitive function: ADASCog." data-id="CD003154-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies, Outcome 2 Cognitive function: ADASCog. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies, Outcome 3 Decline in ADL: ADCS‐ADL23." data-id="CD003154-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies, Outcome 3 Decline in ADL: ADCS‐ADL23. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies, Outcome 4 Behaviour and mood: NPI." data-id="CD003154-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies, Outcome 4 Behaviour and mood: NPI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 1 Clinical Global: CGI." data-id="CD003154-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 1 Clinical Global: CGI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 2 Cognitive function: ADAS‐Cog." data-id="CD003154-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 2 Cognitive function: ADAS‐Cog. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 3 Decline in ADL: NOSGER self‐care subscale." data-id="CD003154-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 3 Decline in ADL: NOSGER self‐care subscale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 4 Behaviour: NOSGER disturbing behaviour subscale." data-id="CD003154-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 4 Behaviour: NOSGER disturbing behaviour subscale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 5 Cognitive function: ADAS‐Cog: post‐hoc subgroup analysis." data-id="CD003154-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 5 Cognitive function: ADAS‐Cog: post‐hoc subgroup analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 6 All‐cause discontinuation." data-id="CD003154-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 6 All‐cause discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 7 Discontinuation due to adverse events." data-id="CD003154-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 7 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 8 Number suffering at least one adverse event." data-id="CD003154-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 8 Number suffering at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 9 Number suffering agitation as an adverse event." data-id="CD003154-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies, Outcome 9 Number suffering agitation as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 1 Clinical Global (24 weeks)." data-id="CD003154-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 1 Clinical Global (24 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 2 Cognitive Function." data-id="CD003154-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 2 Cognitive Function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 3 Decline in ADL (24 weeks)." data-id="CD003154-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 3 Decline in ADL (24 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 4 Behaviour and Mood: NPI." data-id="CD003154-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 4 Behaviour and Mood: NPI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 5 All‐cause discontinuation." data-id="CD003154-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 5 All‐cause discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 6 Discontinuation due to adverse events." data-id="CD003154-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 6 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 7 Number suffering at least one adverse event." data-id="CD003154-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data, Outcome 7 Number suffering at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 1 Clinical Global." data-id="CD003154-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 1 Clinical Global. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 2 Cognitive Function: MMSE." data-id="CD003154-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 2 Cognitive Function: MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 3 Behaviour and Mood: Neuropsychiatric Inventory (NPI) Total." data-id="CD003154-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 3 Behaviour and Mood: Neuropsychiatric Inventory (NPI) Total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 4 All‐cause discontinuation." data-id="CD003154-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 4 All‐cause discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 5 Discontinuation due to adverse events." data-id="CD003154-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 5 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 6 Number suffering at least one adverse event." data-id="CD003154-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 6 Number suffering at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 7 Number suffering at serious adverse events." data-id="CD003154-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 7 Number suffering at serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 8 Number suffering agitation as an adverse event." data-id="CD003154-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Memantine vs placebo for frontotemporal dementia (FTD), Outcome 8 Number suffering agitation as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 1 Clinical Global ‐ by dementia type and severity." data-id="CD003154-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 1 Clinical Global ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 2 Cognitive Function ‐ by dementia type and severity." data-id="CD003154-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 2 Cognitive Function ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 3 Decline in ADL ‐ by dementia type and severity." data-id="CD003154-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 3 Decline in ADL ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 4 Behaviour and mood ‐ by dementia type and severity." data-id="CD003154-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 4 Behaviour and mood ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 5 Number suffering agitation ‐ by dementia type and severity." data-id="CD003154-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 5 Number suffering agitation ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 6 Number suffering agitation ‐ by dementia type and ChEI." data-id="CD003154-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 6 Number suffering agitation ‐ by dementia type and ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 7 All‐cause discontinuation (all durations) ‐ by dementia type and severity." data-id="CD003154-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 7 All‐cause discontinuation (all durations) ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 8 Discontinuation due to adverse events ‐ by dementia type and severity." data-id="CD003154-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 8 Discontinuation due to adverse events ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 9 Number suffering at least one adverse event ‐ by dementia type and severity." data-id="CD003154-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 9 Number suffering at least one adverse event ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 10 Number suffering at least one serious AE ‐ by dementia type and severity." data-id="CD003154-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 10 Number suffering at least one serious AE ‐ by dementia type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 11 Number suffering agitation as an adverse event ‐ by dementia type." data-id="CD003154-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity, Outcome 11 Number suffering agitation as an adverse event ‐ by dementia type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 1 All‐cause discontinuation." data-id="CD003154-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 1 All‐cause discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 2 Discontinuation due to adverse events." data-id="CD003154-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 2 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 3 Number suffering at least one adverse event." data-id="CD003154-fig-0086" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 3 Number suffering at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 4 Number suffering serious adverse events." data-id="CD003154-fig-0087" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 4 Number suffering serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 5 Number suffering agitation as an adverse event." data-id="CD003154-fig-0088" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 5 Number suffering agitation as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 6 Number suffering insomnia as an adverse event." data-id="CD003154-fig-0089" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 6 Number suffering insomnia as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 7 Number suffering confusion as an adverse event." data-id="CD003154-fig-0090" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 7 Number suffering confusion as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 8 Number suffering depression as an adverse event." data-id="CD003154-fig-0091" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 8 Number suffering depression as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 9 Number suffering headache as an adverse event." data-id="CD003154-fig-0092" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 9 Number suffering headache as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 10 Number suffering hypertension as an adverse event." data-id="CD003154-fig-0093" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 10 Number suffering hypertension as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 11 Number suffering dizziness as an adverse event." data-id="CD003154-fig-0094" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 11 Number suffering dizziness as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 12 Number suffering falls as an adverse event." data-id="CD003154-fig-0095" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 12 Number suffering falls as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 13 Number suffering accidental injury as an adverse event." data-id="CD003154-fig-0096" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 13 Number suffering accidental injury as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 14 Number suffering urinary incontinence as an adverse event." data-id="CD003154-fig-0097" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.14</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 14 Number suffering urinary incontinence as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 15 Number suffering diarrhoea as an adverse event." data-id="CD003154-fig-0098" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.15</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 15 Number suffering diarrhoea as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-009-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-009-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 16 Number suffering influenza like symptoms as an adverse event." data-id="CD003154-fig-0099" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.16</div> <div class="figure-caption"> <p>Comparison 9 Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations, Outcome 16 Number suffering influenza like symptoms as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-009-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data, Outcome 1 Cognitive function." data-id="CD003154-fig-0100" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data, Outcome 1 Cognitive function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data, Outcome 2 Decline in ADL: ADCS‐ADL19/23." data-id="CD003154-fig-0101" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data, Outcome 2 Decline in ADL: ADCS‐ADL19/23. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data, Outcome 3 Cognitive Function: SIB/ADASCog/MMSE." data-id="CD003154-fig-0102" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data, Outcome 3 Cognitive Function: SIB/ADASCog/MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data, Outcome 4 Decline in Activities of Daily Living." data-id="CD003154-fig-0103" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data, Outcome 4 Decline in Activities of Daily Living. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 1 Clinical Global." data-id="CD003154-fig-0104" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 1 Clinical Global. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 2 Cognitive Function." data-id="CD003154-fig-0105" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 2 Cognitive Function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 3 Decline in ADL." data-id="CD003154-fig-0106" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 3 Decline in ADL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 4 Behaviour and Mood." data-id="CD003154-fig-0107" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 4 Behaviour and Mood. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 5 Clinical Global ‐ sensitivity analysis for high RoB." data-id="CD003154-fig-0108" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 5 Clinical Global ‐ sensitivity analysis for high RoB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-011-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-011-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 6 Cognitive Function ‐ sensitivity analysis for high risk of bias." data-id="CD003154-fig-0109" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 6 Cognitive Function ‐ sensitivity analysis for high risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-011-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-011-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 7 Decline in ADL ‐ sensitivity analysis on high RoB." data-id="CD003154-fig-0110" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 7 Decline in ADL ‐ sensitivity analysis on high RoB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-011-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-011-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 8 Behaviour and Mood ‐ sensitivity analysis on high RoB." data-id="CD003154-fig-0111" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11 APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 8 Behaviour and Mood ‐ sensitivity analysis on high RoB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-011-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 1 Clinical Global ‐ CIBIC Plus, CGI‐I, or ADCS‐CGIC." data-id="CD003154-fig-0112" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 1 Clinical Global ‐ CIBIC Plus, CGI‐I, or ADCS‐CGIC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 2 Cognitive Function." data-id="CD003154-fig-0113" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 2 Cognitive Function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 3 Decline in ADL ‐ BGP, ADCS‐ADL 19 or 23." data-id="CD003154-fig-0114" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 3 Decline in ADL ‐ BGP, ADCS‐ADL 19 or 23. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 4 Behaviour and Mood (Standardised NPI or NPI‐NH Total)." data-id="CD003154-fig-0115" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks, Outcome 4 Behaviour and Mood (Standardised NPI or NPI‐NH Total). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 1 Clinical Global; 10mg versus 20mg." data-id="CD003154-fig-0116" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 1 Clinical Global; 10mg versus 20mg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 2 Cognitive function; 10mg vs 20 mg." data-id="CD003154-fig-0117" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 2 Cognitive function; 10mg vs 20 mg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 3 Decline in ADL; 10mg versus 20mg." data-id="CD003154-fig-0118" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 3 Decline in ADL; 10mg versus 20mg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 4 Behaviour and mood; 10mg versus 20mg." data-id="CD003154-fig-0119" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 4 Behaviour and mood; 10mg versus 20mg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-013-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-013-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 5 Clinical Global." data-id="CD003154-fig-0120" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 5 Clinical Global. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-013-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-013-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 6 Cognitive function." data-id="CD003154-fig-0121" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 6 Cognitive function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-013-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-013-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 7 Decline in activities of daily living." data-id="CD003154-fig-0122" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 7 Decline in activities of daily living. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-013-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-013-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 8 Behaviour and mood." data-id="CD003154-fig-0123" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13 APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks), Outcome 8 Behaviour and mood. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-013-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months, Outcome 1 Clinical Global: subgroup analysis by +/‐ ChEI." data-id="CD003154-fig-0124" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months, Outcome 1 Clinical Global: subgroup analysis by +/‐ ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months, Outcome 2 Cognitive Function subgroup analysis by +/‐ ChEI." data-id="CD003154-fig-0125" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months, Outcome 2 Cognitive Function subgroup analysis by +/‐ ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months, Outcome 3 Decline in ADL subgroup analysis by +/‐ ChEI." data-id="CD003154-fig-0126" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months, Outcome 3 Decline in ADL subgroup analysis by +/‐ ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months, Outcome 4 Behaviour and Mood: subgroup analysis by +/‐ ChEI." data-id="CD003154-fig-0127" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months, Outcome 4 Behaviour and Mood: subgroup analysis by +/‐ ChEI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 1 Clinical Global." data-id="CD003154-fig-0128" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 1 Clinical Global. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 2 Cognitive Function." data-id="CD003154-fig-0129" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 2 Cognitive Function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 3 Decline in ADL." data-id="CD003154-fig-0130" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 3 Decline in ADL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 4 Behaviour and Mood." data-id="CD003154-fig-0131" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 4 Behaviour and Mood. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 5 Clinical Global." data-id="CD003154-fig-0132" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 5 Clinical Global. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 6 Cognitive Function." data-id="CD003154-fig-0133" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.6</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 6 Cognitive Function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 7 Decline in ADL." data-id="CD003154-fig-0134" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.7</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 7 Decline in ADL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 8 Behaviour and Mood." data-id="CD003154-fig-0135" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.8</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 8 Behaviour and Mood. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 9 All‐cause discontinuation, by type of disease and severity." data-id="CD003154-fig-0136" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.9</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 9 All‐cause discontinuation, by type of disease and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-015-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-015-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 10 Discontinuation due to adverse events, by disease type and severity." data-id="CD003154-fig-0137" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.10</div> <div class="figure-caption"> <p>Comparison 15 APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 10 Discontinuation due to adverse events, by disease type and severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-015-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 1 Clinical Global ‐ mild vs moderate/severe." data-id="CD003154-fig-0138" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 1 Clinical Global ‐ mild vs moderate/severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 2 Cognitive Function ‐ mild vs moderate/severe." data-id="CD003154-fig-0139" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 2 Cognitive Function ‐ mild vs moderate/severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-016-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-016-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 3 Decline in ADL ‐ mild vs moderate/severe." data-id="CD003154-fig-0140" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 3 Decline in ADL ‐ mild vs moderate/severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-016-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-016-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 4 Behaviour and Mood ‐ mild vs moderate/severe." data-id="CD003154-fig-0141" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 4 Behaviour and Mood ‐ mild vs moderate/severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-016-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-016-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 5 All‐cause discontinuation ‐ mild vs moderate/severe." data-id="CD003154-fig-0142" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 5 All‐cause discontinuation ‐ mild vs moderate/severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-016-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-016-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 6 Discontinuations due to adverse events ‐ mild vs moderate/severe." data-id="CD003154-fig-0143" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16 APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks, Outcome 6 Discontinuations due to adverse events ‐ mild vs moderate/severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-016-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 1 Clinical Global: post‐hoc within‐trial subgroup analyses." data-id="CD003154-fig-0144" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 1 Clinical Global: post‐hoc within‐trial subgroup analyses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 2 Cognitive Function: post‐hoc within‐trial subgroup analyses." data-id="CD003154-fig-0145" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 2 Cognitive Function: post‐hoc within‐trial subgroup analyses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 3 Decline in ADL: post‐hoc within‐trial subgroup analyses." data-id="CD003154-fig-0146" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 3 Decline in ADL: post‐hoc within‐trial subgroup analyses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-017-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-017-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 4 Clinical Global: by severity of disease." data-id="CD003154-fig-0147" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 4 Clinical Global: by severity of disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-017-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-017-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 5 Cognitive Function: by severity of disease." data-id="CD003154-fig-0148" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 5 Cognitive Function: by severity of disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-017-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-017-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 6 Decline in ADL: by severity of disease." data-id="CD003154-fig-0149" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 6 Decline in ADL: by severity of disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003154-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/urn:x-wiley:14651858:media:CD003154:CD003154-CMP-017-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_t/tCD003154-CMP-017-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 7 Behaviour and Mood: by severity of disease." data-id="CD003154-fig-0150" src="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.7</div> <div class="figure-caption"> <p>Comparison 17 APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate, Outcome 7 Behaviour and Mood: by severity of disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/media/CDSR/CD003154/image_n/nCD003154-CMP-017-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003154-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Moderate‐to‐severe AD, six to seven months</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg or equivalent compared to placebo for moderate‐to‐severe Alzheimer's disease (AD) 24‐ to 30‐week data. OC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: Alzheimer's disease (AD), moderate‐to‐severe</b> <br/> <b>Intervention</b> : memantine 20 mg or equivalent<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CIBIC+)<br/> 7‐point Likert scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Median CIBIC+ score was 4.60 <sup>3</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 0.21 (0.14 to 0.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.28 to ‐0.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2797<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0010" title="">Analysis 1.1</a>) </p> <p>Converted to CIBIC+ scale; median SD(pooled) = 1.06.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function (SIB)<br/> 100‐point scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Median SIB score at baseline: 75.2.</p> <p>Median change from baseline (positive scale): ‐2.4 <sup>4</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 3.11 (2.42 to 3.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.27 (‐0.34 to ‐0.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3337<br/> (13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0011" title="">Analysis 1.2</a>). </p> <p>Converted to SIB scale (and scale direction inverted); median SD (pooled) = 11.53.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functional performance on activities of daily living: ADCS‐ADL19<br/> 54‐point scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Median ADCS‐ADL19 score at baseline: 33.2</p> <p>Median change from baseline (positive scale): ‐2.8 <sup>5</sup> (i.e. deterioration with time) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 1.09 (0.62 to 1.64)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.16 (‐0.24 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2687<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD for decline in ADL (a negative outcome)</p> <p>(<a href="./references#CD003154-fig-0012" title="">Analysis 1.3</a>). </p> <p>Converted to ADCS‐ADL19 scale (and scale direction inverted); median SD(pooled) = 6.84. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood (NPI)</p> <p>144‐point scale</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median baseline NPI score was 17.0.</p> <p>Median change from baseline (negative scale): 2.80 <sup>6</sup> (i.e. deterioration with time) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 1.84 (1.05 to 2.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.14 (‐0.21 to ‐0.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3674<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0013" title="">Analysis 1.4</a>) </p> <p>Converted to NPI scale; median SD(pooled) = 13.15.</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000<br/> (151 to 189) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.83 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5087<br/> (17 RCTs) </p> <p>924 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control group risk in people with moderate‐to‐severe AD without agitation (<a href="./references#CD003154-fig-0142" title="">Analysis 16.5</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Difference: 13 fewer people per 1000 discontinued treatment for any cause (95% CI 31 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>716 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>737 per 1000<br/> (716 to 759) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>). </p> <p>Median control group risk for moderate‐to‐severe AD studies (<a href="./references#CD003154-fig-0016" title="">Analysis 1.7</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Difference: 21 more people per 1000 suffered adverse events<br/> (95% CI 0 to 43 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(93 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6482</p> <p>(19 RCTs)</p> <p>918 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control risk from all AD studies (except those with agitation) (from <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 10 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 21 fewer to 2 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/> (85 to 128) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.66 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4395<br/> (12 RCTs) </p> <p>321 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all AD studies (apart from those in people with agitation) (<a href="./references#CD003154-fig-0083" title="">Analysis 8.11</a>). </p> <p>Median control group risk for moderate‐to‐severe AD studies (<a href="./references#CD003154-fig-0018" title="">Analysis 1.9</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Difference: 25 fewer people per 1000 suffered agitation as an adverse event<br/> (95% CI 44 to 1 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Some inconsistency in point estimates, but not enough to downgrade </p> <p><sup>2</sup> Some inconsistency in point estimates (downgrade once) </p> <p><sup>3</sup> Median control group values for 8 studies reporting CIBIC+ (<a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a>; <a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>) </p> <p><sup>4</sup> Median control group baseline scores and median control group change from baseline for 5 studies reporting SIB (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>) </p> <p><sup>5</sup> Median control group baseline scores and median control group change from baseline for the 4 studies reporting ADCS‐ADL19 (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>;<a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>) </p> <p><sup>6</sup> Median control group baseline scores and median control group change from baseline for the 10 studies reporting NPI (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Moderate‐to‐severe AD, six to seven months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003154-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vascular dementia ‐ mild‐to‐moderate severity. six months</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg compared to placebo for mild‐to‐moderate vascular dementia. six‐month studies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: vascular dementia, mild‐to‐moderate severity</b> <br/> <b>Intervention</b> : memantine 20 mg<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (mean)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global: (CIBIC+)<br/> 7‐point Likert scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CIBIC+ score<br/> (<a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a>)<br/> was 4.19 </p> <p>(i.e. no change with time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 0.03 (‐0,28 to 0.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.02 (‐0.23 to 0.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome;</p> <p>random effects (<a href="./references#CD003154-fig-0049" title="">Analysis 5.1</a>). </p> <p>Converted to CIBIC+ scale; SD(pooled) = 1.46.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function: ADAS‐Cog<br/> 70‐point scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ADAS‐Cog score at baseline was 23.6.</p> <p>Mean change from<br/> baseline (negative scale) was 1.68 </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 2.15 (1.05 to 3.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.32 (‐0.48 to ‐0.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>569<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0050" title="">Analysis 5.2</a>) </p> <p>[SMD as a negative outcome <a href="./references#CD003154-fig-0074" title="">Analysis 8.2</a>] </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL</p> <p>(NOSGER self care subscale)</p> <p>Subscale 5 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline scores not reported.</p> <p>Change from baseline<br/> for the NOSGER II<br/> self care subscale<br/> (negative scale) was<br/> 0.40 (one study) </p> <p>i.e. deterioration with time</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 0.11 (‐0.35 to 0.54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.04 (‐0.20 to 0.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD for decline in ADL (a negative outcome)</p> <p>(<a href="./references#CD003154-fig-0051" title="">Analysis 5.3</a>). </p> <p>Converted to NOSGER II self‐care subscale (<a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>) SD(pooled) = 2.69. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour: NOSGER disturbing behaviour subscale</p> <p>Subscale 5 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline scores not reported.</p> <p>Change from baseline</p> <p>for the NOSGER<br/> disturbing behaviour subscale (negative scale) was 0.57 (one study) </p> <p>i.e. deterioration with time</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD: 0.47 (0.07 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.37 to ‐0.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0052" title="">Analysis 5.4</a>). </p> <p>Converted to NOSGER II disturbing behaviour subscale (<a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a>) SD(pooled) = 2.34. </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>229 per 1000<br/> (181 to 292) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.83 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>900<br/> (2 RCTs) </p> <p>678 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk for studies in people with vascular dementia (<a href="./references#CD003154-fig-0054" title="">Analysis 5.6</a>.) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 11 more people per 1000 discontinued treatment for any cause (95% CI 37 fewer to 74 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>742 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>764 per 1000<br/> (742 to 787) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>). Control group risk taken from studies in vascular dementia (<a href="./references#CD003154-fig-0056" title="">Analysis 5.8</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 22 more people per 1000 suffered adverse events<br/> (95% CI 0 to 45 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000</p> <p>(95% CI 131 to 230)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82</p> <p>(0.62 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>900</p> <p>(2 RCTs)</p> <p>162 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from vascular dementia studies (<a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 38 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 80 fewer to 19 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>44 per 1000<br/> (26 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/> (0.33 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>900<br/> (2 RCTs) </p> <p>54 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from vascular dementia studies (<a href="./references#CD003154-fig-0057" title="">Analysis 5.9</a>); random effects </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Difference: 33 fewer people per 1000 suffered agitation as an adverse event<br/> (95% CI 52 to 2 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Inconsistency in point estimates (and I² = 48%); some imprecision (95% CI crossed null and was consistent with benefit and no difference) but may be consequence of inconsistency (downgraded once overall) </p> <p><sup>2</sup> Majority of the information at high risk of bias (downgrade once). Some inconsistency (but insufficient to downgrade) </p> <p><sup>3</sup> Majority of the information at high risk of bias for 2 domains (downgrade twice) </p> <p><sup>4</sup> Majority of the information at high risk of bias (downgrade once); some inconsistency and some imprecision (crossed null and 1.25) (downgrade once) </p> <p><sup>5</sup> Majority of the information at high risk of bias (downgrade once); imprecision (162 events and crossed both 0.75 and null)) (downgrade once) </p> <p><sup>6</sup> Majority of the information at high risk of bias (downgrade once); imprecision (only 54 events) (downgrade once) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vascular dementia ‐ mild‐to‐moderate severity. six months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Efficacy outcome measures in Alzheimer's disease (AD) and vascular dementia trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Clinical Global</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cognitive function</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Decline in ADL</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Behaviour and mood</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIBIC‐Plus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CGIC/<br/> CGI‐I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CDR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADAS‐<br/> Cog</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SIB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADCS‐<br/> ADL23</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADL‐19</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BADLS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BGP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DAD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NPI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BEHAVE<br/> ‐AD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alzheimers' disease studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese versions.</p> <p>DAD, Caregiver‐rated Crichton Scale, MMSE, CDR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese versions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE, Caregiver activity survey</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI nursing home version; CMAI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI, NPI‐Agitation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI, MMSE, QOL‐AD, incidence of agitation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FLCI, ASHA FACS (caregiver assessment)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DriveABLE On‐Road Test, MMSE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese versions.MMSE, FAST, BEHAVE‐AD. ADL scale not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EQ‐5D, GHQ‐12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Final values only, no change scores</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese versions; Crichton scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDR sum of boxes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FAST; ADL modified for severe dementia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE; ADL scale not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FAST</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE, ADAS‐Cog</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in total brain volume, Agitation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="15" rowspan="1" valign=""> <p><b>Vascular Dementia or dementia syndrome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0008" title="DitzlerK . Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung1991;41(8):773‐80. ">Ditzler 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (PGI scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician's Global Impression, Syndrom Kurztest, SCAG; ADL scale not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0016" title="GortelmeyerR , ErblerH . Memantine in the treatment of mild to moderate dementia syndrome: a double‐blind placebo‐controlled study. Arzneimittelforschung1992;42(7):904‐13. ">Gortelmeyer 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GBS, Tapping test, Trace test, SCAG; modified ADL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0033" title="OrgogozoJM , ForetteF . Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial). 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000. OrgogozoJM , RigaudAS , StöfflerA , MöbiusHJ , ForettteF . Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomised, placebo‐controlled trial (MMM300 Trial Group). Stroke2002;33:1834‐9. ">Orgogozo 2002 (9408)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (NOSGER)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (NOSGER)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGIC, GBS, MMSE, NOSGER subscales for self‐care ADL and disturbing behaviour</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0034" title="PantevM , RitterR , GortelmeyerR . Clinical and behavioural evaluation in long‐term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie1993;6(2):103‐17. ">Pantev 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment of clinical efficacy, NOSIE‐Index, SCAG</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0047" title="OrgogozoJ , ForetteF , WilcockHG , MoebiusHG , StoefflerA . Memantine in vascular dementia. Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24‐27 January 2002. 2002; Vol. 203‐4:318. WilcockG . Cognitive improvement by memantine in a placebo‐controlled trial in mild to moderate vascular dementia (The MMM 500 trial). 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5‐8, 2000. Stockholm. 2000. WilcockG . Efficacy of memantine has been verified by two double‐blind studies [Wirkssamkeit von Memantine durch zwei Doppelblindstudien belegt]. Neurologie und Rehabilitation2000;6(4):226‐7. WilcockG , MöbiusHJ , Stöffler A on behalf of the MM 500 group. A double‐blind, placebo‐controlled multicentre study of memantine in mild to moderate vascular dementia. International Clinical Psychopharmacology2002;17:297‐305. WilcockG , StöfflerA , SahinK , MöbiusHJ . Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo controlled clinical trials. Proceedings of the 13th European College of Neuropsychopharmacology. 2000a; Vol. 10, issue suppl 3:S360. ">Wilcock 2002 (9202)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (NOSGER)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (NOSGER)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOSGER subscales for self‐care ADL and disturbing behaviour</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0049" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. WinbladB , PoritisN , MöbiusHJ . Clinical improvement in a placebo‐controlled trial with memantine in care‐dependent patients with severe dementia (M‐BEST). In: IqbalK , SwaabDF , WisniewskiHM editor(s). Alzheimer's Disease and Related Disorders Etiology, Pathogenesis and Therapeutics. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons, 1999:633‐40. ">Winblad 1999 (9403)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X (BGP<br/> cognitive subscale) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D‐scale, AD subgroup also reported</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Efficacy outcome measures in Alzheimer's disease (AD) and vascular dementia trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants in the included studies ‐ Alzheimer's disease (AD)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diagnosis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severity of disease</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean MMSE</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% female</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>duration (weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>MODERATE‐TO‐SEVERE AD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0003" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011. [JapicCTI‐R110143 ] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050078. Report on the deliberation results: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. https://www.pmda.go.jp/files/000207435.pdf (accessed 5 April 2018). Pharmaceuticals and Medical Devices Agency, 2010:65‐9. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLOS One2015;10(4):e0123289. [DOI: 10.1016/j.jagp.2013.11.007] NakamuraY , HommaA , KitamuraS , YoshimuraI . Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Japanese Journal of Geriatric Psychiatry2011;22(4):464‐73. NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;9(4):297. [DOI: 10.1016/j.jalz.2013.05.605] ">Asada 2011a (IE3501)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderately severe‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜9.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0013" title="Forest Laboratories Inc Clinical Trials Registry. A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease. http://www.forestclinicaltrials.com2006. ">Forest 2006 (MD‐22)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD Nursing home</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜11.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD agitation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD agitation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe MMSE &lt; 20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD agitation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜74.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜58.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>677</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0019" title="HofbauerRK , SaxtonJ , WoodwardM , et al. Effects of memantine on functional communication in patients with moderate AD: results of 12‐week placebo controlled trial. Alzheimers &amp; Dementia. Data posted on Forest clinical trials register, 2009; Vol. 5(4 suppl 1):P256‐7. [NCT00469456] ">Hofbauer 2009 (MD‐71)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜74.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0021" title="Report on the deliberation results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare (2010). https://www.pmda.go.jp/files/000207435.pdf (accessed 16 January 2016)60‐5. ForestLaboratories . Powerpoint presentation for FDA Advisory Committee 23 September 2004. Slide 28 http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt2004. HommaA , KitamuraS , YoshimuraI . Efficacy of memantine in patients with moderately severe to severe Alzheimer's Disease in Japan ‐ dose‐finding study. Poster at European Federation of Neurological Societies, 11th Congress Brussles 25th ‐ 28th August 2007. 2007. KitamuraS , HommaA , NakamuraY . Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat.20112011;22(4):453‐63. MatsunagaS , KishiT , IwataN . Memantine monotherapy for Alzheimer’s Disease: a systematic review and meta‐analysis. PLoS ONE2015;10(4):e0123289. doi:10.1371/journal.pone.0123289. [DOI: http://dx.doi.org/10.1016/j.jagp.2013.11.007] NakamuraY , KitamuraS , HommaA . Efficacy and safety of memantine in people with moderate‐to‐severe Alzheimer's disease: results of a pooled analysis of randomized, double‐blind placebo‐controlled trials in Japan. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:(var.pagings):P297. ">Homma 2007 (IE2101)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe MMSE 5‐14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜10.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>295</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> <p>(52% severe 5 to 9)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0024" title="LorenziM , BeltramelloA , MercuriNB , et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs &amp; aging Vol. 28, issue 3:205‐17. ">Lorenzi 2011 (SC05‐03)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜14.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0025" title="Completed memantine efficacy study: moderate to severe Alzheimers dementia ‐ China. http://www.lundbecktrials.comOctober 2006. LiW , ZhaoJH , SunSG , ZhangJW , SuoAQ , MaMM . [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua yi xue za zhi2011;91(5):301‐3. PhulR . Clinical Trial Report Summary. Kindly supplied on 17 January 2008. ">Lundbeck 2006 (10116)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE 5‐18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>546</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜78.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜10.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜72.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderately severe‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>404</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate‐to‐severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜10.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0050" title="European Medicines Evaluation Agency (EMEA). Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/axura/094802en6.pdf2004:16. WinbladB , GrahamSM , LeesGS , MobiüsHJ , RubyJ , McDonaldS . Efficacy and tolerability of memantine in nursing home patients with severe dementia of the Alzheimer's type. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimor. Feb 21‐24, 2004. 2004. WinbladB , PoritisN . Memantine in severe dementia: results of the 9M‐BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). International Journal of Geriatric Psychiatry1999;14(2):135‐46. ">Winblad 1999 (9403) AD</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>severe</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜74.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>MILD‐TO‐MODERATE AD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0002" title="JAPIC trials registry. http://www.clinicaltrials.jp/user/ctiMain_e.jsp 14 Feb 2011; Vol. JapicCTI‐R110144. [JapicCTI‐R110144] JAPIC trials registry. http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐050079. ">Asada 2011 (MA3301)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>367</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate MMSE 10‐23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0004" title="AshfordJW , AdamsonM , BealeT , LaD , HernandexB , NodaA , et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer Dementia. Journal of Alzheimer’s Disease2011;26:331‐6. [DOI: 10.3233/JAD‐2011‐0021] ">Ashford 2011 (95722)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐ to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0005" title="Anonymous . Forest press release. http://ir.frx.com/phoenix.zhtml?c=83198&amp;p=irol‐newsArticle&amp;ID=482107&amp;highlight= (Accesed 5 April 2018) 7 Jan 2003. BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. BakchineS , Pascual‐GangnantL , HeftingN , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. European Neuropsychopharmacology2005;15(3):S567–8. [DOI: 10.1016/S0924‐977X(05)81189‐7] DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005. 2005. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. ">Bakchine 2008 (99679)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>470</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate 11‐23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜18.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>307</p> <p>and 306 (vit E)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜79.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜3<br/> (97% male) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜27.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0037" title="PetersO , FuentesM , JoachimLK , JessenF , LuckhausC , KornhuberJ . Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naive patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer’s &amp; Dementia: Translational Research &amp; Clinical Interventions2015;1:198‐204. ">Peters 2015 (MEGACOMBI2)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜72.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜22.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜63.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0035" title="BakchineS , Pascual‐GangnantL , LoftH . Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Results of a randomised, placebo‐controlled 6‐month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 2005. CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PeskindER , PotkinSG , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, February 21‐24. 2004. PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. PeskindER , PotkinSG , PomaraN , OttBR , McDonalS , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. CINP Cogress, Paris. June 2‐24. 2004. PomaraN , OttB , PeskindE , ResnickEM . Efficacy of memantine for cognition in mild to moderate Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. PomaraN , OttBR , PeskindE , ResnickEM . Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo‐controlled randomized trial.. Alzheimer Dis Assoc Disord2007;21:60‐4. PotkinSG , PeskindER , PomaraN , McDonaldS , XieY , GergelI . Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. 56th Annual meeting of the American Academy of Neurology,San Francisco CA, April 24‐May 1. 2004. ">Peskind 2004 (MD‐10)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>403</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜75.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜16.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0042" title="SchmidtR , RopeleS , EbenbauerB , WindischM , StoefflerA , FazekasF . Memantine effects on brain volume, glucose metabolism and cognition in AD patients ‐ a randomized, double‐blind, placebo‐controlled neuroimaging pilot study. 11th Congress of European Federation of Neurological Societies. Brussels. 25th‐28th August 2007. 2007. SchmidtR , RopeleS , PendlB , OfnerP , EnzingerC , SchmidtH , et al. Longitudinal multimodal imaging in mild to moderate Alzheimer's disease: a pilot study with memantine. Journal of Neurology, Neurosurgery Psychiatry2008;79(12):1312‐7. ">Schmidt 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0155" title="WangH‐F , YuJ‐T , TangS‐W , JiangT , TanC‐C , MengX‐F , et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta‐analysis and trial sequential analysis. Journal of Neurology, Neurosurgery, and Psychiatry2015;86(2):135‐43. [DOI: 10.1136/jnnp‐2014‐307659] ">Wang 2015</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild‐to‐moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜12.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003154-bbs2-0048" title="Anonymous . Clinical trial report summary 10112. http://www.lundbecktrials.com/ 28 May 2010. WilkinsonD , FoxN , BarkhofF , PhulR , ScheltensP . Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. 14th InternationalCongress of the International Psychogeriatric Conference,Montreal. 1‐5th September 2009. WilkinsonD , FoxNC , BarkhofF , PhulR , LemmingO , ScheltensP . Memantine and brain atrophy in Alzheimer's Disease: a 1‐year randomized controlled trial. Journal of Alzheimers Disease2012;29(2):459‐9. ">Wilkinson 2012 (10112)</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderate</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants in the included studies ‐ Alzheimer's disease (AD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), six to seven months, memantine with concomitant cholinesterase inhibitors (ChEIs)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg or equivalent compared to placebo, with concomitant ChEI, for moderate‐to‐severe AD. 24‐30 week data. OC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: Alzheimer's disease, moderate‐to‐severe</b> <br/> <b>Intervention</b> : memantine 20 mg or equivalent, with concomitant ChEI<br/> <b>Comparison:</b> placebo, with concomitant ChEI </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CIBIC+)<br/> 7‐point Likert scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The median CIBIC+ score was 4.5 <sup>3</sup> (i.e. deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.21 (0.06 to 0.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 (‐0.32 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1125<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference. Random effects (<a href="./references#CD003154-fig-0026" title="">Analysis 2.8</a>) </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>)] </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function (SIB)<br/> 100‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean SIB score at baseline: 77.6.</p> <p>Mean change from baseline (positive scale): ‐1.2 <sup>4</sup> (i.e. slight deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 2.48 (1.45 to 3.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.24 (‐0.33 to ‐0.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1852<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>) </p> <p>Converted to SIB scale (and scale direction inverted); median SD(pooled) = 10.34.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL: (ADCS‐ADL19)<br/> 54‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ADCS‐ADL19 score at baseline: 34.3.</p> <p>Mean change from baseline (positive scale): ‐2.2 <sup>5</sup> (i.e. deterioration over time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.95 (0.22 to 1.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.13 (‐0.24 to ‐0.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1319<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD for decline in ADL as a negative outcome (<a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>) </p> <p>Converted to ADCS‐ADL19 scale (and scale direction inverted); median SD(pooled) = 7.33. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood (NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median baseline NPI score was 16.5.</p> <p>Median change from baseline (negative scale): 2.80 <sup>6</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 2.20 (1.10 to 3.29)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.18 (‐0.27 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1855<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>) </p> <p>Converted to NPI scale; median SD(pooled) = 12.20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 per 1000<br/> (139 to 175) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.83 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5087<br/> (17 RCTs) 924 events </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR for all moderate‐to‐severe AD studies (apart from those with agitation) (<a href="./references#CD003154-fig-0142" title="">Analysis 16.5</a>). </p> <p>Median control group risk for 6 studies in 2089 people with moderate‐to‐severe AD without agitation, receiving ChEIs (<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 12 fewer people per 1000 discontinued treatment for any cause (95% CI 29 fewer to 7 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>639 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>658 per 1000<br/> (639 to 677) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>). </p> <p>Median control group risk for moderate‐to‐severe AD studies in people receiving ChEIs (<a href="./references#CD003154-fig-0029" title="">Analysis 2.11</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 19 more people per 1000 suffered adverse events<br/> (95% CI 0 to 38 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(93 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6482</p> <p>(19 RCTs)</p> <p>918 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control risk from all AD studies (except those with agitation) (from <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 10 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 21 fewer to 2 more)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 per 1000<br/> (27 to 63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.60 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1225<br/> (5 RCTs) </p> <p>3</p> <p>79 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control group risk for studies in people with moderate‐to‐severe AD without agitation, receiving ChEIs (<a href="./references#CD003154-fig-0031" title="">Analysis 2.13</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 4 fewer people per 1000 suffered agitation as an adverse event<br/> (95% CI 18 fewer to 18 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). We adopt the convention that a negative mean difference always means an improvement (i.e. favouring memantine)<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Some inconsistency or variation in the point estimates (downgraded once for inconsistency) </p> <p><sup>2</sup> 79 events; imprecision around relative effect (CI crossing 1.25 and 0.75)(downgraded twice) </p> <p><sup>3</sup> Median control group values for 3 studies reporting CIBIC+ (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>) </p> <p><sup>4</sup> Mean control group baseline scores and mean control group change from baseline for 2 studies reporting SIB (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>) </p> <p><sup>5</sup> Mean control group baseline scores and mean control group change from baseline for the 2 studies reporting ADCS‐ADL19 (<a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>) </p> <p><sup>6</sup> Median control group baseline scores and median control group change from baseline for the 5 studies reporting NPI (<a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>; <a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>; <a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), six to seven months, memantine with concomitant cholinesterase inhibitors (ChEIs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), six to seven months, monotherapy</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg or equivalent compared to placebo, monotherapy, for moderate‐to‐severe AD. 24‐to 30‐week data observed case (OC)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: Alzheimer's disease, moderate‐to‐severe</b> <br/> <b>Intervention</b> : memantine 20 mg or equivalent, as monotherapy<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global<br/> (CIBIC+) </p> <p>7‐point Likert scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The median CIBIC+ score was 4.64 <sup>3</sup> (i.e. deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.22 (0.11 to 0.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.30 to ‐0.10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1672<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>). </p> <p>Converted to CIBIC+ scale; median SD(pooled) = 1.09.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function<br/> (SIB) </p> <p>100‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median SIB score at baseline: 68.3.</p> <p>Median change from baseline (positive scale): ‐5.6 <sup>4</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 3.97 (2.77 to<br/> 5.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.33 (‐0.43 to ‐0.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1485<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>) </p> <p>Converted to SIB scale (and scale direction inverted); median SD(pooled) = 12.04.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL<br/> (ADCS‐ADL19)<br/> 54‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ADCS‐ADL19 score at baseline: 30.5.</p> <p>Mean change from baseline (positive scale): ‐4.1<sup>5</sup> (i.e. deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 1.33 (0.20 to 2.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.30 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1368<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD for decline in ADL as a negative outcome (<a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>) </p> <p>Converted to ADCS‐ADL19 scale (and scale direction inverted); median SD(pooled) = 6.67. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood</p> <p>(NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median baseline NPI score was 18.5.</p> <p>Median change from baseline (negative scale): 1.95 <sup>6</sup> </p> <p>(i.e. slight deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 1.57 (0.16 to 2.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.10 (‐0.19 to ‐0.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1819<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome (<a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>) </p> <p>Converted to NPI scale; median SD(pooled) = 15.70.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175 per 1000<br/> (156 to 196) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.83 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5087<br/> (17 RCTs) </p> <p>924 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR for all studies in people with moderate‐to‐severe AD (apart from those with agitation) (<a href="./references#CD003154-fig-0142" title="">Analysis 16.5</a>). </p> <p>Median control group risk for 10 studies in 2459 people with moderate‐to‐severe AD without agitation, receiving monotherapy (<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 13 fewer people per 1000 discontinued treatment for any cause (95% CI 32 fewer to 8 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>760 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>783 per 1000<br/> (760 to 806) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>).Median control group risk for moderate‐to‐severe AD studies in people receiving monotherapy (<a href="./references#CD003154-fig-0029" title="">Analysis 2.11</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 23 more people per 1000 suffered adverse events<br/> (95% CI 0 to 46 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(93 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6482</p> <p>(19 RCTs)</p> <p>918 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control risk from all AD studies (except those with agitation) (from <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 10 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 21 fewer to 2 more)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 per 1000<br/> (84 to 149) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/> (0.51 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1016<br/> (4 RCTs) </p> <p>154 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control group risk for studies in people with moderate‐to‐severe AD without agitation, receiving monotherapy (<a href="./references#CD003154-fig-0031" title="">Analysis 2.13</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 52 fewer people per 1000 suffered agitation as an adverse event<br/> (95% CI 80 to 15 fewer) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Some inconsistency in point estimates, but insufficient to downgrade </p> <p><sup>2</sup> Some imprecision (193 events and borderline for CI crossing 1; CI crossed 0.75) and some inconsistency in point estimates ‐ downgrade once overall </p> <p><sup>3</sup> Median control group values for 4 studies reporting CIBIC+ (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>) </p> <p><sup>4</sup> Median control group baseline scores and mean control group change from baseline for 3 studies reporting SIB (<a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>) </p> <p><sup>5</sup> Mean control group baseline scores and mean control group change from baseline for the 2 studies reporting ADCS‐ADL19 (<a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>) </p> <p><sup>6</sup> Median control group baseline scores and median control group change from baseline for the 4 studies reporting NPI (<a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>; <a href="./references#CD003154-bbs2-0040" title="DoodyR , WirthY , SchmittF , MobiusHJ . Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2004;18(2):227‐32. DoodyR , WirthY , SchmittF , MoebiusHJ . Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FerrisS . Clinical trial of memantine in severe Alzheimer disease: rationale and design. Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15‐20 1999, Vancouver. 1999. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. GauthierS , WirthY , MoebiusHJ . Positive behavioural effects of memantine treatment in patients with Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MoebiusHJ , WirthY , GauthierS . Memantine: behavioral benefits for moderate to severe Alzheimer's patients. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005:P02.095. ReisbergB , DoodyR , StöfflerA , SchimittF , FerrisS , Möbius HJ for the Memantine Study group. Memantine in moderate to severe Alzheimer´s Disease. New England Journal of Medicine2003;348:1333‐41. ReisbergB , FerrisS . Experimental therapeutic shows promise for people with moderately severe to severe Alzheimer's disease. World Alzheimer Congress 2000. 2000. ReisbergB , FerrisS , SahinK , WindscheifU , MöbiusHJ . Results of a placebo‐controlled 6 month trial with memantine in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(suppl 3):S363‐4. ReisbergB , MöbiusHJ , StöfflerA , SchmittF , DoodyR , FerrisS . Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease. The 8th Conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002. ReisbergB , StöfflerA , FerrisSH , SchmittF , DoodyRS . A placebo controlled study of memantine in advanced Alzheimer's disease. Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001. ReisbergB , WindscheifU , FerrisSH , HingoraniVN , StöfflerA , MöbiusHJ . Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo‐controlled 6 month trial. Conference proceedings Worl Alzheimer Congress; 9‐13 July, 2000. Washington. 2000. ReisbergB , WindscheifU , FerrisSH , StöfflerA , Möbius HJ and the Memantine Study Group. Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14, 2000. San Juan, Puerto Rico. 2000. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28‐week randomized double‐blind, placebo‐controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden. 2002:Abstract No 167. WimoA , WinbladB , StoefflerA , WirthY , MoebiusHJ . Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics2003;21(5):327‐40. ">Reisberg 2003 (9605)</a>; <a href="./references#CD003154-bbs2-0044" title="FDA. Peripheral and Central Nervous System Drugs Advisory Committee September 24, 2003. Presentation by Forest, Slide 28.. http://www.fda.gov/ohrms/dockets/ac/03/slides/3979S1_01_F‐Forest‐Backup.ppt. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies2005. PetersonL . American Neurological Association. November 2003. http://www.trends‐in‐medicine.com/Nov2003/AmNeuro113p.pdf. vanDyckCH , TariotPN , MeyersB , ResnickEM , Memantine MEM‐MD01 Study Group. A 24‐week randomized, controlled trial of memantine in patients with moderate‐to‐severe Alzheimer Disease. Alzheimer Disease and Associated Disorders2007;21(12):136‐43. ">van Dyck 2007 (MD‐01)</a>; <a href="./references#CD003154-bbs2-0046" title="WangT , HuangQ , ReimanEM , ChenK , TanC‐C , MengX‐F , et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24‐week, randomized, clinical trial. Journal of Clinical Psychopharmacology2013;33(5):636‐42. [DOI: 10.1097/JCP.0b013e31829a876a] XiaoS , WangT , HuangQ , ChenK , ReimanE . Change of biological marker and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24‐week double‐blind, randomized, placebo‐controlled study. Alzheimer's &amp; Dementia2011;7(4):S298. XiaoS , WangT , HuangQ , ChenK , ReimanE . Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double‐blind, randomized, placebo‐controlled study. Journal of Nutrition, Health &amp; Aging2012;Conference: 5th Conference Clinical Trials on Alzheimer's Disease Monte Carlo Monaco. Conference Start: 20121029 Conference End: 20121031. Conference Publication:(var.pagings):855. ">Wang 2013</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), six to seven months, monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), selected for agitation</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg or equivalent compared to placebo, for moderate‐to‐severe AD, selected for agitation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: Alzheimer's disease, moderate‐to‐severe, selected for agitation</b> <br/> <b>Intervention</b> : memantine 20 mg or equivalent<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global<br/> (CIBIC+) </p> <p>7‐point Likert scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The CIBIC+ score from one study was 4.63 <sup>5</sup> (i.e. deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.14 (‐0.17 to 0.44)</p> <p>(random effects)</p> <p>24 week study only:</p> <p>MD: ‐0.05 (‐0.35 to 0.25) (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.11 (‐0.34 to 0.13) (random effects)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>443<br/> (3 RCTs) </p> <p>24 week study: 275 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0037" title="">Analysis 3.5</a>). </p> <p>Heterogeneity between 12 weeks (2 studies) and 24 weeks.</p> <p>Converted to CIBIC+ scale; SD(pooled) = 1.29 (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function<br/> (SIB) </p> <p>100‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean SIB score at baseline: 68.1.</p> <p>Median change from baseline (positive scale): ‐5.23 <sup>6</sup> </p> <p>(i.e. deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 4.34 (‐5.89 to<br/> 14.58) (random effects) </p> <p>24 week study only:</p> <p>MD: ‐0.48 (‐2.57 to 1.61) (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.24 (‐0.84 to 0.36)</p> <p>(random effects)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0038" title="">Analysis 3.6</a>). </p> <p>[SMD as a negative outcome]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL<br/> (ADCS‐ADL19)<br/> 54‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ADCS‐ADL19 score at baseline: 32.5.</p> <p>Mean change from baseline (positive scale): ‐1.08<sup>7</sup> (i.e. slight deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: ‐1.48 (‐3.15 to 0.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (‐0.02 to 0.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0039" title="">Analysis 3.7</a>) </p> <p>[SMD for decline in ADL as a negative outcome]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood</p> <p>(NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median baseline NPI score was 33.3.</p> <p>Median change from baseline (negative scale): ‐8.6 <sup>8</sup> </p> <p>(i.e. improvement with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 1.51 (‐5.03 to 8.05)</p> <p>(random effects)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.07 (‐0.41 to 0.27)</p> <p>(random effects)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (random effects) (<a href="./references#CD003154-fig-0040" title="">Analysis 3.8</a>) </p> <p>[SMD as a negative outcome]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> <p>(Cohen Mansfield Agitation Inventory)</p> <p>range 29 ‐ 203 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean baseline CMAI score was 57.7</p> <p>Mean change from baseline (negative score) was ‐6.1<sup>9</sup> (i.e. improvement with time) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD: 0.50 (‐3.71 to 4.71)</p> <p>(random effects)</p> <p>2 studies in 422 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (‐0.12 to 0.33)</p> <p>2 studies in 306 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>455</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD and SMD as negative outcomes</p> <p>(<a href="./references#CD003154-fig-0033" title="">Analysis 3.1</a>; <a href="./references#CD003154-fig-0034" title="">Analysis 3.2</a>). </p> <p>One study reported final scores (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>), so not included in SMD. One study reported CMAI‐C (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>), so not included in MD meta‐analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188 per 1000<br/> (135 to 260) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10 (0.79 to 1.52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>555<br/> (3 RCTs) </p> <p>113 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR for all 3 studies in people with moderate‐to‐severe AD selected for agitation (<a href="./references#CD003154-fig-0041" title="">Analysis 3.9</a>). </p> <p>Median control group risk for 3 studies in 555 people with moderate‐to‐severe AD selected for agitation (<a href="./references#CD003154-fig-0041" title="">Analysis 3.9</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 17 more people per 1000 discontinued treatment for any cause (95% CI 36 fewer to 89 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>618 per 1000<br/> (600 to 636) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>).Mean control group risk for 2 moderate‐to‐severe AD studies in people selected for agitation (<a href="./references#CD003154-fig-0043" title="">Analysis 3.11</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 18 more people per 1000 suffered adverse events<br/> (95% CI 0 to 36 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Inconsistency in point estimates between 24 week and 12 week studies (downgrade once); imprecision (crossed null and SMD 0.30) (downgrade once) </p> <p><sup>2</sup> Inconsistency between 24 week and 12 week studies (I² =90%) (downgrade twice); imprecision (very wide CI crossing SMD +0.30 and ‐0.30 (downgrade twice) </p> <p><sup>3</sup> Imprecision (crossed null and SMD 0.40) (downgrade once); some inconsistency in point estimates and risk of bias from baseline differences (downgrade once across the two domains) </p> <p><sup>4</sup> Inconsistency (I² = 62%, P = 0.07) (downgrade once); risk of bias (due to baseline differences) (downgrade once); imprecision (wide CI: SMD crossing ‐0.2 and 0.4) (downgrade twice) </p> <p><sup>5</sup> Control group value for 1 study reporting CIBIC+ (<a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>)) </p> <p><sup>6</sup> Mean control group baseline scores and mean control group change from baseline for 2 studies reporting SIB (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> <p><sup>7</sup> Mean control group baseline scores and mean control group change from baseline for the 2 studies reporting ADCS‐ADL19 (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> <p><sup>8</sup> Median control group baseline scores and median control group change from baseline for the 3 studies reporting NPI (<a href="./references#CD003154-bbs2-0014" title="Forest LaboratoriesInc . A randomised, double‐blind, placebo‐controlled evaluation of the effectiveness and safety of memantine in non‐institutionalised agitated patients with moderate to severe Alzheimr's disease. http://www.forestclinicaltrials.com2006. NCT00097916 . An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's Disease [A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in non‐institutionalized agitated patients with moderate to severe Alzheimer's disease]. ClinicalTrials.gov NCT00097916April 2006. ">Forest 2006 (MD‐23)</a>; <a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> <p><sup>9</sup> Mean control group baseline scores and mean control group change from baseline for the 2 studies reporting CMAI (<a href="./references#CD003154-bbs2-0015" title="FoxC , CrugelM , MaidmentI , AuestadBH , CoultonS , TreloarA , et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double‐blind placebo controlled trial. PLOS One2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185] ">Fox 2012 (MAGD)</a>; <a href="./references#CD003154-bbs2-0018" title="HerrmannN , GauthierS , BonevaN , LemmingOM , 10158 Investigators. A randomized, double‐blind, placebo‐controlled trial of memantine in a behaviorally enriched sample of patients with moderate‐to‐severe Alzheimer's disease. International Psychogeriatrics2013;25(6):1‐9. [DOI: 10.1017/S1041610213000239] NCT00857649 . Efficacy and safety of Memantine in moderate to severe Alzheimer's disease. ClinicalTrials.gov NCT00857649 17 January 2012. ">Herrmann 2012 (10158)</a>) </p> <p><sup>10</sup> Some inconsistency for two studies reporting CMAI and some imprecision (SMD crossing 0.3 and null) (downgrade once overall) </p> <p><sup>11</sup> Imprecision (113 events) (downgrade once) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings: moderate‐to‐severe Alzheimer's disease (AD), selected for agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of findings: mild Alzheimer's disease (AD) (MMSE 20 to 23) observed case (OC) ‐ six‐month studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine 20 mg compared to placebo for mild AD (MMSE 20‐23) observed case (OC) ‐ six‐month studies for dementia</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population: mild Alzheimer's disease</b> <br/> <b>Intervention</b> : memantine 20 mg<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo<br/> (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CIBIC+)<br/> 7‐point Likert scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median CIBIC+ score<br/> was 4.1 <sup>5</sup> (i.e. no change with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.09 (‐0.12 to 0.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.08 (‐0.27 to 0.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0045" title="">Analysis 4.1</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0138" title="">Analysis 16.1</a>)] </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function (ADAS‐Cog)<br/> 70‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline ADAS‐Cog scores not reported.</p> <p>Median change from baseline in ADAS‐Cog score (negative scale): ‐1.7 <sup>6</sup> (i.e. improvement with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.21 (‐0.95 to 1.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03 (‐0.19 to 0.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>619<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0046" title="">Analysis 4.2</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0139" title="">Analysis 16.2</a>).] </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL (ADCS‐ADL23)<br/> 78‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline ADL scores not reported.</p> <p>Median change from<br/> baseline in ADCS‐ADL23<br/> (positive scale) was ‐0.34 <sup>7</sup> (i.e. no change with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: ‐0.07 (‐1.80 to 1.66)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (‐0.14 to 0.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference for decline in ADL (<a href="./references#CD003154-fig-0047" title="">Analysis 4.3</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0140" title="">Analysis 16.3</a>)] </p> <p>Direction of scale reversed for ADL outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and mood: (NPI)<br/> 144‐point scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline NPI scores not reported.</p> <p>Median change from baseline in NPI was ‐2.4</p> <p>(i.e. slight improvement with time) <sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: ‐0.29 (‐2.16 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (‐0.14 to 0.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference.</p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0141" title="">Analysis 16.4</a>)]. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174 per 1000<br/> (108 to 281) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.74<br/> (1.08 to 2.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>528<br/> (4 RCTs) </p> <p>72 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control group risk for mild AD studies (<a href="./references#CD003154-fig-0142" title="">Analysis 16.5</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 74 more people per 1000 discontinued treatment for any cause (95% CI 8 to 181 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442 per 1000<br/> (429 to 455) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>).Control group risk taken from <a href="./references#CD003154-bbs2-0020" title="HollandP , TappenR , FisherL , CurtisAL . Effect of memantine on the progression of driving impairment in mild Alzheimer's disease. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P886‐7. HollandPJ , TappenRM , FisherL , CurtisAL , ApterJ . Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease. Journal of Nutrition, Health and Aging2013;Conference: 6th Conference Clinical Trials on Alzheimer's Disease San Diego, CA United States. Conference Start: 20131114 Conference End: 20131116. Conference Publication:(var.pagings):823‐4. NCT00476008 . Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease [Delaying the progression of driving impairment in individuals with mild Alzheimer’s disease]. https://clinicaltrials.gov/ct2/show/NCT004760082013. ">Holland 2013</a> study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Difference: 13 more people per 1000 suffered adverse events<br/> (95% CI 0 to 26 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(93 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6482</p> <p>(19 RCTs)</p> <p>918 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and median control risk from all AD studies (except those with agitation) (from <a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 10 fewer people per 1000 suffered serious adverse events</p> <p>(95% CI 21 fewer to 2 more)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number suffering agitation as an adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported by any study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> All studies are post‐hoc subgroups (downgrade once on risk of bias); imprecision ‐ 427 patients and SMD estimate crosses null and is consistent with appreciable benefit and no benefit (downgrade once) </p> <p><sup>2</sup> All studies are post‐hoc subgroups (downgrade once on risk of bias) </p> <p><sup>3</sup> All studies are post‐hoc subgroups (downgrade once on risk of bias) and some inconsistency in the point estimates (but not sufficient to downgrade) </p> <p><sup>4</sup> Majority of the information from post‐hoc subgroups (downgrade once on risk of bias); imprecision: 72 events, and CI crossed 1.25 (downgrade once); inconsistency (I² = 49%) downgrade once </p> <p><sup>5</sup> Median control group values for 3 studies reporting CIBIC+ (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>) </p> <p><sup>6</sup> Median control group change from baseline for 4 studies reporting ADAS‐Cog (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>) </p> <p><sup>7</sup> Median control group change from baseline for the 4 studies reporting ADCS‐ADL23 (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>) </p> <p><sup>8</sup> Median control group change from baseline for the 4 studies reporting NPI (<a href="./references#CD003154-bbs2-0006" title="BakchineS , LoftH . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study. Journal of Alzheimer’s Disease2008;13(1):97‐107. BakchineS , LoftH (Replaced by Bakchine 2008) . Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double‐blind, placebo‐controlled 6‐month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97‐107]. Journal of Alzheimer’s Disease2007;11(4):471‐9. OlinJ . Personal communication2015. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24(1):20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006 [poster]. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006 [poster]. 2006. ">Bakchine 2008 (99679) SG</a>; <a href="./references#CD003154-bbs2-0010" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. ">Dysken 2014 SG</a>; <a href="./references#CD003154-bbs2-0036" title="PeskindER , PotkinSG , PomaraN , OttBR , GrahamSM , OlinJT , et al. Memantine treatment in mild to moderate Alzheimer Disease: A 24‐week randomized, controlled trial. American Journal of Geriatric Psychiatry2006;14:704‐15. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. ">Peskind 2004 (MD‐10) SG</a>; <a href="./references#CD003154-bbs2-0039" title="WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at European Federation of Neurological Societies, 10th Congress Glasgow 2nd‐5th September 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th ‐ 20th July 2006. 2006. WinbladB , JonesRW , WirthY , StöfflerA , MöbiusHJ . Memantine in moderate to severe Alzheimer’s Disease: a meta‐analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders2007;24:20‐7. ">Porsteinsson 2008(MD‐12)S</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of findings: mild Alzheimer's disease (AD) (MMSE 20 to 23) observed case (OC) ‐ six‐month studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of findings: Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine compared to placebo for Parkinson's disease dementia (PDD) and Dementia with Lewy Bodies (DLB)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB)<br/> <b>Intervention</b> : memantine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CIBIC+)</p> <p>7‐point Likert scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIBIC+ score from 1 study was 4.1 (i.e. no change)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.49 (0.13 to 0.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.35 (‐0.60 to ‐0.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0058" title="">Analysis 6.1</a>) </p> <p>Back transformed to CIBIC+ scale using SD(pooled) = 1.39 (from 1 study (<a href="./references#CD003154-bbs2-0027" title="MarshL , BiglanK , WilliamsJR . Randomised, placebo‐controlled trial of memantine for dementia in Parkinson's disease. Poster at World PD Congress, Miami, FLorida. 14 December 2009. ">Marsh 2009 PDD</a>)). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive Function: (MMSE)</p> <p>30‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE score: 20.0 (at 24 weeks).</p> <p>Change from baseline (positive scale): ‐0.5 (i.e. slight deterioration with time)</p> <p>(one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 1.9 (0.07 to 3.73)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.50(‐1.00 to 0.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study at 24 weeks and one at 16 weeks only for this outcome; highly heterogeneous.</p> <p>So 24 week study reported only (<a href="./references#CD003154-bbs2-0001" title="AarslandD , BallardC , WalkerZ , BostromF , AlvesG , KossakowskiK , et al. Memantine in patients with Parkinson's Disease dementia or dementia with Lewy Bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurology2009;8(7):613‐8. LarssonV , AarslandD , BallardC , MinthonL , LondosE . The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry2010;25(10):1030‐8. StubendorffK , LarssonV , BallardC , MinthonL , AarslandD , LondosE . Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open2014;4(7):e005158. [DOI: 10.1136/bmjopen‐2014‐005158] WesnesK , AarslandD , BallardC , LondosE . Memantine improves attention and verbal episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies: a double‐blind, placebo‐controlled multicentre trial. Alzheimer's &amp; Dementia2013;9(4):890. [DOI: 10.1016/j.jalz.2013.08.252] WesnesKA , AarslandD , BallardC , LondosE . Improvements to attention and verbal episodic memory with memantine in Parkinson's Disease dementia and dementia with Lewy Bodies. Journal of Nutrition, Health &amp; Aging2013;17(9):781‐2. [DOI: 10.1007/s12603‐013‐0399‐7] WesnesKA , AarslandD , BallardC , LondosE . Memantine improves attention and episodic memory in Parkinson's Disease dementia and dementia with Lewy Bodies. International Journal of Geriatric Psychiatry2015;30(1):46‐54. [DOI: http://dx.doi.org/10.1002/gps.4109] ">Aarsland 2009</a>). MMSE scale direction was reversed (<a href="./references#CD003154-fig-0059" title="">Analysis 6.2</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL (ADCS‐ADL23)</p> <p>78‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADCS‐ADL23 score at baseline: 48</p> <p>Change from baseline (positive scale): ‐0.1 (i.e. no change with time)</p> <p>(one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 3.07 (‐1.25 to 7.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.27 (‐0.67 to 0.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD decline in ADL as a negative outcome (<a href="./references#CD003154-fig-0060" title="">Analysis 6.3</a>). Random effects. </p> <p>Back transformed to ADCS‐ADL23 scale, using results from one study (<a href="./references#CD003154-bbs2-0012" title="EmreM . A randomised, double‐blind, placebo‐controlled 6 month study of the efficacy and safety of memantine in patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). 13th Congress of European Federation of Neurological Societies (EFNS). 12‐15 September 2009. Emre M and 11018 study investigators. A randomised, double‐blind, placebo‐controlled, 6‐month study of the efficacy and safety of memantine in patients with PDD or DLB. 9th International conference on Alzheimer's and Parkinson's disease. Prague. 11‐15 March 2009. EmreM , TsolakiM , BonucelliU , DestéeA , TolosaE , KutzelniggA , et al. Memantine for patients with Parkinson's disease or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2010 August 20;9(10):969‐77. ">Emre 2010 (11018)</a>). SD(pooled) = 11.38. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood</p> <p>(NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median NPI score at baseline: 13.0</p> <p>Median change from baseline (negative scale): 1.4<br/> (i.e. slight deterioration with time) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 2.18 (‐1.21 to 5.57)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.18 (‐0.43 to 0.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random effects. Analysed as mean difference (<a href="./references#CD003154-fig-0061" title="">Analysis 6.4</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0076" title="">Analysis 8.4</a>)] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause</p> <p>discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169 per 1000<br/> (111 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.55 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>312<br/> (4 RCTs) </p> <p>64 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from PDD or DLB studies (<a href="./references#CD003154-fig-0062" title="">Analysis 6.5</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 32 fewer people per 1000 discontinued treatment for any cause<br/> (95% CI 90 fewer to 56 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at</p> <p>least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>515 per 1000<br/> (500 to 530) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>). Median control group risk for PDD or DLB studies (<a href="./references#CD003154-fig-0064" title="">Analysis 6.7</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 15 more people per 1000 suffered adverse events<br/> (95% CI 0 to 30 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at</p> <p>least one serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> <p>(59 to 255)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.43<br/> (0.69 to 2.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220</p> <p>(2 RCTs)</p> <p>26 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from PDD or DLB studies (<a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 37 more people per 1000 suffered serious adverse events</p> <p>(95% CI 27 fewer to 169 more)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number suffering agitation as an adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported for either study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Majority of the information at high risk of bias and number of patients estimated (downgrade once); imprecision ‐ 243 patients (below optimal information size) (downgrade once) </p> <p><sup>2</sup> Reporting bias (2 larger studies did not report outcome) and high risk of bias for remaining study (downgrade once), inconsistency with 16 weeks study high (I² = 75%) (downgrade once), imprecision (only 63 patients, wide CI) (downgrade once) </p> <p><sup>3</sup> Majority of information at high risk of bias (downgrade once), inconsistency in point estimates (I² = 40%) (downgrade once) and imprecision (243 participants and CI crossed null and consistent with both benefit and no difference) (downgrade once) </p> <p><sup>4</sup> Majority of information at high risk of bias (downgrade once), some inconsistency in point estimates (I² = 20%) (not downgraded) and imprecision (243 patients; CI crossed null and included benefit and no difference) (downgrade once) </p> <p><sup>5</sup> Imprecision: CI crossed both 1.25 and 0.75, and CI fairly wide around absolute effect (downgrade twice) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of findings: Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0010"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Summary of findings: frontotemporal dementia (FTD)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Memantine compared to placebo for Frontotemporal dementia (FTD)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : frontotemporal dementia<br/> <b>Intervention</b> : memantine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo (median)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in change score between memantine and placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI) meta‐analysis findings</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Global (CGIC)</p> <p>7‐point Likert scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGIC score from 1 study was 4.8</p> <p>(i.e. deterioration with time)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 0.56 (‐0.11 to 1.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.31 (‐0.67 to 0.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD as a negative outcome</p> <p>(<a href="./references#CD003154-fig-0065" title="">Analysis 7.1</a>) </p> <p>Back transformed to CGIC scale using SD (pooled) = 1.80 (from 1 study (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive Function: (MMSE)</p> <p>30‐point scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE score: 25.1 (at 26 weeks).</p> <p>Change from baseline (positive scale): ‐0.9 (i.e. deterioration with time)</p> <p>(one study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐0.30 (‐1.83 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09 (‐0.35 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study at 6 months and one at 12 months for this outcome; some heterogeneity so 6‐month study reported only (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>) </p> <p>(<a href="./references#CD003154-fig-0066" title="">Analysis 7.2</a>). MMSE scale direction was reversed.<br/> [SMD as a negative outcome (<a href="./references#CD003154-fig-0074" title="">Analysis 8.2</a>)] </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Performance on ADL</p> <p>% DAD score = yes at 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline score: 58.3%. Change from baseline (positive scale): ‐19.5% (i.e. deterioration)</p> <p>(one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 12.10% (‐1.40 to 25.60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decline in ADL not reported in either study. Percentage with DAD score = yes reported in <a href="./references#CD003154-bbs2-0045" title="VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. English title not available. [Etude contrôlée, en double aveugle, en groupe parallèle,de l’efficacité et de la tolérance de la mémantine (20 mg)versus placebo chez des patients présentant une variante comportementale de démence frontotemporale]. Revue Neurologique2010;166:S46‐8. VercellettoM , Boutoleau‐BretonnièreaC , VolteaubC , PuelcM , AuriacombedS , SarazineM , et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer’s Disease2011;23:749‐59. VercellettoMM , Boutoleau‐BretonniereCJ , VolteauC , PuelM , AuriacombeS , SarazinM , et al. Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double‐blind, parallel group, placebo‐controlled trial. Neurology2009;72(11):A12. ">Vercelletto 2011</a> at 12 months. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour and Mood</p> <p>(NPI)</p> <p>144‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI score at baseline: 21.5.</p> <p>Change from baseline (negative scale): 0.3<br/> (i.e. no difference) (one study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: 3.16 (‐3.61 to 8.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.17 (‐0.62 to 0.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as mean difference (<a href="./references#CD003154-fig-0067" title="">Analysis 7.3</a>). </p> <p>Baseline score and change from baseline for 26‐week study (<a href="./references#CD003154-bbs2-0007" title="BoxerAL , KnopmanDS , KauferDI , GrossmanM , OnyikeC , Graf‐RadfordN , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2013;12(2):149‐56. [DOI: 10.1016/S1474‐4422(12)70320‐4] ForestLaboratories . Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. https://clinicaltrials.gov/ct2/show/NCT005459742007. ">Boxer 2013</a>). </p> <p>[SMD as a negative outcome (<a href="./references#CD003154-fig-0076" title="">Analysis 8.4</a>)] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Binary outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with placebo (median)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk with memantine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause</p> <p>discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109 per 1000<br/> (38 to 288) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.54 (0.54 to 4.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>133<br/> (2 RCTs) </p> <p>15 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from FTD studies; control group risk from 26 week study (<a href="./references#CD003154-fig-0068" title="">Analysis 7.4</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 38 more people per 1000 discontinued treatment for any cause (95% CI 33 fewer to 217 more) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at</p> <p>least one adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>687 per 1000<br/> (667 to 707) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8033<br/> (29 RCTs) </p> <p>5371 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR from all studies (<a href="./references#CD003154-fig-0086" title="">Analysis 9.3</a>).Control group risk for 26‐week FTD study </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 20 more people per 1000<br/> suffered adverse events<br/> (95% CI 0 to 40 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering at least one severe adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> <p>(14 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.30 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>133</p> <p>(2 RCTs)</p> <p>17 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from FTD study at 26 weeks (<a href="./references#CD003154-fig-0082" title="">Analysis 8.10</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 14 fewer people per 1000<br/> suffered adverse events<br/> (95% CI 34 fewer to 32 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number suffering agitation as an adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000 (0.5 to 208)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21<br/> (0.01 to 4.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>81 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR and control group risk from FTD study at 26 weeks (<a href="./references#CD003154-fig-0072" title="">Analysis 7.8</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Difference: 38 fewer people per 1000<br/> suffered adverse events<br/> (95% CI 48 fewer to 160 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD:</b> mean difference; <b>RR:</b> Risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High</b> certainty: we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate</b> certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low</b> certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low</b> certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Majority of the information at high risk of bias (downgrade once); imprecision ‐ 117 patients (below optimal information size) (downgrade once) </p> <p><sup>2</sup> Inconsistency in point estimates (I² = 23%) (downgrade once) and Imprecision (122 patients and wide confidence interval) (downgrade twice) </p> <p><sup>3</sup> Imprecision (39 participants and CI crossed null and consistent with both benefit and no difference) (downgrade twice); indirect outcome (percentage DAD score at 12 months) and borderline high risk of bias (differential missing data) (downgrade once) </p> <p><sup>4</sup> Some inconsistency in point estimates and Imprecision (122 patients and wide confidence interval) (downgrade twice overall) </p> <p><sup>5</sup> Inconsistency in point estimates (downgrade once); Imprecision: 15 events and CI crossed both 1.25 and 0.75 (downgrade twice) </p> <p><sup>6</sup> Imprecision: 17 events and wide CI (downgrade twice) </p> <p><sup>7</sup> Imprecision: 2 events and very wide CI (downgrade twice): high risk of bias ‐ number discontinuing treatment greater than number of events (downgrade twice) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Summary of findings: frontotemporal dementia (FTD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0011"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Subgroup analysis: concomitant ChEI therapy versus monotherapy; six to seven month studies in moderate‐to‐severe Alzheimer's disease (AD)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Number of Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Number of Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Standardised Effect Estimate</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Heterogeneity (I²)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Test for<br/> subgroup differences</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Domain</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>with ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>no ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>with ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>no ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>with ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>no ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>with ChEI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>no ChEI</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical Global</p> <p>(<a href="./references#CD003154-fig-0019" title="">Analysis 2.1</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1125</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20<br/> (‐0.28 to ‐0.13) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.21</p> <p>(‐0.32 to ‐0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20</p> <p>(‐0.30 to ‐0.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.99</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive Function</p> <p>(<a href="./references#CD003154-fig-0020" title="">Analysis 2.2</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3337</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1852</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1485</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28</p> <p>(‐0.35 to ‐0.21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24</p> <p>(‐0.33 to ‐0.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33</p> <p>(‐0.43 to ‐0.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 44%, P = 0.18</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decline in<br/> Activities of Daily </p> <p>Living (<a href="./references#CD003154-fig-0021" title="">Analysis 2.3</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2687</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1319</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1368</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.17</p> <p>(‐0.24 to ‐0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.13</p> <p>(‐0.24 to ‐0.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20</p> <p>(‐0.30 to ‐0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.43</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Behaviour and Mood</p> <p>(<a href="./references#CD003154-fig-0022" title="">Analysis 2.4</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3674</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1855</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1819</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.14</p> <p>(‐0.21 to ‐0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.18</p> <p>(‐0.27 to ‐0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10</p> <p>(‐0.19 to ‐0.01)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 35%, P = 0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause discontinuation</p> <p>(<a href="./references#CD003154-fig-0027" title="">Analysis 2.9</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4548</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2089</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2459</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.93</p> <p>(0.82 to 1.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.94</p> <p>(0.78 to 1.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.92</p> <p>(0.78 to 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%,</p> <p>P = 0.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> <p>(<a href="./references#CD003154-fig-0029" title="">Analysis 2.11</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3390</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1625</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1765</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.02</p> <p>(0.98 to 1.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05</p> <p>(0.98 to 1.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.99</p> <p>(0.94 to 1.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 46%,</p> <p>P = 0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation as an</p> <p>adverse event</p> <p>(<a href="./references#CD003154-fig-0031" title="">Analysis 2.13</a>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3854</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1965</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1889</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.79</p> <p>(0.64 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.93</p> <p>(0.65 to 1.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72</p> <p>(0.55 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 25.1%,</p> <p>P = 0.25</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="14"> <div class="table-footnote"> <p>Six studies were conducted on patients with moderate‐to‐severe disease receiving ChEI therapy, these were: </p> <p><a href="./references#CD003154-bbs2-0009" title="DyskenMW , GuarinoPD , VertreesJE , AsthanaS , SanoM , LlorenteM , et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimer's &amp; Dementia2014;10(1):36‐44. [DOI: 10.1016/j.jalz.2013.01.014] DyskenMW , SanoM , AsthanaS , VertreesJE , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161]. JAMA2014;311(1):33‐44. [DOI: 10.1001/jama.2013.282834.] ">Dysken 2014</a>: patients were on ongoing ChEI therapy with any ChEI (donepezil, rivastigmine or galantamine), as maintenance dosage for at least 4 weeks </p> <p><a href="./references#CD003154-bbs2-0017" title="Forest Laboratories, Inc. announces positive results of memantine study of once‐daily formulation. Press release 5 Feb 08. AlvaG , GrossbergG , HendrixS , EllisonN , AndersenKA , EdwardsJ . Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer's disease. Neurology2017;88(16 Suppl 1):P3.087. AtriA , CummingsJL , HendrixS , EllisonN , AndersenKA , EdwardsJ . Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2017;13(7):1232. [DOI: 10.1016/j.jalz.2017.07.430] AtriA , HendrixS , PejovicV , GrahamS . Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: an analysis of area under the curve. Neurology2014;82(10):P1.006. AtriA , ToccoM , HendrixS , PejovicV , GrahamSM . Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis. American Journal of Geriatric Psychiatry2014;22(3):S120‐21. [DOI: 10.1016/j.jagp.2013.12.138] Forest LaboratoriesInc . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate‐to‐severe dementia of the Alzheimer's Type. http://www.forestclinicaltrials.com2005. GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(4):S782. [DOI: 10.1016/j.jalz.2011.05.2245] GrahamS , HendrixS , MillerM , PejovicV , ToccoM . Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer's Dementia2012;8(4):P591. [DOI: 10.1016/j.jalz.2012.05.1611] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Extended‐release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial. American Journal of Geriatric Psychiatry2013;21(3):S139. [DOI: 10.1016/j.jagp.2012.12.184] GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Responder analysis in a trial of once‐daily, extended‐release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. American Society of Consultant Pharmacists, ASCP Annual Meeting and Exhibition; 2011 11 16‐18; Phoenix, AZ United States. 2011. GrahamSM , HendrixS , MillerML , PejovicV , ToccoM . Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended‐release memantine (28 mg, once daily). Annals of Neurology2012;72:S42. GrahamSM , ToccoM , HsuH‐A , XieL , PerhachJL . The effect of extended‐release memantine on behavioral domains in patients with moderate to severe Alzheimer's disease. American Psychiatric Association; 163rd Annual Meeting; New Research Abstracts; 2010 May 22‐26; New Orleans (LA). 2010. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamS . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: subset analysis of a randomized clinical trial. Neurology2015;84(14 Suppl):P7.101. GrossbergG , AlvaG , HendrixS , HofbauerR , PejovicV , GrahamSM . Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial. Alzheimer's &amp; Dementia2014;10(4):P450. [DOI: 10.1016/j.jalz.2014.05.612] GrossbergGT , ManesF , AllegriR , Gutierrez‐RobledoLM , GlogerS , XieL , et al. A multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial of memantine extended‐release capsule (28 mg, once daily) in patients with moderate to severe Alzheimers disease. Alzheimer's &amp; Dementia2008;4(4):T793. [DOI: 10.1016/j.jalz.2008.05.2476] GrossbergGT , ManesF , AllegriRF , Gutiérrez‐RobledoLM , GlogerS , XieL , et al. The safety, tolerability, and efficacy of once‐daily memantine (28 mg): a multinational, randomized, double‐blind, placebo‐controlled trial in patients with moderate‐to‐severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs2013;27(6):469‐78. [DOI: 10.1007/s40263‐013‐0077‐7] ThibaultCS‐L , StillmanIO , ChenS , GetsiosD , ProskorovskyI , HernandezL , et al. Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer's disease in the United States. Alzheimer's &amp; Dementia2014;Conference: Alzheimer's Association International Conference 2014 Copenhagen Denmark. Conference Start: 20140712 Conference End: 20140717. Conference Publication:P596‐7. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. Neurology2013; Vol. 80, issue Meeting Abstracts 1:P01.012. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial. Annals of Neurology2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. Alzheimer's &amp; Dementia2013;Conference: Alzheimer's Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Effects of once‐daily, extended‐release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease. Annals of Neurology2011;70 Suppl 15:S54. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease. Annals of Neurology2012;Conference: 137th Annual Meeting of the American Neurological Association Boston, MA United States. Conference Start: 20121007 Conference End: 20121010. Conference Publication:(var.pagings):S42. ToccoM , HendrixS , MillerM , PejovicV , GrahamS . Sustained cognitive improvement with extended‐release memantine (28 mg, once daily) in moderate to severe alzheimer's disease. Consultant Pharmacist2012;Conference: American Society of Consultant Pharmacists Fall 2012 National Harbor, MD United States. Conference Start: 20121106 Conference End: 20121109. Conference Publication:(var.pagings):717. ">Grossberg 2008 (MD‐50)</a>: patients were on ongoing ChEI therapy with a stable dose of any ChEI for 3 months or longer, patients must remain on the same dose throughout the study. </p> <p><a href="./references#CD003154-bbs2-0022" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine in moderate to severe Alzheimer's Disease. New England Journal of Medicine2012;366:893‐903. [ISRCTN49545035] JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al. DOMINO‐AD team. DOMINO‐AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease ‐ a multicentre RCT. Trials2009;10:57. KnappM , KingD , RomeoR , AdamsJ , BaldwinA , BallardC , et al. Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial). International Journal of Geriatric Psychiatry2017;32(12):1205‐16. ">Howard 2012 (DOMINO‐AD)</a>: patients were on ongoing ChEI therapy with donepezil for at least 3 months and had received a dose of 10 mg for at least the previous<br/> 6 weeks. Patients were randomised to continue or discontinue donepezil. The patient’s prescribing clinician was considering a change in drug treatment. </p> <p><a href="./references#CD003154-bbs2-0032" title="KishiT , MatsunagaS , OyaK , NomuraI , IkutabanT , IwataN . Memantine for Alzheimer’s Disease: an updated systematic review and meta‐analysis. Journal of Alzheimer’s Disease2017;60:401‐25. NakamuraY , KitamuraS , NagakuboT , KobayashiM , HommaA . Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease ‐ Efficacy and safety. Japanese Journal of Geriatric Medicine2016;54:1147‐58. ">Nakamura 2016</a>: patients had been on donepezil for at least four weeks when recruited and then had 12 weeks single blind observation period on donepezil. Only those stable continued to the double blind period. </p> <p><a href="./references#CD003154-bbs2-0038" title="Completed memantine efficacy study: mild to moderate Alzheimer's dementia. http://www.lundbecktrials.com2005. DoodyRS , TariotPN , PfeifferE , OlinJT , GrahamSM , BellJM . Meta‐analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6‐9 2005 .. 2005. PorsteinssonAP , GrossbergGT , MintzerJ , OlinJT . Memantine treatment in patients with mild‐to‐moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, controlled trial. Current Alzheimer Research2008;5:83‐9. ">Porsteinsson 2008 (MD‐12)</a>: patients were on ongoing ChEI therapy with any ChEI for 6 months or longer, and a stable dosing regimen for 3 months or longer (donepezil 5‐10 mg/day; rivastigmine 6, 9 or 12 mg/day; galantamine 16 or 24 mg/day) </p> <p><a href="./references#CD003154-bbs2-0043" title="CummingsJL , SchneiderE , PeskindE , TariotP , GrahamSM , BellJM . Effect of memantine on behavioral outcomes in Alzheimer's disease. In: IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. CummingsJL , SchneiderE , TariotPN , GrahamSM , Memantine MEM‐MD‐02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology2006;67:57‐63. FeldmanH , SchmittFA , DoraiswamyPM , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's Disease. In: 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005. 2005. FeldmanH , SchmittFA , PFeifferE , GrahamSM , BellJM . Memantine and individual activities of daily living in moderate to severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. FeldmanHH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. Activities of daily living in moderate‐to‐severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord2006;20:263‐8. FinucaneTE . Memantine for patients with Alzheimer Disease. JAMA2004;291(14):1695. Forest LaboratoriesI . A randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies 2005. GauthierS , WirthY , MobiusHJ . Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry2005;20(5):459‐64. SchmittFA , vanDyckCH , WichemsCH , OlinJT , for the Memantine MEM‐MD‐02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders2006;20(4):255‐62. TariotP , FarlowM , GrossbergT , GrahamS , McDonaldS , GergelI , for the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. A randomized controlled trial. JAMA2004;291:317‐24. TariotPN . Memantine for patients with Alzheimer Disease: reply to Funicane. JAMA2004;291(14):1695. vanDyckCH , SchmittFA , OlinJT , Memantine MEM‐MD‐02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry2006;14:428‐37. ">Tariot 2004 (MD‐02)</a>: patients were on ongoing ChEI therapy with donepezil for more than 6 months before entry into the trial and at a stable dose (5‐10mg/day) for at least 3 months. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Subgroup analysis: concomitant ChEI therapy versus monotherapy; six to seven month studies in moderate‐to‐severe Alzheimer's disease (AD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0012"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Comparison of analyses in people with moderate‐to‐severe AD, selected versus not selected for agitation at six to seven months</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Patients not selected for agitation (with moderate‐to‐severe AD)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Patients selected for agitation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With / without ChEI<br/> (24‐28 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No ChEI<br/> (24‐28 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With ChEI<br/> (24‐28 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With / without ChEI, mainly with<br/> (12 &amp; 24 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With ChEI<br/> (24 weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>With / without ChEI ‐<br/> majority without<br/> (12 weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical</p> <p>global</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.28 to ‐0.13)</p> <p>n = 10 studies;</p> <p>2797 patients</p> <p>I² = 0%, P = 0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.30 to ‐0.10)</p> <p>n = 7; 1672 patients</p> <p>I² = 0%, P = 0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.21 (‐0.32 to ‐0.09)</p> <p>n = 3; 1125 patients</p> <p>I² = 13%, P = 0.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.11 (‐0.34 to 0.13)</p> <p>n = 3; 443 patients</p> <p>I² = 25%, P = 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (‐0.20 to 0.28)</p> <p>n = 1; 324 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.59 to 0.02)</p> <p>n = 2; 168 patients</p> <p>I² = 0%, P = 0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive</p> <p>function</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.35 to ‐0.21)</p> <p>n = 13; 3337 patients</p> <p>I² = 30%, P = 0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33 (‐0.43 to ‐0.23)</p> <p>n = 8; 1485 patients</p> <p>I² = 41%, P = 0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24 (‐0.33 to ‐0.14)</p> <p>n = 6; 1852 patients</p> <p>I² = 13%, P = 0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not pooled</p> <p>I² = 90%, P = 0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.17 to 0.27)</p> <p>n = 1, 324 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.56 (‐0.92 to ‐0.21)</p> <p>n = 1; 129 patients</p> <p>(with ˜20% ChEI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decline</p> <p>in ADL</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.17 (‐0.24 to ‐0.09)</p> <p>n = 11; 2687 patients</p> <p>I² = 0%, P = 0.582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.30 to ‐0.09)</p> <p>n = 7; 1368 patients</p> <p>I² = 10%, P = 0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.13 (‐0.24 to ‐0.03)</p> <p>n = 5; 1319 patients</p> <p>I² = 0%, P = 0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (‐0.02 to 0.43)</p> <p>n = 2; 309 patients</p> <p>I² = 0%, P = 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (‐0.01 to 0.47)</p> <p>n = 1; 276 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.02 (‐0.70 to 0.67)</p> <p>n = 1; 33 patients</p> <p>(with ChEI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour</p> <p>and mood</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.14 (‐0.21 to ‐0.08)</p> <p>n = 14; 3674 patients</p> <p>I² =6%, P = 0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10 (‐0.19 to ‐0.01)</p> <p>n = 9; 1819 patients</p> <p>I² = 0%, P = 0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.18 (‐0.27 to ‐0.09)</p> <p>n = 6; 1855 patients</p> <p>I² = 10%, P = 0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.07 (‐0.41 to 0.27)</p> <p>n = 3; 470 patients</p> <p>I² = 62%, P = 0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (‐0.14 to 0.30)</p> <p>n = 1; 324 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.69 to 0.29)</p> <p>n = 2; 146 patients</p> <p>I² = 43%, P = 0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI</p> <p>(SMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.21 (‐0.45 to 0.04)</p> <p>n = 1; 261 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (‐0.12 to 0.33)</p> <p>n = 2; 306 patients</p> <p>I² = 0%, P = 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (‐0.14 to 0.33)</p> <p>n = 1; 273 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI (final values):</p> <p>SMD: ‐0.19 (‐0.52 to 0.13) <br/> n = 1; 149 patients </p> <p>CMAI (community):</p> <p>SMD: 0.21 (‐0.48 to 0.89)</p> <p>n = 1; 33 patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion</p> <p>with</p> <p>agitation (RR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.601 to 0.96)</p> <p>6 studies; 2 241 patients</p> <p>I² = 0%, P = 0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.51, 0.91)</p> <p>4 studies; 1016 patients</p> <p>I² = 0%, P = 0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.54 to 1.31)</p> <p>3 studies; 1225 patients</p> <p>I² = 0% and 0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.39 (1.04 to 5.50)</p> <p>2 studies; 403 patients</p> <p>I² = 0%, P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.20 (0.92 to 5.27)</p> <p>1 study; 369 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.26 to 97.00)</p> <p>1 study; 34 patients (with ChEI)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Comparison of analyses in people with moderate‐to‐severe AD, selected versus not selected for agitation at six to seven months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003154-tbl-0013"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies (participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity (I²)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GRADE rating</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia (<a href="./references#CD003154-fig-0089" title="">Analysis 9.6</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (5354), 221 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.73 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 14%, P = 0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW (downgraded on imprecision and reporting bias &lt; 70% patients had AE data)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confusion (<a href="./references#CD003154-fig-0090" title="">Analysis 9.7</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (4509), 167 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.91 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW (downgraded on imprecision and reporting bias &lt; 70% patients had AE data)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression (<a href="./references#CD003154-fig-0091" title="">Analysis 9.8</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3052), 83 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.70 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (twice), inconsistency in point estimates (once) and reporting bias &lt;40% patients had AE data (twice)) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache (<a href="./references#CD003154-fig-0092" title="">Analysis 9.9</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (4889), 240 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (1.00 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 9%,P = 0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW (downgraded on imprecision (once) and reporting bias &lt;70% patients had AE data)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension (<a href="./references#CD003154-fig-0093" title="">Analysis 9.10</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (3175), 87 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 (1.14 to 2.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 1%, P = 0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (twice), inconsistency in point estimates (once) and reporting bias &lt;40% patients had AE data (twice)) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness (<a href="./references#CD003154-fig-0094" title="">Analysis 9.11</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (6395), 323 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59 (1.28 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MODERATE (downgraded on inconsistency in point estimates)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Falls (<a href="./references#CD003154-fig-0095" title="">Analysis 9.12</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (6743), 589 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.84 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIGH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Accidental injury (<a href="./references#CD003154-fig-0096" title="">Analysis 9.13</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3813), 214 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.62 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (once) and twice on reporting bias (&lt; 50% patients and 1 in 4 studies) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary incontinence (<a href="./references#CD003154-fig-0097" title="">Analysis 9.14</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (2724), 76 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.73 to 1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (twice), inconsistency in point estimates (once) and reporting bias &lt;4 0% patients had AE data (twice)) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea (<a href="./references#CD003154-fig-0098" title="">Analysis 9.15</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (6186), 318 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.66 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW (downgraded on imprecision (once), some inconsistency in point estimates and reporting bias &lt;70% patients had AE data (once further)) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Influenza‐like symptoms (<a href="./references#CD003154-fig-0099" title="">Analysis 9.16</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2836), 129 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.87 to 1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%, P = 0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VERY LOW (downgraded on imprecision (once), and reporting bias &lt; 40% patients and 1/6 studies had AE data (twice)) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/full#CD003154-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.28, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.34, ‐0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.24, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and Mood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.21, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.82, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuations due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number suffering at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.97, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number suffering serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number suffering agitation as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe Alzheimer's disease 24‐ to 30‐week data. OC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global: subgroup analysis by +/‐ ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.28, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.30, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 With concomitant cholinesterase inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.32, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function subgroup analysis by +/‐ ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.35, ‐0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.43, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 With concomitant cholinesterase inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.33, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL: subgroup analysis by +/‐ ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.24, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.30, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 With concomitant cholinesterase inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.24, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and Mood: subgroup analysis by +/‐ ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.21, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.19, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 With concomitant cholinesterase inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.27, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cognitive function (sMMSE):subgroup analysis within randomised study ‐ per protocol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.35 [‐2.39, ‐0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.11 [‐3.74, ‐0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 With concomitant cholinesterase inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐2.18, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Decline in ADL (BADL): subgroup analysis within randomised study ‐ per protocol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.46 [‐6.45, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 With concomitant cholinesterase inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐3.21, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 NPI: subgroup analysis within randomised study ‐ per protocol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.23 [‐14.08, 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 With concomitant cholinesterase inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.99 [‐13.13, ‐0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinical Global: CIBIC+ mean difference; ChEI subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.33, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause discontinuation ‐ by ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.82, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.78, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 with concomitant ChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Discontinuations due to adverse events ‐ by ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.72, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 With concomitant ChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.75, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events ‐ by ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.98, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.94, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 with concomitant ChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2040</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.98, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serious adverse events ‐ by ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 With concomitant ChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.83, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number suffering agitation as an adverse event ‐ by ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.51, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 with concomitant ChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.60, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Memantine + donepezil vs memantine + placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Cognitive function (sMMSE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Decline in ADL (BADLS scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Behaviour and mood (NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Memantine 20 mg or equivalent vs placebo in patients taking versus not taking cholinesterase inhibitors with moderate to severe Alzheimer's disease 24‐ to 30‐week data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cohen Mansfield Agitation Inventory (MD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐4.71, 3.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐10.06, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐1.29, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cohen Mansfield Agitation Inventory (SMD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.12, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.48, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.14, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 NPI agitation subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.90, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number suffering agitation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.04, 5.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.26, 97.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.92, 5.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical Global <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.34, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.59, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.20, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cognitive Function: SIB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.34 [‐14.58, 5.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.00 [‐16.15, ‐3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [‐1.61, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Decline in ADL: ADCS‐ADL19 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [‐0.19, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐4.18, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐0.03, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Behaviour and Mood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.51 [‐8.05, 5.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.76 [‐14.09, 6.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [‐2.19, 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.79, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.78, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.63, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Discontinuations due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.88, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Number suffering at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.95, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Number suffering serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.85, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Memantine 20 mg or equivalent vs placebo for moderate‐to‐severe AD with agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical global: CIBIC+ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.30, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive function: ADASCog <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ADAS cog at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐1.38, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 MMSE at 12 months ‐ final values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.15 [‐3.47, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL: ADCS‐ADL23 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐1.66, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and mood: NPI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [‐1.58, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Memantine 20 mg vs placebo for mild AD (MMSE 20‐23) OC six‐month studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global: CGI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.23, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive function: ADAS‐Cog <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.15 [‐3.25, ‐1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL: NOSGER self‐care subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.20, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour: NOSGER disturbing behaviour subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.37, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cognitive function: ADAS‐Cog: post‐hoc subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Mild‐to‐moderate (MMSE &gt;14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.64 [‐2.83, ‐0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Moderate (MMSE ≤ 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.51 [‐7.21, ‐1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.83, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.73, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number suffering at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number suffering agitation as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.33, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Memantine 20 mg vs placebo for mild‐to‐moderate vascular dementia. Six‐month studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.60, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐3.68, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [‐1.28, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐3.73, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL (24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.65, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and Mood: NPI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.09 [‐4.84, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐15.60, 10.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐5.57, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.55, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.54, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number suffering at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Memantine vs placebo for Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). ITT‐LOCF Data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Memantine vs placebo for frontotemporal dementia (FTD)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.67, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.67, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐1.10, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function: MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐2.03, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐1.23, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐5.06, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Behaviour and Mood: Neuropsychiatric Inventory (NPI) Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.16 [‐8.06, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐8.01, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.5 [‐14.60, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.58, 4.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.35, 4.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number suffering at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.75, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number suffering at serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.07, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number suffering agitation as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Memantine vs placebo for frontotemporal dementia (FTD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.21, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Alzheimer's disease ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.27, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Alzheimer's disease ‐ moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.28, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Alzheimer's disease with agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.20, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Vascular dementia ‐ mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.15, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Parkinson's disease dementia / DLB ‐ mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.60, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Fronto Temporal Dementia ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.67, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.28, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Alzheimer's disease ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.19, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Alzheimer's disease ‐ moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.34, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Alzheimer's disease with agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.17, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Vascular dementia ‐ mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.48, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 PDD/DLB ‐ mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Fronto Temporal Dementia ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.35, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.16, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Alzheimer's disease ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.14, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Alzheimer's Disease ‐ moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.24, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Alzheimer's disease with agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.01, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Vascular dementia ‐ mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.20, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 PDD/DLB ‐ mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.45, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Fronto Temporal Dementia ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and mood ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.17, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Alzheimer's Disease ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.14, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 AD ‐ moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.21, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Alzheimer's disease with agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.14, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Vascular dementia ‐ mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.37, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 PDD/DLB ‐ mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.43, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Fronto Temporal Dementia ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.62, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number suffering agitation ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.71, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Alzheimer's disease mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.70, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Alzheimer's disease moderate‐to‐severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.58, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 AD with agitation (increased severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.04, 5.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Vascular dementia mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.33, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Fronto Temporal Dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Mixed dementia mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.71, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number suffering agitation ‐ by dementia type and ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.69, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Alzheimer's disease monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.49, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Alzheimer's disease with concomitant ChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.68, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Alzheimer's disease with agitation with concomitant ChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.04, 5.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Vascular dementia monotherapy implied</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.33, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Fronto Temporal Dementia ‐ monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Mixed dementia ‐ unclear ChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.71, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause discontinuation (all durations) ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Alzheimer's Disease ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.08, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Alzheimer's disease ‐ moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Alzheimer's disease with agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.79, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Vascular dementia mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.83, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 PDD/DLB mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.55, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Fronto Temporal Dementia mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.58, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 AIDS complex dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.52, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Mixed dementia mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.30, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Discontinuation due to adverse events ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.90, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Alzheimer's Disease ‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.03, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Alzheimer's Disease ‐ moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Alzheimer's disease with agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.88, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Vascular dementia mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.73, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Fronto Temporal Dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.37, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 AIDS Complex dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.37, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 PDD/DLB mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.54, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number suffering at least one adverse event ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [1.00, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Alzheimer's disease mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.98, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Alzheimer's disease moderate‐to‐severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.97, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Alzheimer's disease with agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.95, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Vascular dementia mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Fronto Temporal Dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.75, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 PDD/DLB mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 AIDS complex dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Mixed dementia mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.91, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number suffering at least one serious AE ‐ by dementia type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Alzheimer's disease mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Alzheimer's disease moderate‐to‐severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Alzheimer's disease with agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.85, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Vascular dementia mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.62, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Fronto Temporal Dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.30, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 PDD/DLB mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.69, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Number suffering agitation as an adverse event ‐ by dementia type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.71, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Alzheimer's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.66, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 AD with agitation (increased severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.04, 5.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Vascular dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.33, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Parkinson's Disease Dementia / Dementia Lewy Bodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Fronto Temporal Dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 Mixed dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.71, 3.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">SUMMARY: memantine 20 mg/day or equivalent vs placebo at six to seven months, by dementia type and by severity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.92, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number suffering at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [1.00, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number suffering serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number suffering agitation as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.71, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number suffering insomnia as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number suffering confusion as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.91, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number suffering depression as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.70, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number suffering headache as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.00, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number suffering hypertension as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.14, 2.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Number suffering dizziness as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.28, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Number suffering falls as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number suffering accidental injury as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.62, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number suffering urinary incontinence as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Number suffering diarrhoea as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Number suffering influenza like symptoms as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.87, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Adverse reactions: memantine vs placebo for mild to severe dementia. All diagnoses, all durations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cognitive function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 3) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 4) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 PP then Retrieved dropout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 PP then retrieved dropout ‐ AChEI only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 PP then Retrieved dropout ‐ no AChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 5) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 6) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 7) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13 Per protocol then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Decline in ADL: ADCS‐ADL19/23 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 1) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 2) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 3) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 4) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 5) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 6) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 7) OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 PP then Retrieved Dropout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 PP then Retrieved Dropout ‐ AChEI only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 PP then Retrieved dropout ‐ no AChEI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 OC then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Per protocol then LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cognitive Function: SIB/ADASCog/MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.33, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.33, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Missing at random assumption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.47, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.69, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Retrieved dropout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.64, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Decline in Activities of Daily Living <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 OC only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.19, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 LOCF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.21, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Missing at random assumption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.29, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.50, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Retrieved dropout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.47, 0.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">APPENDIX 3: Comparison of LOCF and OC analyses: memantine 20 mg or equivalent versus placebo for Alzheimer's disease. 24‐to 30‐week data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.26, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.24, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.17, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and Mood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.19, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical Global ‐ sensitivity analysis for high RoB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.26, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cognitive Function ‐ sensitivity analysis for high risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.23, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Decline in ADL ‐ sensitivity analysis on high RoB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.15, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Behaviour and Mood ‐ sensitivity analysis on high RoB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">APPENDIX 4: memantine vs placebo for mild to severe Alzheimer's disease. OC. 12‐52 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global ‐ CIBIC Plus, CGI‐I, or ADCS‐CGIC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.26, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.53, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 6‐7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.26, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 &gt; 7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐1.04, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.24, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.34, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 6‐7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.28, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 &gt; 7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.23, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL ‐ BGP, ADCS‐ADL 19 or 23 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.17, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.46, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 6‐7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.19, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 &gt;7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.11, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and Mood (Standardised NPI or NPI‐NH Total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.19, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.54, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 6‐7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.18, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 &gt; 7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.41, ‐0.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">APPENDIX 4: subgroup analysis by duration: memantine 20 mg or equivalent vs placebo for mild‐to‐severe Alzheimer's disease. OC. 12‐52 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global; 10mg versus 20mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.12, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive function; 10mg vs 20 mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.48, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL; 10mg versus 20mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐1.86, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and mood; 10mg versus 20mg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐1.06, 4.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical Global <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.50, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cognitive function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.45, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Decline in activities of daily living <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.92, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Behaviour and mood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐3.25, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">APPENDIX 4: memantine 10 mg versus 20 mg memantine for Alzheimer's disease (12‐24 weeks)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global: subgroup analysis by +/‐ ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.26, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Monotherapy (studies ordered by decreasing mean severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.28, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 With concomitant ChEI (studies ordered by decreasing mean severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.30, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function subgroup analysis by +/‐ ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.28, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Monotherapy (studies ordered by decreasing mean severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.32, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 With concomitant ChEI (studies ordered by decreasing mean severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.28, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL subgroup analysis by +/‐ ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.19, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Monotherapy (studies ordered by decreasing mean severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.24, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 With concomitant ChEI (studies ordered by decreasing mean severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.19, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and Mood: subgroup analysis by +/‐ ChEI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Monotherapy (studies ordered by decreasing mean severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.17, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 With concomitant ChEI (studies ordered by decreasing mean severity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.24, ‐0.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">APPENDIX 4: subgroup analysis by presence/absence of ChEI; 20 mg; six to seven months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.26, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.27, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.19, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and Mood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical Global <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.26, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.26, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.30, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cognitive Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.27, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.22, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.36, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Decline in ADL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.19, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.13, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.28, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Behaviour and Mood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.11, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.25, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause discontinuation, by type of disease and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Alzheimer's disease mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Alzheimer's disease moderate‐to‐severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Discontinuation due to adverse events, by disease type and severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.88, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Alzheimer's disease mild‐to‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.04, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Alzheimer's disease moderate‐to‐severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">APPENDIX 4: subgroup analysis by severity/stage of AD: memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global ‐ mild vs moderate/severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.26, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.27, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.28, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function ‐ mild vs moderate/severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.30, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.19, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.34, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL ‐ mild vs moderate/severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.20, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.14, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.24, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour and Mood ‐ mild vs moderate/severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.14, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.21, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause discontinuation ‐ mild vs moderate/severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.08, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuations due to adverse events ‐ mild vs moderate/severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.86, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.06, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">APPENDIX 4: subgroup analysis by severity/stage of AD: mild versus moderate/severe memantine 20 mg or equivalent vs placebo. OC. 24‐28 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003154-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global: post‐hoc within‐trial subgroup analyses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.27, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 severe (MMSE mean &lt;10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.43, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 moderate (subgroup MMSE 10 to &lt;20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.30, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 mild (subgroup MMSE ≥20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.27, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive Function: post‐hoc within‐trial subgroup analyses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.34, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 severe (MMSE &lt;10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.67, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 moderate (subgroup MMSE 10 to &lt;20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.37, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 mild (subgroup MMSE ≥20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.19, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Decline in ADL: post‐hoc within‐trial subgroup analyses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.18, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 severe (MMSE mean &lt;10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.35, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 moderate (subgroup MMSE 10 to &lt;20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.23, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 mild (subgroup MMSE ≥20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.14, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical Global: by severity of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.26, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 severe (MMSE mean &lt;10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.33, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 moderate/severe (MMSE mean 10‐12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.34, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 moderate (post hoc within‐trial subgroup)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.31, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 mild (post hoc within‐trial subgroup MMSE ≥20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.27, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cognitive Function: by severity of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.29, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 severe (MMSE mean &lt;10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.57, ‐0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 moderate/severe (MMSE mean 10‐12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.32, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 moderate (post hoc within‐trial subgroup)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.40, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 mild (post hoc within‐trial subgroup and mean MMSE ≥20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.17, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Decline in ADL: by severity of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.19, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 severe (MMSE mean &lt;10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.59, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 moderate/severe (MMSE mean 10‐12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.25, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 moderate (post hoc within‐trial subgroup)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.25, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 mild (post hoc within‐trial subgroup and mean MMSE ≥20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.12, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Behaviour and Mood: by severity of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 severe (MMSE mean &lt;10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.40, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 moderate/severe (MMSE mean 10‐12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.23, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 moderate (post hoc within‐trial subgroup)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.17, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 mild (post hoc within‐trial subgroup MMSE ≥20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.14, 0.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">APPENDIX 4: subgroup analysis by severity/stage of AD: severe versus moderate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003154.pub6/references#CD003154-tbl-0030">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003154.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003154-note-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003154-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003154-note-0022">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003154-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD003154-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003154-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD003154-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003154-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003154-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003154\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003154\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003154\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003154\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003154\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003154.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003154.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003154.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003154.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003154.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716996152"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003154.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716996156"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003154.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dad193cdcf3f1',t:'MTc0MDcxNjk5Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 